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Abstract
Tuberculosis (TB) is one of the leading causes of mortality in developing countries and 
infants are at particular risk. Currently, the only licensed vaccine is Bacillus Calmette- 
Guerin (BCG), which has variable efficacy. BCG has been shown to provide heterologous 
protection against unrelated pathogens and enhance immunity to other Expanded 
Programme on Immunization (EPI) vaccines when given at birth. However, only one 
recently published study has shown an enhanced pro-inflammatory effect of BCG among 
vaccinated neonates and the immunological mechanisms of this effect in infants are not 
known. Further studies are required if this BCG effect is to be understood.
This thesis describes the differences in soluble and cellular responses to vaccine specific 
and non-specific heterologous antigens and EPI antibody levels between infants 
vaccinated with BCG at 6 weeks and those delayed until 18 weeks of age using flow 
cytometry, multiplex cytokine arrays and vaccine antibody assays.
We found low plasma cytokine levels and little cytokine production to PPD (the BCG-recall 
antigen) regardless of vaccination status. However, the BCG vaccinated group had lower 
production of IL-10 with both Toll like receptor (TLR) agonists and unrelated pathogen 
stimulation when compared to their unvaccinated counterparts, and this was more 
prominent in females than males. This contrasts with previous studies showing enhanced 
pro-inflammatory responses to TLR agonists and killed pathogens following BCG 
vaccination. The infants received BCG Denmark in these latter studies, whereas BCG 
Russia was used in our study, therefore strain differences in heterologous effects of BCG 
may be one explanation for the discrepancy.
When cellular responses were analyzed by flow cytometry low cellular responses were 
observed in both groups. However, we observed a significantly higher proportion of IFNy+
CD8+ cells 1 week after vaccination compared to the unvaccinated group in response to 
PPD and Candida albicans stimulation.
Despite their different vaccine schedules, protective antibody levels to polio, tetanus and 
hepatitis B vaccines were obtained by all subjects; although no boosting effect of BCG 
was seen in contrast to previous studies when BCG was given at birth. A tuberculin skin 
test (TST) was performed at 18 weeks of age as a functional measure of delayed type 
hypersensitivity to Mtb. Due to the influence of BCG vaccination on TST induration, the 
vaccinated infants had significantly higher indurations than the unvaccinated infants and 
this was more pronounced in males.
Our findings are in contrast to a study in South Africa, but support findings from a study in 
Uganda, where delayed BCG vaccination significantly reduced responses to BCG 
compared to infants vaccinated at birth, suggesting an impact of environment (including 
exposure to non-tuberculous mycobacteria) in masking the immune response to BCG, 
differences in vaccine strains might be a major reason for differences observed in our 
study and the other South African studies However, two major limitations of our study are 
the lack of a vaccine group at birth as per the current vaccine schedule, and a post­
vaccination follow up for the infants vaccinated at 18 weeks to determine differences in 
immunity to BCG with a further delay in vaccination.
In conclusion, BCG vaccination given at 6 weeks of age showed no difference in Th1 
responses, but decreased IL-10 responses after TLR agonist and unrelated pathogen 
stimulation compared to unvaccinated infants. These effects, together with TST 
induration, were influenced by sex. Importantly, however, delaying vaccination did not 
have an effect on other EPI vaccine antibody levels, with all infants reaching protective 
levels by 18 weeks of age. This study provides further insight into BCG effects in infants in 
a West African setting.
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1. Introduction:
1.1 Tuberculosis
1.1.1 Epidemiology of tuberculosis
Tuberculosis (TB) is a significant public health problem and a third of the world is 
estimated to be latently infected (WHO, 2012) with the highest burden in sub-Saharan 
Africa and South-East Asia(Fig 1-1). The latest WHO report estimates almost 9 million 
new cases of TB occur per annum with 1.4 million deaths (WHO, 2012); almost half of 
which are HIV associated (Fig 1-2).
Transmission occurs within air droplets (aerosols), which enter alveolar passages of 
exposed individuals and are ingested by alveolar macrophages. Standard pulmonary 
tuberculosis treatment requires 2 months intense phase therapy with rifampicin, isoniazid, 
ethambutol and pyrazinamide followed by 4 months of continuation phase with rifampicin 
and isoniazid (CDC, 2011). Fortunately most people get cured after using these drugs 
however the increasing prevalenqe of multiple drug resistant (MDR) TB and extensively 
drug-resistant (XDR) TB strains has exacerbated the problem (Raviglione & Smith, 2007). 
Multidrug resistant TB (MDR-TB) is caused by organisms that are resistant to isoniazid 
and rifampicin, which are the two most effective drugs against TB. Half a million cases of 
MDR-TB were estimated to have occurred in 2011, and 60% of these came from Brazil, 
China, the Russian federation, India and South Africa (WHO, 2012). More worrying is the 
emergence of XDR TB which is defined as TB resistant to at least four core anti-TB drugs. 
These generally include the two most powerful, plus resistance to any of the 
fluoroquinolones (e.g. ciprofloxacin) and at least one of the injectable second-line drugs 
(e.g. amikacin). By March of 2013, 84 countries had reported at least one case of XDR-TB 
(WHO, 2012).
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1.1.2 The immune response in tuberculosis
1.1.2.1 Innate immune response
The innate immune response is the first line of defense of the immune system. Several 
studies suggest that innate defenses play a significant role in the immune response to 
tuberculosis( Ernst, 1998; Kaufmann, 2001; Abel et al., 2002).
Macrophages and c-type lectins
Macrophages are long-lived phagocytes that are detrimental to many microbial 
pathogens. Alveolar macrophages are the first point of contact of Mtb in the lungs and 
generally the preferred habitat of the bacteria. Although sterile eradication of the bacteria 
is seldom achieved, activated macrophages can control the growth of the microbe 
(Kaufmann, 2001). A number of surface receptors have been shown to be critical for Mtb 
detection by phagocytes, including complement receptors, mannose receptors (MR), 
dendritic cell-specific intercellular adhesion molecule (ICAM-3)-grabbing non-integrin (DC- 
SIGN), mannose binding lectin (MBL) and dectin-1 (Ernst, 1998). The initial interaction 
with these surface receptors influences the subsequent fate of Mtb within the 
macrophage. Autophagy influences the fate of the bacteria, with activation of 
macrophages leading to phagosome maturation and killing of the bacteria in macrophages 
(Gutierrez et al., 2004). The microbe can evade destruction by macrophages through 
inhibition of phagosome-lysosome fusion (Armstrong & Hart, 1971).
Toll-like receptors
The control of Mtb infection begins with the mycobacterial structural component such as 
mycolic acid and peptidoglycan being recognized (Mishra et al., 2011) via pattern 
recognition receptors (PRRs) on immune cells. The best known of the PRRs are the Toll 
Like receptors (TLRs) and Nod-Like receptors (NLRs). TLRs are a family of type 1 
transmembrane receptors which are characterized by an extracellular leucine-rich repeat 
(LRR) domain and an intracellular Toll/IL-1 receptor (TIR) domain (Medzhitov et al., 1997).
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TLRs expressed by macrophages and dendritic cells (DCs) recognize a wide range of 
bacterial molecules including lipopeptides (TLR2), lipopolysaccharide (TLR4), bacterial 
CpG DNA (TLR 9) and many others. The cell wall of mycobacteria have been shown to 
contain several proinflammatory TLR2 ligands including lipoproteins (Brightbill et al., 1999; 
Means et al., 1999); thus TLR2 (acting as a heterodimer with TLR1 or TLR6) recognizes 
invading mycobacteria leading to the stimulation of APC effector functions (reviewed in 
Zuniga et al., 2012). TLR9 and possibly TLR4 are also thought to be stimulated by Mtb 
(Heldwein & Fenton, 2002). Studies in mice have demonstrated a role for both TLR2 and 
TLR4 in the long-term control of Mtb infection. Abel et al showed that immune recognition 
by TLR4 may be involved in protective mechanisms during chronic Mtb infection in mice 
(Abel et al., 2002). Another study from the same group showed the inability of TLR2'/_ 
mice to form mycobacterial granulomas, increasing susceptibility to Mtb infection and 
reducing bacterial clearance (Drennan et al., 2004).
Nod-Like Receptors
Nod-Like receptors (NLR) are cytoplasmic proteins that contain a leucine-rich region at 
the C-terminus and a central nucleotide-binding oligomerization domain (NOD). There are 
over twenty known mammalian NLRs but only two have been shown to be involved in 
immunity against TB. NOD2 is a receptor for bacterial peptidoglycans; it may play a role in 
the host immune response to Mtb infection as it mediates the production of a-defensins 
which have bactericidal activity against mycobacteria (Kobayashi et al, 2005). NOD2 has 
also been shown to work together with TLR2 in mediating the immune response 
(Ferwerda et al., 2005). The NOD-, LRR- and pyrin domain-containing 3 (NLRP3) has 
also been shown to recognize one or more of the ESX1-secreted substrates (Mishra et al., 
2009). Mtb interaction with PRRs results in the activation of downstream innate immune 
mediators which are involved in the phagocytosis of mycobacteria and signaling pathways 
related to the production of IL-12, TNF-a and IL-1(3 production (Court et al., 2010; 
Carvalho et al., 2011).
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Neutrophils
Neutrophils are polymorphonuclear cells (PMNs) with abundant granules in their 
cytoplasm that present a large amount of bactericidal molecules. They are the most 
abundant leukocytes in the blood, with a lifespan ranging from a few hours to up to 5 days 
in the bloodstream (Borregaard, 2010; Pillay et al., 2010). Neutrophils are the first immune 
cells that arrive at the site of infection (Raja, 2004) and can destroy the pathogen by both 
oxidative (oxygen dependent) and non-oxidative (oxygen independent) mechanisms via 
phagocytosis of the pathogen or release of microbicidal granules (Amulic et al, 2012). 
Oxidative mechanisms result in the generation of reactive oxygen species, whilst non- 
oxidative mechanism results in degranulation - the release of preformed oxidants and 
proteolytic enzymes from granules. Anti-microbial compounds from granules not only kill 
bacteria, but may also act as chemoattractants for T-cells and immature dendritic cells, 
which then recruit more neutrophils to the infection site as well as initiate the adaptive 
immune response (Burg & Pillinger, 2001). Abundant amounts of neutrophils have been 
detected in the bronchoalveolar lavage fluid of pulmonary TB patients, more bacilli were 
found in the neutrophils than macrophages collected from sputum, bronchoalveolar lavage 
and cavities of these patients (Eum et al., 2010). It has been suggested by Blomgran and 
Ernst that in vivo neutrophils could be important in the induction of CD4+ T cell responses 
by delivering Mtb to dendritic cells, promoting the migration of DCs and making antigen 
presentation much more efficient thus favoring the T cell response (Blomgran & Ernst, 
2011). A recent study using micro array data from active TB patients, latent TB infection 
and healthy individuals, supports a role of neutrophils in pathogenesis of TB probably due 
to an over-activation of IFNy and type I IFNs, showing an important role of neutrophils in 
TB disease pathology(Berry et al., 2010).
Natural killer Cells (NK Cells)
Natural killer cells mediate antimycobacterial activity and are important in the defense 
against pathogens such as viruses, bacteria and certain parasites that use cytolytic
granules and cytokine production to mediate their effector functions (Kirwan & Burshtyn, 
2007). They have the ability to bind ligands on most cell surfaces via surface binding 
proteins; their functional activation is determined by the interaction between stimulatory 
and inhibitory signals (Zuniga et al., 2012). Acting as intermediaries between the innate 
and adaptive immune response, they stimulate dendritic cells which in turn promote T cell 
responses (Kirwan & Burshtyn, 2007). NK cells were shown to be recruited to the lungs in 
a murine model of TB, and produced IFN-y as well as perforin, however this was deemed 
not protective due to lack of infection after depletion with lytic antibodies (Junqueira-kipnis 
et al., 2003). NK cells in humans have been shown to produce IFN-y after 72 hour 
cultures with BCG with the addition of IL-2, and Mtb with the addition of IL-12 (Portevin et 
al, 2012) indicating that priming of NK cells with cytokines is sufficient to make them 
respond to mycobacteria.
Dendritic Cells (DCs)
Dendritic cells are phagocytes that are involved in both the innate and adaptive immune 
response due to their role as professional antigen presenting cells (APCs), responsible for 
the initiation of adaptive immune responses. In mice, depletion of DCs resulted in 
impairment of the CD4+ T cell response and an inability to control the bacterial load after 
M tb infection (Tian et al., 2005). As well as their role as APC, studies in humans have 
shown that DCs also play a role in phagocytosis of the bacteria alongside macrophages 
(Henderson, Watkins, & Flynn, 1997).
1.1.2.2 Adaptive immune response to Mtb
General T cells
The adaptive immune response is the second line of defense with recognition of specific 
antigens expressed by pathogens. Specificity is determined by antigen specific receptors 
on T and B lymphocytes. Adaptive immunity is further enhanced by TLR recognition of 
microbes, which activate APCs such as DCs. Following stimulation, T cell antigen 
receptors (TCRs) on naive T cells bind to foreign peptides and the presence of Major
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Histocompatibility complex class II (MHC II) on antigen presenting cells such as DCs, 
signaling through the TCR and APC derived co-stimulatory molecules such as CD28 and 
CD80/86, naive T cells divide to become effector T cells. Depending on the local cytokine 
milieu, transcription factors are activated committing them to a particular T cell subset, 
leading to a rise in T cell numbers at about a week after initiation of response. 1 -2 weeks 
into the response, approximately 90% of the activated T cells die, leaving behind long- 
lived memory T cells (reviewed by Pepper & Jenkins, 2011). Some of these T cells 
become effector memory T cells (TEm) capable of producing cytokines within hours of T- 
cell receptor stimulation, or central memory T cells (TCm) which are slower to respond to 
antigen stimulation, but when re-stimulated secrete IL-2, proliferate extensively and 
acquire lymphokine effector production (Pepper & Jenkins, 2011; reviewed by Sallusto, 
Geginat, & Lanzavecchia, 2004). Central memory cells express CCR7 (a chemokine 
receptor) and CD62L, have few effector functions, but home to secondary lymphoid 
organs, whilst the effector memory cells lose CCR7 expression, have effector function and 
home to inflamed non-lymphoid tissues in humans (Sallusto et al., 1999; Geginat, 
Sallusto, & Lanzavecchia, 2001; Sallusto et al., 2004). Central memory cells have a higher 
proliferative potential than effector memory cells which gives them an edge in their ability 
to persist in vivo and efficiency in mediating protection (Lanzavecchia & Sallusto, 2005). 
CD4+ T cells (helper T (Th cells)) are activated by engagement of their unique TCR with 
Major Histocompatibility Class II (MHC II) molecules on APCs, while CD8+ T cells 
(Cytotoxic T lymphocytes) are activated via MHC Class I. CD4+ T cells are specialized to 
activate CD8+ T cells, B cells and, importantly for TB immunity, macrophages. Helper T 
cells have been sub-characterized into different subsets based on their cytokine secretion 
pattern. Th1, Th17 and T follicular helper (Tfh) cytokines are proinflammatory and are 
generally induced after viral, bacterial and fungal infections, whilst Th2 cytokines are anti­
inflammatory and are generally induced after parasitic and helminthic infections (Sallusto 
& Lanzavecchia, 2009).
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Regulatory T cells (Tregs) constitute approximately 5-10% of peripheral CD4+ T cells and 
are important for the maintenance of peripheral tolerance and regulation of immune 
responses by a variety of mechanisms including the secretion of the immunosuppressive 
cytokines IL-10 and TGF-(3.
Mtb specific T cell responses
Induction of cell-mediated immunity and granuloma formation is critical in the early control 
of Mtb infection. Different subsets of T cells have been shown to be involved in this 
process. Granuloma formation restricts the dissemination of the bacteria providing 
defense for the lungs against TB. However, if granulomas break down this can lead to 
aerosol transmission of TB (Rook & Hernanadez-Pando, 1996).
Mycobacteria specific CD4+ T cells are typically T helper 1 (Th1) and produce pro- 
inflammatory cytokines such as IFN-y and TNF-a. Various studies have shown the 
indispensable role that IFN-y plays in the immune response against TB (Cooper et al., 
1993; Flynn et al., 1993). It has also been shown that patients with mutations in their IFN- 
y-receptor genes are susceptible to disseminated mycobacterial infections (Newport et al, 
1996). Other Th1 cytokines such as TNF-a and IL-12 have also been implicated in the 
immune response against TB. Treatment of patients with autoimmunity with anti-TNF-a 
antibodies enhances susceptibility to the development of active TB (Bruns et al., 2009) 
and the same has been shown in patients with a defect in their IL-12 receptor gene 
(DeJong et al., 1998). A Th1 response is essential for protection against TB and the 
induction of Th2 cytokines could antagonize this response (Lucey et al, 1996), but may 
also reduce immunopathology. IL-10 transgenic mice had a higher Mtb bacterial burden 
(Murray et al, 1997) and anergic human TB patients produced high amounts of IL-10 both 
before and after treatment suggesting immune suppression of Mtb (Boussiotis et al., 
2000). IL-4 has been shown to play a role in disease progression since higher IL-4 
expression was found in patients with pulmonary cavities (van Crevel et al., 2000).
Demissie et al found not only strong early secreted antigenic target-6 (ESAT-6, one of the 
immunodominant TB antigens) responses in exposed individuals who later progressed to 
disease, but increased IL-4 production and a decreased IFN-y production in these 
individuals as they progressed (Demissie et al., 2006). Both studies point to the 
importance of Th1/Th2 homeostasis, with a predominant Th1 response required for 
protective immunity.
T helper 17 (Th17) cells are a relatively recently discovered subset producing IL-17, IL-21 
and IL-22, and have also been implicated in TB control in mice and humans (Khader & 
Cooper, 2007; Scriba et al, 2008). Although IL-17 producing cells work in concert with 
IFN-y producing cells, some studies have suggested a possible protective role of Th-17 
cells in the absence of IFN-y (Wozniak et al, 2006).
While CD4+ T cells are the major effector cells in protection to TB, CD8 knockout mice are 
susceptible to Mtb, suggesting that CD8 T cells also play a protective role (Sousa et al., 
2000). In this regard Mtb growth in vitro was shown to be inhibited by human CD1d 
restricted CD8+ T cells (Stenger et al, 1997). Differentiation and maturation of CD8+ T 
cells (Cytotoxic T Lymphocytes (CTL)) is mediated by the co-stimulatory signals produced 
by antigen presenting cells (APC) or by CD4+ T cells and engagement of the MHC Class I 
receptor. CD8 T cell clones undergo rapid proliferation in the secondary lymphoid tissues 
following activation leading to a rise in effector cells that migrate to the periphery to 
resolve infection (Bannard, Kraman, & Fearon, 2009). Once activated CTL are able to kill 
Mfb-infected targeted cells. Two mechanisms have been shown to be involved in the 
killing of cells; perforin mediated killing seems to be crucial for elimination of infected 
targeted cells (Canaday et al., 2001), while the antimicrobial peptide granulysin kills 
intracellular mycobacteria upon release by CD8 T cells (Stenger, et al, 1998). The second 
mechanism is by inducing apoptosis via the Fas-mediated pathway which controls 
lymphocyte homeostasis by elimination of unwanted T cells (Watson et al., 2000). 
Although CD4+ T cells are the primary effector cells in TB, CD8+ T cells preferentially
recognized heavily infected cells suggesting this may be essential during more severe TB 
infections (Lewinsohn et al., 2003).
Regulatory T cells (Tregs)
In patients with TB, Tregs have been shown to accumulate and proliferate at different 
sites of infection (Guyot-Revol et al, 2006; Chen et al., 2007) and in the peripheral blood 
(Ribeiro-Rodrigues et al., 2006). Increasing numbers of Tregs in blood has been 
associated with disease progression (Guyot-Revol et al., 2006). In Gambian TB cases and 
contacts, FOXP3 (transcription factor for Tregs) levels were higher in the blood of patients 
than in the blood of both infected and uninfected contacts(S Burl et al., 2007).
B cell responses
B cells have been shown to be vital for immune protection against a wide range of 
microbes and vaccines, however little is known about their protective role in TB infection. 
Studies of B cell deficiency have questioned the need for B cells in protection against TB 
in both mice (Johnson et al., 1997) and humans (Doffinger, Patel, & Kumararatne, 2005). 
However, murine studies have demonstrated protective efficacy of a mAb against 
mycobacterial arabinomannan and heparin-binding hemaglutinin (Teitelbaum et al., 1998; 
Hamasur et al., 2004).
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Figure 1-3: The immune response to TB. Exposure to tuberculosis results in the activation of 
the innate immune response. The bacterium infects the macrophages, some individuals 
clear the infection at this stage whilst some go on to generate T cell responses and memory 
(Walzl et al, NRI 2011).
1.1.2.3 Infant Immunity
While the neonatal immune system affords some protection at birth, responses are 
suboptimal to a range of pathogens, resulting in susceptibility of infants to severe disease 
(Prabhudas et al., 2011). Reduction in the innate immune response to TLRs and 
subsequent impairment of T cell activation, are partly responsible for reduction in acquired 
immunity. Interestingly, while the production of IFN-y, IL-12p70 and IFN-a from monocytes 
is reduced in neonates compared to adults, neonatal mononuclear cells produce more IL- 
10 and IL-17 compared to adult cells (Kollmann et al., 2009), while plasma contains lower
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levels of Th-1 type cytokines and higher levels of IL-6 (a Th-2 polarizing cytokine) 
throughout the first weeks of life in neonates (Angelone et al., 2006).
1.1.2 Vaccine-induced protection against TB
1.1.2.1 Bacillus Calmette-Guerin (BCG)
The Mycobacterium bovis derived vaccine, Bacillus Calmette Guerin (BCG), is the most 
widely used vaccine in the world today with more than 3 billion doses administered to date 
at an average of 120 million doses annually (Fig. 1-4). The main burden of TB is 
associated with adult pulmonary disease, which is also the main source of new infections. 
Although BCG protects against childhood miliary and pulmonary tuberculosis (Colditz et 
al., 1995), protection against adult pulmonary TB is widely variable (0-80%) which has 
been attributed to strain variation, genetic and nutritional differences between populations 
as well as exposure to environmental mycobacteria (Fine, 1995). WHO recommends 
vaccination of neonates at the birth with a single intradermal dose in high TB endemic 
countries, including The Gambia. However, a study comparing immunogenicity between 
adolescents in the UK and Malawi showed higher immunogenicity in the UK than in 
Malawi, thought to be due to exposure to environmental mycobacteria (Black et al., 2002).
Immaturity of the neonatal immune system has been suggested as another factor in 
reduced BCG efficacy (Siegrist & Kovarik, 1998). Several studies in South African children 
have shown higher protective responses in children who had BCG delayed to the age of 
10 weeks (Hussey et al., 2002; Kagina et al., 2009). However, a study in The Gambia 
showed that BCG vaccination induced IFN-y responses to adult levels regardless of 
whether it was given at birth or delayed to two months, but the response was higher in 
those vaccinated at birth (Ota et al., 2002). Another study from The Gambia showed a 
stronger Th1 and Th17 response in infants vaccinated at birth compared to those delayed 
to 4.5 months (Burl et al., 2010). This latter study attributed this difference to exposure to 
non-tuberculous mycobacteria, similar to the study in Malawi.
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Figure 1-4: Global BCG immunization coverage; WHO 2011
1.2.1 The neonatal Immune response to BCG
The immune response to BCG is generally an adaptive response; however recent data 
have shown that the innate immune system is likely to play a significant role in the 
activation of an immune response against BCG, particularly in neonates. A South African 
study showed certain TLR polymorphisms were associated with an increased Th-1 type 
BCG induced response in whole blood ten weeks after BCG vaccination of infants 
(Randhawa et al., 2011). Soares et al showed that BCG is capable of inducing 
polyfunctional (cells producing more than 1 cytokine at the same time) CD4+ T cell 
responses in infants (Soares et al., 2008), including non-IFN-y cytokines (such as IL-17 
and IL-22). Similarly, in a murine model it has been shown that BCG-specific IL-17
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producing T cells (Th17 cells) conferred significant protection against systemic 
tuberculosis in IFN-y knockout mice (Wozniak et al, 2010). Wild type mice were able to 
mobilize neutrophils during the early stages of BCG infection but IL-17'7' mice were not, 
thus suggesting a role for IL-17 in the induction of neutrophils after BCG vaccination
i
(Umemura et al., 2007). An increase in IL-17 is closely related to induction of IFN-y 
responses post-BCG vaccination demonstrating its importance in BCG-induced immunity 
in infants and adults (Li et al., 2012).
1.3 Expanded Program on Immunization
The most successful and cost-effective public health intervention to date is immunization. 
National immunization programs have not only led to greatly reduced mortality and 
morbidity but also to the total eradication of smallpox (CDC, 2006). The World Health 
Organization (WHO) launched the Expanded Program on Immunization (EPI) in 1974 as 
part of global efforts to increase vaccination as a worldwide strategy to decrease morbidity 
and mortality from infections (Machingaidze, Wiysonge, & Hussey, 2013). However, 
despite Africa having the highest mortality rates from vaccine-preventable diseases, it still 
remains behind in terms of the introduction and implementation of vaccination programs 
(Machingaidze et al., 2013).
The Gambian EPI was introduced in 1979 following the 1978 yellow fever epidemic in the 
Upper River Region of The Gambia (Jobe, 2006). At present all infants are vaccinated at 
birth with BCG, oral polio vaccine (OPV), and Hepatitis B vaccine (HepB). At 2 months a 
three month intensive course is begun with the pentavalent vaccine consisting of 
Haemophilus influenza (Hib), HepB, diphtheria-tetanus and whole cell Pertusis (DTwP); 
alongside 3 doses of OPV, and the 13-valent pneumococcal conjugate vaccine (PCV-13) 
(Table 1-1). Measles and yellow fever vaccines are administered at 9 months of age with 
a fifth dose of OPV. At 16 months of age a booster dose of the Pentavalent vaccine is 
given with a final dose of OPV at 18 months (Payne, et al, 2013). Vaccine coverage has 
been estimated to be more than 90% by 1 year of age in Gambian infants (WHO, 2010).
Table 1-1; The Gambia Immunization Schedule
Age of infant Vaccines given
Birth BCG, Hepatitis B (HepB), Oral Polio Vaccine ( OPV)
2 months OPV, Penta (HepB, DTP, Hib), PCV-13, Rotavirus*
3 months OPV, Penta (HepB, DTP, Hib), PCV-13, Rotavirus*
4 months OPV, Penta (HepB, DTP, Hib), PCV-13, Rotavirus*
9 months OPV, measles, yellow fever
16 months DTP Booster
18 months OPV, Measles
* introduced as part of the EPI schedule in August 2013.
1.4 Gender differences in vaccine induced immune responses
Immune responses in experimental animals have shown that females are more likely to 
develop a Th1 response after exposure to a pathogen, and in humans women develop 
higher antibody levels and stronger cell mediated immunity (Moxley et al., 2002). 
Adolescent Israeli females had higher measles antibody titres both before and after 
vaccination, with a 50% higher geometric mean post-vaccination titre when compared to 
males (Green et al., 1994). Following a systematic review, Cook observed that females 
had higher antibody levels to hepatitis A and B, rubella, measles (vaccination in 
adulthood) diphtheria (primary vaccination and undernourished infants) tetanus, brucella 
and rabies, whilst males had higher levels after pneumococcal polysaccharide (adults), 
diphtheria (a booster dose), measles (pre-pubertal), yellow fever, Men A and Men C 
(Cook, 2008). In the above mentioned review it was also observed that females had less 
clinical disease with influenza, Hep A and Hep B whilst males had less clinical episodes
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with pneumococcal disease. In high mortality settings such as Guinea Bissau, live 
vaccines have been shown to provide beneficial non-specific effects (defined by Flanagan 
et al as “any event that could not be accounted for by induction of immunity against 
vaccine-targeted disease”) whilst inactivated vaccines appeared to have a deleterious 
effect on survival (Flanagan et al., 2011). Thus mortality decreased after BCG and 
Measles vaccines (live vaccines) but increased after DTP (inactivated) vaccination (Aaby 
et al., 2012). An increase in female mortality up to 2-fold was observed in Gambia, 
Senegal and Guinea Bissau in infants 4 months to 5 years olds after the introduction of 
the High Titre Measles Vaccine (HTMV), whilst DTP in rural Guinea Bissau increased 
mortality in girls by up to 2.5% (Aaby et al., 2003; Aaby et al., 2004). However, this type 
of measles vaccine is no longer in use and a recent systematic review has not associated 
DTP vaccination with increased mortality (WHO, 2014).
It has been suggested that OPV could also have a gender-differential effect on mortality 
as missing OPV at birth was significantly associated with reduced mortality in boys and a 
slight tendency for increased mortality in girls (Benn et al., 2008). Several studies have 
observed that BCG vaccination has more beneficial effects on mortality in girls than boys 
(Kristensen, Aaby, & Jensen, 2000; Stensballe et al., 2005; Roth et al., 2006).
1.5 Heterologous (or non-specific) effects of BCG
Live vaccines such as BCG and measles vaccine have been shown in some studies to 
have substantial survival benefits in infants leading to decreased death from infections 
including pneumonia and sepsis (Aaby et al., 2011). Roth et al found a correlation 
between the presence of a BCG scar, a positive tuberculin skin test and reduced mortality 
in females after controlling for socioeconomic, cultural and health-related risk factors 
(Roth et al., 2006).
These early observational studies have been followed by randomized trials, which confirm 
these effects. Thus BCG vaccination of low birth weight infants has been shown in
40
randomized trials to reduce subsequent mortality by 46% (Aaby et al., 2011; Biering- 
Sorensen et al., 2012). The immunological mechanisms behind these effects are yet to be 
fully elucidated but several mechanisms have been proposed. BCG vaccination of 
Gambian infants has been shown to boost antibody responses to other EPI vaccines 
including HepB, OPV and DTP (Ota et al., 2002). More recently Ritz et al found higher 
antibody responses to Haemophilus influenzae and tetanus toxoid in Australian infants 
vaccinated at birth than in unimmunized infants (Ritz, et al 2013). BCG vaccination has 
also been shown to protect against leprosy (Fine, 1999), and has a well established 
therapeutic effect on bladder cancer (Alexandroff, et al., 1999).
A recent study investigating the mechanism of heterologous protection against other 
diseases in a murine model found that the innate immune response was enhanced due to 
a functional reprogramming of phagocytes via a NOD-2 mediated epigenetic change in 
the level of histone methylation. This induced protective responses against infections 
other than TB such as Candida albicans and E coli LPS, and S aureus (Kleinnijenhuis et 
al., 2012). In 2012, the Strategic advisory group of experts (SAGE) on immunizations 
requested for WHO to review evidence on heterologous effects of vaccines. After 
reviewing the data SAGE concluded in July this year that the epidemiological data support 
beneficial effects of BCG on all-cause mortality, hence the recommendation of BCG at 
birth should be reinforced (WHO, 2014). Further investigation into the effect BCG has on 
susceptibility to other infections and the mechanisms underlying these effects are 
essential. Understanding these effects would help in determining strategies to optimize 
EPI schedules.
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We hypothesize that:
• Delaying BCG until 18 weeks of age will result in lower innate and adaptive 
immune responses to both vaccine and non-vaccine related antigens compared to 
infants vaccinated at 6 weeks.
• The delay in BCG vaccination will also result in lower responses to TLR agonists 
and provide no boosting effect to EPI vaccines.
• Sustained responses to both vaccine and non-vaccine antigens will be evident in 
infants vaccinated at 6 weeks of age compared to those with delayed vaccination.
Project Aims
• To determine differences in the innate and adaptive immune responses at 1 week 
and 12 weeks) post-BCG vaccination compared to BCG-naive infants
• To establish whether BCG vaccination at 6 weeks enhances antibody responses 
to other EPI vaccines given at 8,12 and 16 weeks of age.
• To establish whether BCG vaccination at 6 weeks enhances in vitro responses to 
innate stimuli and whole killed organisms at 1 and 12 weeks post-vaccination.
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Chapter 2: Materials and Methods
2.1 Ethical Approval and Study Design
This study was approved by the Medical Research Council (MRC) Scientific Coordinating 
Committee (SCC) and the MRC/Gambia Government joint ethics committee (SCC 
number, 1233).
Expectant mothers presenting at Sukuta health centre were sensitized about the study, 
and following the birth of their baby, they were provided with specific study information
and invited to join. If written informed consent was provided, babies received Hepatitis B
(HepB) vaccine and the Oral Polio Vaccine (OPV, Sanofi Pasteur, France) within 48h of 
birth but not BCG. Exclusion criteria included low birth weight (< 2.5 kg), a baby with a 
congenital defect, or likelihood of moving outside the study area.
At 6 weeks of age the infants were randomized into two groups with even distribution of 
males and females.
• Group one had BCG vaccine at 6 weeks of age
• Group two had BCG delayed until 18 weeks of age
Apart from BCG (Serum Institute of India, India) all other vaccines were given according to 
The Gambian EPI schedule (Table 1-1). Every child was assessed for TB exposure at 
each visit, and general health information and anthropometric data were collected. 142 
mothers were sensitized and 137 gave informed consent. This resulted in a total of 66 
girls and 71 boys randomized to the two arms (Figure 2-1). At 8, 12 and 16 weeks all 
infants received Pentavalent vaccine (DTwP, Hib, HepB), OPV and PCV-13 as per the 
EPI schedule. Blood samples were processed within 8 hours of collection.
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Figure 2-1: Recruitment and enrolment of participants. Mothers were sensitized, consented 
and recruited into the study, babies were bled at pre-vaccination visit (6 weeks), 1-week post 
vaccination (7 weeks), and 12-weeks post vaccination (18 weeks)
2.2 Sample collection (Figure 2-2)
4.5 mL of venous blood was collected into EDTA tubes at 6, 7 and 18 weeks by a trained 
fieldworker nurse using a 21 gauge needle inserted in the back of the child’s hand. 0.5 
mL of venous blood was collected directly into Paxgene tubes for RNA profiling to be used 
for determining correlations with immunological findings. These latter results will not be 
discussed in this thesis.
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Figure 2-2: Study intervention and sampling procedures at Sukuta field site. 
Infants were bled at 3 times points, at time point 0 (6 weeks/baseline), 1 (7 weeks/ 
1 week post-vaccination) and at 2 (18 weeks/ 12 weeks post-vaccination). All 
infants received the other EPI vaccines as per schedule, those in Group 1 
(vaccinated group) received BCG at 0, and all infants received TST after blood 
was drawn at 2, infants in group 2 then received BCG after TST was read.
2.3 Tuberculin Skin Test (TST)
At 18 weeks of age a TST was performed on all participants after taking the final blood 
sample but before BCG vaccination of group 2. 0.1 mL of 2 tuberculin units (TU; SSI, 
Denmark) was injected into the infants forearm and the area marked. Induration was 
measured in mm both longitudinally and transversely by a trained MRC fieldworker nurse 
48-72 hours later, and the average of the induration is used for analysis. A TST induration 
of >10 mm was considered suggestive of Mtb infection. At each visit a TB questionnaire
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was completed; if anyone in the family had symptoms of TB, the family was visited and 
TST performed on everyone in the compound. Any individual with a positive induration 
>10mm was sent to a nearby TB clinic for further clinical investigation, and unvaccinated 
infants were immediately withdrawn, and investigated for tuberculosis infection including a 
chest x-ray.
2.4 Sample Processing
2.4.1 Plasma collection
Anti-coagulant treated (EDTA) whole blood was centrifuged at 1500 rpm for ten minutes. 
Plasma was removed and 1 mL stored at -20°C prior to analysis.
2.4.2 Vaccine antibody assays
Stored plasma samples were used to investigate EPI antibody levels using the techniques 
below for the different vaccines.
2.4.2.1 Polio Neutralization Antibody assay: Briefly Human Epithelial-2 (Hep-2) 
Cincinnati cells were thawed from Liquid Nitrogen and resuscitated in Growth Medium 
(10% FCS in DMEM (Dulbecco’s Modified Eagle Medium (Life Technologies), with 10mM 
L glutamine and 10mM Pen/Strep). Freezing medium was washed off and cells counted 
7mLs of the Growth medium if viability was greater than 90% in a 25cm3 cell culture flask. 
Cells were incubated for 2-3 days (until confluency was observed) at 37°C 5% C 02, after 
which the cells were split using 2.5% EDTA Trypsin (Sigma, UK). During trypsinisation 
culture medium was poured off, and monolayer rinsed with 5 mLs 0.02% EDTA in PBS, 
and flaked off culture flask with 1 mL of 2.5% of EDTA Trypsin (Sigma Aldrich) after which 
a viability count is done. Cells were transferred into a 75cm3 flask and grown to 
confluency. On the day of the experiment, samples were diluted 1:4 with PBS and 
decomplemented at 56°C for 30 minutes. 50pL of maintenance medium (2% FCS in 
DMEM) and the same volume of diluted serum added, the first dilution being 1:8, a double 
dilution was done until the dilution of 1:1024. 50pL of prepared virus (virus diluted in
maintenance medium) (Polio 1 diluted to 1:1000000 from 1:100 and Polio 3 was diluted to 
1:150000 from 1:100) added to all wells except the negative control and incubated for an 
hour at 37°C 5% C 02. Hep-2 cells were split and diluted to a final concentration of 2 X 105 
cells/mL in maintenance medium and 100pL of Hep-2 cells were added. Cytopathic effect 
(lack of a visible monolayer) of the virus on Hep-2 cells was read 5 days after incubation.
2.4.2.2 Hepatitis Antibody ELISA
A commercial kit was obtained from Diasorin (Italy) and samples were processed 
according to manufacturer’s instructions. Briefly, plasma samples together with a positive 
and negative control (in kit) were aliquoted on to plates coated with Hepatitis B surface 
antigen (HBsAg), incubated for 1 hour at 37°C and washed using an automated plate 
washer (ASYS Atlantis, Biochrom, UK). A tracer solution was added and samples were 
incubated and washed as described above. Chromogen/substrate solution was added on 
to all wells, incubated for 30 minutes at room temperature in the dark after which a stop 
solution (in kit supply) was added and absorbance was read within 15 minutes with a 
spectrophotometer and fluorescence intensity read at 450 nm.
2.4.2.3 DTP Multiplex Immunoassay (MIA):
Measurement of antibody levels to diphtheria, tetanus and pertusis was done via a 
multiplex immunoassay developed in the serology lab after technology transfer from the 
national institute of public health and the environment (RIVM), Netherlands(van 
Gageldonk et al., 2008). Briefly, filter plates were pre-wet with PBS and standards were 
diluted from 1:200 to 1: 204, 800 for the pertussis antigen and 1:50 to 1:819,200 for the 
diphtheria and tetanus toxoids whilst samples were diluted into 1:200 and 1:4,000 
dilutions. Beads conjugates with the antigens above were added on to the pre-wetted 
plates before 25pL of samples were added. Samples were incubated for 30 minutes on a 
shaker at room temperature, filter washed three times. Detection antibody is added, 
incubated and washed as above. R-Phycoerythrin (PE) conjugated to Goat anti-human is 
added on to samples, incubated and washed as above, PBS is added and samples are
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shaken for 5 minutes at room temperature. Samples are read with the Bio-Plex 200 
system within 15 minutes and analyzed using the Bio-Plex manager 4.0 software (Bio- 
Rad, Belgium).
2.4.3 Peripheral Blood Mononuclear Cell (PBMC) Separation
PBMCs were collected using the density gradient centrifugation method. Whole blood 
diluted 1:1 with Roswell Park Memorial institute (RPMI)(Sigma, UK) was layered on 
Lymphoprep (Fresenius Kabi Norge AS, Norway) and spun at 1500 rpm for 30 minutes 
without the brake. The PBMC layer was harvested washed in RPMI twice and cells 
counted. For every 10 million cells 500pL of Fetal Calf Serum (FCS)(Gibco, Life 
technologies) was added, left on ice for 30 minutes and another 500pL of 20% Dimethyl 
SulphOxide (DMSO) (Sigma Aldrich, UK) was added. The cells were transferred into a Mr. 
Frosty container, stored at -70°C and transferred to liquid nitrogen within 24 hours.
2.4.4 Thawing of PBMCs
PBMCs were collected from Liquid Nitrogen and thawed rapidly at 37°C in a water bath. 
Cells were resuspended in warm 10% FCS in RPMI (R10), and washed twice. Cells were 
counted, resuspended in R10 and 25 units/mL of Benzonuclease (Sigma, UK) and rested 
at 37°C 5% C 02 for 6 hours with a loose lid.
2.4.5: Multi-cytokine assays
2.4.5.1 Whole blood stimulation
10Opil/test of whole blood was added to 1 well of a 96-well plate and incubated at 
37°C/5% C 02for 16 hours with PPD (10pg/mL; SSI, Denmark), tetanus toxoid (10pg/mL), 
LPS (TLR4 agonist; 1pg/mL; Invivogen), heat killed Listeria monocytogenes (TLR2 
agonist; 109/mL; Invivogen) and CLO-75 (TLR7/8 agonist; 10pg/mL; Invivogen). After 
overnight incubation, 100pl of RPMI was added to each well, mixed and plate spun at 
1500rpm, for 10 minutes. Supernatants were carefully harvested and stored at -20°C until 
required.
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2.4.5.2 PBMC stimulation
1.0 x 106 cells were aliquoted and 0.1 x 106were stimulated and incubated for 16 hours at 
37°C 5% C 02. In addition to the antigens used for the whole blood stimulation Escherichia 
coli (106cells/mL), Streptococcus pneumoniae (105 celis/mL) and Candida albicans (105 
cells/mL) were used to assess response to other organisms. The antigens were obtained 
from Prof Mihai Netea (Radboud University Nijmegen medical). Supernatants were 
collected after the addition of 100pL of RPMI and centrifugation at 1500rpm for 10 
minutes.
2.4.5.3 Multiplex cytokine assay
Cytokines were assessed using Bioplex Pro custom made kits (Bio-Rad, Belgium). 
Supernatants were spun at 1500rpm for 5 minutes to pellet any precipitation in the 
samples. Cytokines included Th1 (IFN-y, TNF-a and IL-2), Th2 (IL4, IL10); Th17 (IL17); 
and IL-12p70 as an innate factor. IL10 can also be produced by Tregs and Th1 cells and 
TNF-a by innate cells (including macrophages). The assays were carried out according to 
the manufacturer’s instructions but with a 1:2 dilution of reagents. Briefly, coupled 
magnetic beads were diluted 1:2 with assay buffer, and added on 96-well filter plates after 
plates were pre-wet. Plates were washed using a vacuum manifold station. 50pL of 
samples and standards were added. Lyophilized standards were diluted with culture 
medium, left on ice for 30 minutes and to get the first standard (S1), 128 pi of standards 
were diluted with 72 pL of medium. A 1:4 serial dilution followed from S1 to S8 (the 
standard with the lowest concentration). Plates were incubated for 30 minutes on a 
shaker. Detection antibodies used were diluted 1:2 and 25pL added followed by 
incubation at room temperature on a shaker. Streptavidin PE was added as per 
manufacturer’s instructions, incubated for 10 mins and assay buffer added. The cytokine 
responses were read using the Bioplex 200 system, Luminex x-map technology and bio­
plex pro software version 4.0 (Bio-Rad, Belgium). All values less than the lowest value of 
the standard within the standard curve were given the value of the lowest standard and all
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values higher than the highest standard were given the value of the highest standard. The 
lowest and higher values for each analyte are as follows: cytokines (S8 (lowest)-SI 
(highest)); IL-2 (0.88-14426), IL-4 (0.35-5693), IL-10 (1.45-23718), IL-12p70 (2.65-43449), 
IL-17 (2.33-38209), IFNy (2.05-33560), TNFa (6.69-109604). Background (Unstimulated) 
results were subtracted from antigen-stimulated results to obtain specific levels of 
cytokines.
2.4.6: Intracellular cytokine staining 
2.4.6.1 Whole Blood
350pl of whole blood was used for each test. Antigens used were purified protein 
derivative of M. tuberculosis (PPD; 10pg/mL, SSI) and Esat-6/CFP-10 (EC; 2.5pg/mL, 
Proimmune) as vaccine specific antigens. Controls included PMA/lonomycin 
(0.1pg/1pg/mL, Sigma, UK) as a positive control and unstimulated (media alone) as a 
negative control. Samples were incubated for two hours prior to addition of Brefeldin A 
(BFA; 10pg/mL final concentration) and incubated overnight at 37°C/5% C 02. 0.5mMol of 
EDTA was added and incubated for 15 minutes before red cells were lysed with RBC 
lysing buffer (BD, USA). PBS was later added to wash off the red cells and spun at 1500 
rpm for 10 minutes. Supernatant was decanted before the addition of freezing medium 
(10% Dimethyl Sulphoxide (DMSO) in PBS) and cells were stored at -70°C for subsequent 
flow cytometry.
2.4.6.2 PBMC cultures
PBMC were resuspended to 0.5 x106 cells per mL per antigen; where cell numbers were 
too low for all stimulations priority was given to vaccine-specific responses. The same 
stimulants were used as for whole blood stimulations (described above) with the addition 
of Tetanus toxoid, E. coli, S. pneumoniae and C. albicans. Cells were incubated for 2 
hours at 37°C, 5% C02 after which BFA (10pg/mL) was added and cells were incubated 
for a further 16 hours. The next day, cells were centrifuged, supernatant was removed, 
and the cells stained with a surface marker cocktail consisting of CD3-PerCP cy5.5, CD3
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APC efluor 750 and CD8 APC efluor 780. Cells were incubated for 30 minutes at 4°C and 
washed with 1mL of PBS/1 % FCS/0.2% Sodium Azide (FACS buffer). Supernatant was 
removed and cells washed in fix/perm solution (ebioscience, UK). Permeabilisation was 
then performed using perm/wash solution (ebioscience, UK), followed by addition of the 
cytokine panel: IL-2 FITC, IL-17 PE, TNF-a PE-Cy7, IL-10 efluor-450 and IFN-y APC. 
Prior to staining a Live-Dead Fixable yellow (Invitrogen, USA) stain was used in order to 
gate out dead cells from the analysis. Cells were acquired on a CyanADP (Beckman 
Coulter, USA) flow cytometer using Summit v4 software and analyzed using FlowJo 
v10.0.2 (Treestar, USA). At least 100,000 lymphocytes were acquired.
2.4.7 Statistical analysis
A Non-parametric Mann Whitney U test was used to assess for differences between two 
groups and Kruskal-Wallis test used to assess for differences between three groups. A p- 
value of <0.05 was considered significant. False discovery rate of 5% was used to correct 
for multiple testing and a q-value of <0.035 was considered significant.
Flow cytometry data was exported to Pestle (Mario Roederer, Vaccine Research Center, 
National Institute of Allergy and Infectious Diseases (National Institutes of Health) and 
Spice v5 (this software is provided free of charge by the National Institute of Allergy and 
Infectious Disease) for polyfunctional cytokine analysis.
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Chapter 3: Optimization experiments: a comparison of cryopreserved PBMC versus 
EDTA-whole blood cultures
3.1 Introduction
According to the WHO, whole blood is “a venous, arterial or capillary blood sample in 
which the concentrations and properties of cellular and extra-cellular constituents remain 
relatively unaltered when compared with their in-vivo state” whilst anticoagulants are 
defined as “additives that inhibit blood and/or plasma from clotting ensuring that the 
constituent to be measured non-significantly changes prior to the analytical process” 
(WHO, 2002). Several types of anticoagulants are available using different mechanisms, 
Ethylene Diamine Tetra Acetate (EDTA) and citrate work by binding calcium ions, and the 
heparinates work by inhibiting thrombin activity. Stimulated whole blood collected in EDTA 
tubes produce very low cytokine responses compared to stimulated whole blood collected 
in heparin tubes using porcine blood cells (Duvigneau et al., 2007)
Calcium ions (Ca2+) function as a universal second messenger in virtually all eukaryotic 
cells including immune cells (Feske, 2007) and signals have been described in all cells of 
the immune system, contributing to activation, effector functions, gene expression and 
differentiation. Calcium ions are essential for T cell activation following cross-linking of the 
T cell receptor (TCR) (Premack & Gardner, 1992). Ca2+ influx must be maintained for at 
least an hour to drive cell activation events that lead to IL-2 expression after which T cell 
activation becomes antigen independent (Lewis, 2001). T cells deficient for Ca2+ influx 
have impaired IL-2 production and T-cell proliferation in vitro and defective T-Cell 
mediated immune responses in vivo due to the lack of TCR-mediated Ca2+ signals (Feske, 
2007).
Cryopreservation of Peripheral Blood mononuclear Cells (PBMCs) allows batch analysis
of donors at different time-points, thus reducing inter-assay variability. However,
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cryopreservation and thawing has been shown to differentially affect immune subsets. 
Proportions of CD4+ and CD8+ T cells, CD14+ monocytes, CD16+ NK Cells and CD20+ 
B cells do not change considerably (Allsopp & Nicholls, 1998), but na'i've T cells are highly 
susceptible to the freeze/thawing process (Kvarnstrom et a l , 2004) and functionality of T 
and NK cells is reduced (Fujiwara S, et al., 1986). Thus, analysis in fresh cells versus 
cryopreserved cells, and the type of anti-coagulant used will affect the downstream 
immune profiles generated and is an important consideration in any vaccine study.
Hypothesis:
• Blood collected in heparin tubes will have significantly greater cytokine responses 
following antigenic stimulation than blood collected in EDTA tubes.
• Cryopreserved PBMC from our study subjects will have better soluble cytokine 
levels (detected by Bioplex cytokine arrays) following antigen stimulation than 
supernatants stored from study subjects following stimulation of EDTA blood.
3.2 Aims
• To compare cytokine production after antigenic stimulation of whole blood 
collected in EDTA versus heparin to determine if there is a difference in activation 
with the different anti-coagulants.
• To determine if cryopreserved cells could be used in place of whole blood for 
soluble cytokine identification following antigen-stimulation compared to fresh 
PBMC, stored supernatants from EDTA blood (study subjects) and fresh whole 
blood.
3.3 Methods
3.3.1 Whole blood flow Cytometry
Venous blood from two adults was collected into EDTA and Heparin tubes. 200uL blood 
was stimulated with either PMA/lonomycin (positive control; Sigma, UK) to a final
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concentration of 0.1/1|jg/mL or media alone (negative control) overnight at 37°C, 5% C02. 
After the first two hours, Brefeldin A (BFA) (Sigma, UK) was added to a final concentration 
of 10ug/ mL to limit cytokine release from the Golgi complex. For flow cytometry analysis, 
cells were stained with previously titrated CD3 Pycoerythrin-Cy7, CD4 PerCP and CD8 
Pacific Blue (all from Becton-Dickinson, USA) for 30 minutes at room temperature (RT) in 
the dark. Red cells were lysed using 2mL of 1X FACS lysing buffer (Becton Dickinson, 
USA) for 10 minutes at RT in the dark. Following centrifugation at 1500rpm for 5 minutes, 
supernatant was removed and 1X Perm 2 Buffer (Becton Dickinson, USA) was added in 
order to permeabilise the cells. Tubes were incubated for 20 mins at RT, centrifuged at 
1800rpm for 5 minutes and supernatant removed. Cytokine antibodies were then added: 
IL-2 PE, TNF-a FITC and IFN-y APC (all from e bioscience, UK) and incubated for 30 
minutes at RT. Following washing, cells were resuspended in FACS buffer and acquired 
using a 9-colour CyanADP flow cytometer (Beckman-Coulter, USA) using Summit v.4.0 
software followed by analysis with FlowJo v.7.6.3 (Treestar, USA).
3.3.2 Cell culture conditions for the Luminex assay
Venous blood was collected from five adults into EDTA and Heparin vacutainers. 100 pi 
of whole blood was set up for three culture conditions: PMA/lonomycin, PPD (10pg/mL; 
SSI) and media alone (negative control). The remaining whole blood was layered on 
lymphoprep and PBMCs collected. After cell counting, 0.1 x106 PBMC per test were 
stimulated with the same culture conditions as above. Five PBMC samples cryopreserved 
previously from study subjects were thawed, counted and stimulated as above. Following 
overnight incubation at 37°C, 5% C02, 100pL of RPMI was added, supernatants 
harvested and stored at -20°C. Corresponding supernatants previously stored from EDTA 
stimulated cultures of study subjects were retrieved for comparison to fresh EDTA, fresh 
heparin, fresh PBMC and cryopreserved PBMC to determine the optimal stimulation 
conditions.
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3.3.3 Luminex cytokine assay
Samples were analysed using a customized Bioplex Pro cytokine kit (Bio-Rad, Belgium) 
as per manufacturer’s instructions (See Chapter 2) for IL-1p, IL-4, IL-10, IFN-y, TNF-a and 
IL-12p70. Plates were read using the Bioplex 200 system, Luminex x-map technology and 
bio-plex pro software version 4.0 (Bio-Rad, Belgium).
3.3.4 Statistical analysis
No statistical analysis was done for the flow cytometry data as data were generated from 
a small number of subjects for optimization only. A non-parametric Mann-Whitney U test 
was used to analyze for differences within groups for the Luminex assay. A p-value of 
<0.05 was considered significant.
3.4 Results
3.4.1 Whole blood collected in heparin tubes had a higher frequency of lymphocytes and 
cytokines than whole blood collected in EDTA tubes.
Differences were evident in the PMA/lonomycin stimulated samples when the lymphocyte 
population was analysed (Fig 3-1), these differences might be due to the effect of EDTA 
interaction with PMA/ionomycin stimulation, as PMA/lonomycin is a calcium ionophore 
and EDTA is a chelating agent. No differences were found in terms of cytokine production 
between the unstimulated samples (Fig 3-2). Heparin collected samples had almost twice 
as many lymphocytes as the EDTA collected samples. Importantly, the frequencies of all 
three cytokines (IFN-y, IL-2 and TNF-a) were virtually undetectable in the stimulated 
EDTA blood but were present in high levels in the heparinised samples for both CD4 and 
CD8 T cells (Fig 3-3 and 3-4).
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Figure 3-1: Lymphocyte population from PMA stimulated samples. A) EDTA 
collected sample B) Heparin collected sample; Heparin collected tubes produced 
twice the amount of lymphocytes than EDTA collected tubes. Gates indicate 
represent lymphocyte population as shown by the arrows, higher lymphocyte 
population in PMA/ionomycin stimulation probably due to overstimulation of these 
cells
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Figure 3-2: Cytokine responses from unstimulated EDTA samples (A and B) and Heparin 
collected samples (C and D); A and C, there was no difference in the IL-2 population from 
samples collected from both tube types; B and D, IFNy and TNFa responses were not different 
between samples collected from both types of tubes. Plots are representative of the two 
individuals used for optimizations.
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Figure 3-3: Cytokine responses generated by CD4 T cells in response to PMA/ionomycin in the 
same individual: A and B) responses from EDTA sample; C and D) responses from Heparinised 
samples; A and C) IL-2 responses were much higher in the heparin collected samples than EDTA 
collected samples, B and D) TNFa and IFNy were much higher in the heparinised samples than the 
EDTA samples
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Figure 3-4:CD8 T cell cytokine response after PMA/ionomycin stimulation: A and B) EDTA samples did 
not produce a lot cytokines; whilst C and D) Heparin collected tubes produced as much as 10 times 
more cytokines than the EDTA samples . These differences might have been due to the effect of 
lonomycin and EDTA on Calcium ions
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3.4.2 PPD-induced cytokine responses higher in supernatants from fresh PBMCs 
than EDTA whole blood.
Since all blood samples were collected in EDTA as per the original study design, we could 
not use the whole blood stimulated samples for cytokine analysis. However, we had 
PBMCs stored for most of the study subjects (and thus EDTA washed off during the 
PBMC separation procedure). Thus, we next wanted to compare our PBMC supernatant 
responses with the frozen supernatants obtained from antigen-stimulated whole EDTA- 
blood (previously collected from the study subjects) to determine whether frozen PBMC 
would respond well to stimulation. These were compared to fresh PBMC. Responses to 
PMA/lonomycin were highest amongst fresh cells and thawed cells with very little or no 
response seen from EDTA samples (Fig. 3-5). Stimulation with PPD induced significantly 
higher levels of IL-1 in heparinised blood from adults or frozen PBMC from the study 
subjects (p=0.0055; Fig. 3-6a). IL-10 (Th2/regulatory cytokine) levels were highest in 
heparinised samples and comparable for thawed and fresh cells (p-value 0.0079; Fig 3-6b 
ii), IL-4 production was more abundant in PBMC than whole blood stimulated cultures 
(Fig. 3-6b i). Cytokine responses were significantly higher from thawed cells compared to 
EDTA-cultures, particularly for TNF-a and IL-10 (Fig 3-6c ii). These results indicate that 
frozen PBMC, whilst not as optimal as fresh cells, would still provide strong cytokine 
responses following stimulation with our antigens of interest and were significantly better 
than our stored EDTA-blood samples. Despite the fact that IFNy levels after PMA 
stimulation were low the PPD levels were quite normal, suggesting a detrimental effect of 
PMA stimulation on cryopreserved cells probably due to high polyclonal stimulation of the 
already attenuated cells.
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Figure 3-6: PPD induced cytokine production from different cell types collected from 
adults and infants, whole blood from EDTA and Heparin tubes were cultured overnight 
together with Fresh PBMCs collected from healthy adult donors, and cryopreserved cells 
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supernatants previously stored from study subjects after whole blood overnight cultures 
a) innate cytokine production b) Th2 cytokine production c) Th1 cytokine production; 
black- supernatants from adults; peach- supernatants from infants; Kruskal-Wallis test 
was used to analyze data generated. * P-value <0.05; ** p-value <0.01
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3.5 Discussion
The original study design for this project involved collecting blood from study subjects into 
EDTA vacutainers followed by overnight stimulation with specific and non-specific 
antigens. Stimulated cultures were stored at -70°C (for ICS) or -20°C (for Luminex) prior to 
analysis. However, we soon discovered that EDTA is a chelating agent in addition to its 
anticoagulation properties and therefore is not recommended for whole blood stimulation 
assays. We therefore needed to determine if cryopreserved cells taken from the same 
subjects could be used instead. Importantly, we were able to show that cryopreserved 
cells can be used for stimulation experiments, inducing high levels of cytokines in 
response to stimulation. Furthermore it also meant we could control for inter-assay 
variability by allowing us to assay study subjects with blood samples from each visit 
simultaneously.
Ca2+ has been shown to play an important role in T cell signalling before antigen 
independent signalling begins (Feske, 2007). We showed that stimulated whole blood 
collected in heparin tubes had a better cytokine response than whole blood collected in 
EDTA tubes. EDTA works by inhibiting the Ca-flux thus resulting in impaired responses to 
antigen stimulation. We showed that 0.1x106 cells were sufficient to generate significant 
amounts of cytokines after stimulation. Thawed cells from study subjects produced higher 
amounts of cytokines compared to their EDTA-whole blood stimulated counterparts from 
the same subjects. Thawed cells were able to produce almost the same amount of 
cytokines as the fresh cells even though they were from different populations (adults and 
infants) that are at completely different stages of immune development.
Heparinised samples produced more cytokines in response to PPD than their EDTA 
counterparts from the same subjects, in concurrence with the results from the flow 
cytometric data. Heparinised whole blood samples collected from adults were the only 
ones that showed production of IFN-y in response to PPD, although some response could 
be seen from the fresh cells collected from adults these were lower in the thawed cells
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collected from the infants. An explanation for this might be that the whole blood samples 
contain a diverse milieu of cell types some of which are capable of producing IFN-y 
responses and the PBMCs contain predominantly lymphocytes, thus production from one 
type of cell would be expected to be lower than in a sample with a mix of cells. PPD 
induced cytokine production was assessed and this response may be affected by BCG 
vaccination and also exposure to non-tuberculous mycobacteria (NTM). This might be 
responsible for the high cytokine responses in heparin collected samples and fresh 
PBMCs for some of the cytokines as adults were not only exposed but have also been 
BCG-vaccinated.
In conclusion, we demonstrated significant cytokine responses using cryopreserved cells, 
thus allowing the study to continue with this modification. For future studies we 
determined that down-stream analysis of cytokine in supernatants and by ICS cannot be 
done using EDTA samples.
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Chapter 4: Analysis of soluble cytokine profiles induced by BCG 
vaccination
4.1 Introduction
Bacillus Calmette-Guerin (BCG) vaccination induces protection against childhood TB as 
well as heterologous protection against unrelated pathogens such as Candida albicans 
and Staphylococcus aureus and regression of bladder cancer (Alexandroff et al., 1999; 
Kleinnijenhuis et al., 2012). Protective correlates of BCG vaccination remain largely 
unknown hence immunogenicity based on the induction of cytokines, particularly IFN-y, is 
commonly used as a measure of vaccine efficacy. This chapter describes mycobacterium- 
specific and heterologous responses induced by BCG using longitudinal analysis of 
multiplex cytokine profiles in plasma and antigen-stimulated culture supernatants of 
vaccinated and unvaccinated infants. The overall aim of this work was therefore provide 
further insight into mycobacterial and non-mycobacterial protective immunity induced by 
BCG.
4.1.1 Induction of an innate immune response after BCG vaccination
The innate immune system is diverse and comprises a variety of cells including NK cells,
neutrophils, macrophages and dendritic cells. It is critical at every stage of human
development as it provides rapid protection against invading pathogens before the
generation of an adaptive immune response. Genetically conserved pattern recognition
receptors (PRRs) such as Toll-Like receptors (TLRs) recognise pathogen associated
molecular patterns (PAMPs) and are essential for microbial recognition by macrophages
and dendritic cells (Medzhitov & Janeway, 1997; Medzhitov et al., 1997). PRR signaling
induces proinflammatory cytokine and chemokine production, phagocyte recruitment,
complement activation and APC mobilization (West, Koblansky, & Ghosh, 2006). The
importance of TLR ligands in the immune response to bacteria was shown by the use of
TLR ligands as adjuvants in vaccination of mice, resulting in much better induction of Th1
responses (Iwasaki & Medzhitov, 2004). In addition, mice deficient in Myeloid
Differentiation 88 (MyD88) were inefficient in Th1 differentiation but instead generated Th2
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responses (Schnare et al., 2001;Kaisho et al., 2002). Age-dependent differences in 
responses to TLR stimulation have been observed in humans with an early bias toward 
Th2-polarising cytokines leaving the neonate susceptible to microbial infections and 
contributing to vaccine response impairment (reviewed by Levy, 2007; Belderbos et al., 
2009; Burl et al., 2011). BCG vaccination at birth has been shown to induce high levels of 
Th1 cytokines such as IFN-y (Marchant et al., 1999; Ota et al., 2002; Vekemans et al., 
2001), thus altering the balance between the Th1 and Th2 responses and possibly 
preventing allergy development down the line. One aim of this chapter was to determine if 
TLR ligands could induce differential cytokine profiles in vaccinated compared to 
unvaccinated infants.
4.1.2 Role of adaptive cytokines in BCG immunogenicity
Cytokines are cell signaling molecules that regulate different immune cell functions such 
as proliferation, apoptosis and antibody production, as well as stimulating cell recruitment 
to sites of inflammation, infection and trauma. Cytokines are important in the 
differentiation of naive T cells into different cell subsets: IL-12 drives T helper (Th)1 
differentiation whilst IL-4 drives Th2 differentiation (Akira, Takeda, & Kaisho, 2001); IL-10 
and IL-13 together with IL-4 activate B cells, whilst IFN-y activates the cytotoxic T cell 
pathway (Dinarello, 2000) and innate cells (Soudja et al., 2014). Several studies have 
demonstrated the induction of robust IFN-y, IL2 and TNF-a responses after BCG 
vaccination (Marchant et al., 1999; Vekemans et al., 2001; Ota et al., 2002; Burl et al., 
2010; Kleinnijenhuis et al., 2012), while Th2 cytokines, although produced after 
vaccination, are induced at a much lower magnitude (Ota et al., 2002; Soares et al., 
2008). IL-17 has also been shown to be induced in neonates after BCG vaccination (Burl 
et al., 2010; Kagina et al., 2010; Li et al., 2012). Despite all these effects, immune 
correlates of protection against TB are yet to be properly defined.
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4.1.3 Heterologous and sex differential effects of BCG against unrelated pathogens 
and diseases
A meta-analysis of clinical trial data of the effects of BCG vaccination from the US and UK 
in the 1940s and 50s estimates a 25% reduction in mortality from diseases other than TB 
with a 95% Cl of 6-41% (Shann, 2010). Recent randomized trials in low-birth weight 
neonates indicated that BCG vaccination reduces neonatal mortality in this group by up to 
17% with a mortality rate ratio of 0.83 (0.63-1.08) (Aaby et al., 2011). BCG is being used 
in Brazil to protect household contacts of leprosy, which is caused by Mycobacterium 
leprae, a meta-analysis of experimental data has indicated that BCG vaccination offers an 
average of 26% protection against leprosy (95% Cl 14-37%) whilst observational studies 
suggest a 61% protective effect (95% Cl 51-70%) (Setia et al., 2006). A decrease in 
fungal burden in the kidney together with better survival rates was observed in BCG 
vaccinated mice after Candida albicans inoculation (Kleinnijenhuis et al., 2012). Apart 
from its effectiveness against other unrelated infectious pathogens/diseases; it has been 
shown to be effective in its use as a therapeutic against bladder cancer after repeated 
instillations in the bladder (Alexandroff et al., 1999). Interestingly, a lot of the effects of 
BCG vaccine appear to be sex-differential and this has also been shown with other 
vaccines. For example, girls that received diphtheria, tetanus and pertussis (DTP) and 
hepatitis B vaccine virus HBV in rural Gambia had a much higher mortality rate when 
compared to males (Aaby, Jensen, & Walraven, 2006), while the BCG response was 
strongly related to survival (all-cause mortality) in girls when compared to boys in Guinea 
Bissau (Roth et al., 2006). Clearly there is a need for further investigation into the 
heterologous protective effects against non-mycobacterial infections, and sex-related 
differences in regards to the BCG vaccines. These data will help determine the optimal 
vaccine schedule and will enable health care workers to know the benefits of giving BCG 
alone or in combination with other vaccines.
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This chapter describes longitudinal changes in ex-vivo cytokine profiles in plasma and in 
vitro cryopreserved PBMC-stimulated culture supernatants in BCG-vaccinated compared 
to unvaccinated subjects. Responses to expanded programme on immunization (EPI) 
vaccine-specific and unrelated antigens were analyzed as well as to TLR agonists, to 
determine the impact of BCG vaccination on infant immunity and to increase our 
knowledge of protective markers induced by BCG.
Hypothesis:
• Infants vaccinated at 6 weeks would have higher cytokine immune responses to 
Toll-Like receptor agonists (naive responses) and heat killed unrelated pathogens 
(heterologous responses)
Aims:
• Examine longitudinal changes in ex-vivo and in vitro cryopreserved PBMC- 
stimulated culture supernatants in BCG vaccinated subjects compared to 
unvaccinated subjects
• Measure cytokine responses to mycobacterial antigens, EPI vaccine specific 
responses, as well as TLR agonists.
4.2 Methods
4.2.1 Overnight culture conditions
Peripheral Blood Mononuclear cells (PBMCs) were thawed and rested for 6 hours as 
described in Chapter 2. 100,000 cells were stimulated per condition for 10 different 
conditions in 100pL of culture medium overnight for 16 hours at 37°C 5%C02. The culture 
conditions were: medium only (negative control), PMA/ lonomycin (Positive control), 
Purified protein derivative (PPD) and Tetanus Toxoid (TT) (vaccine specific responses), 
Lipopolysaccharide (LPS, TLR4), Heat killed Listeria monocytogenes (HKLM, TLR2) and 
CLO-75 (TLR 7/8) (innate agonists) and heat killed unrelated pathogens (Candida 
albicans, Streptococcus pneumoniae, and Escherichia coli (kind gift of Mihai Netea,
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Radbound University Medical Centre, Nijmegen, Netherlands)). After the overnight 
stimulation, 100pL of culture medium was added; samples were spun at 3000 rpm for 10 
minutes, supernatants were collected and stored at -20°C.
4.2.2 Cytokine analysis via multiplex bead array
Samples were analyzed as described in Chapter 2. Briefly, 50pL of samples were added 
onto beads (diluted 1 in 2 with buffer) coupled with the cytokines of interest (IFN-y, TNF-a, 
IL-2, IL-4, IL-17, IL-10 and IL-12) and incubated for 30 mins. Biotinylated secondary 
antibody (diluted 1 in 2 with buffer) was added and another 30 minute incubation at room 
temperature done. Streptavidin-PE was added, samples incubated for 10 mins and results 
read on the Bioplex-200 systems using Bioplex manager v4.0 software (Bio-Rad, 
Belgium).
4.2.3 Statistical analysis
The Heat map was generated on excel after subtraction of negative median values from 
median values of antigen stimulated samples. Conditional formatting was then carried out 
based on percentiles, lower percentiles, mid percentiles and high percentiles. All statistical 
analysis was done using GraphPad Prism V6 following background subtraction. Mann- 
Whitney U test was carried out to test between two groups and Kruskal-Wallis test used to 
test between three groups. A p-value less than 0.035 was considered significant after 
adjusting for multiple comparisons (q-value).
4.3 Results
4.3.1 Ex-vivo plasma cytokine levels
The underlying cytokine milieu in BCG vaccinated compared to unvaccinated infants was 
determined by analyzing plasma cytokine levels. Type I cytokines (IL-2, IL-12 and IFN-y) 
were higher than Th2 cytokines in all subjects and increased over time in both groups (Fig 
4-1A-B), IL-4 levels increased steadily in both groups, whilst IL-10 increased significantly 
in the unvaccinated from 1 week post-vaccination to 12 week post-vaccination (Fig 4-1C)
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but did not increase in the vaccinated group. IL-17 levels however, decreased in both 
groups at 1 week post-vaccination and increased at 12 week post-vaccination (Fig 4-1 D). 
There were no differences observed between the two groups at any time point in terms of 
plasma cytokine levels.
70
pg
/m
l 
pg
/m
i
A B
IFNy
5000
4000
3000
2000
1000
500
400
300
200
100
O'
Group/visit
IL -1 0
1500
1000
500
200
150-
100 -
N
Group/visit
T N Fa
1300 -
800-
100 - -  
80- 
60- 
40 
20 H 
0
•• • •••
• • •  °  o a. •
^  *5* f, -^--
Group/visit
IL -17
300
250
200
150
100
50 
50-r
40
30
20
10
0
ogo
°o<PoOqO
H I-
"^ oXaoo .  *
VS*
Group/visit
Figure 4-1: Ex-vivo cytokine levels in plasma of BCG vaccinated and unvaccinated infants. 
BCG vaccinated and naive subjects had variable Th1, Th2 and Th17 cytokine levels at 0 
(pre-vaccination/ 6 weeks), 1 (1-week post-vaccination/7 weeks) and 12 (12 weeks post­
vaccination/18 weeks). Closed purple circles represent unvaccinated and open red circles 
represent the vaccinated group. *- q value <0.035, **- p< 0.01, ***p< 0.0001.
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4.3.2 Cytokine production after antigenic stimulation
4.3.2.1 Global responses
A heat map was generated in order to obtain a global picture of cytokine profiles (Fig 4-2). 
Median levels of IL-2, IL-4 and IL-12 were relatively low (blue) following all stimulations, 
while TNF-a, IFN-y and IL-10 were relatively high (red). There appeared to be little or no 
reactivity to TT and reactivity to PPD (used as a marker of BCG vaccine-related 
responses) induced surprisingly low levels of IL-10 and IFN-y even in the vaccinated 
group. When the fold-change for each cytokine was analyzed at the different time-points, 
the BCG-vaccinated group had higher Th1 increases than the unvaccinated group after 
PPD stimulation (IFN-y: 1 week post-vaccination -12 weeks post-vaccination = 5 fold and 
2-fold respectively; TNF-a: baseline-12 weeks post-vaccination = 25 fold and 7-fold 
respectively). In contrast, but in-line with our data discussed in the previous section, the 
unvaccinated group had higher IL-10 fold changes (74-fold compared to 5-fold for the 
vaccinated group). In response to TLR agonist stimulation there was a general decrease 
in all cytokine levels at 1 week post-vaccination but an increase again by 12 weeks post­
vaccination in the vaccinated, whilst an increase at 1 week post-vaccination was observed 
in the unvaccinated but this decreased at 12 weeks post-vaccination. Heat killed S. 
pneumoniae and E. coli also produced IFN-y, TNF-a and IL-10 responses, with higher 
IFN-y and TNF-a in the unvaccinated infants, and the vaccinated group had lower IL-10 
responses. Background values were high for IFN-y and TNF-a suggesting spontaneous 
production, most likely from innate cells.
72
BCG-Unvaccinated BCG-vaccinated at 6-weeks
Antigen IL-2 IL-4 IL-10 IL-12p70 IL-17 IFN-v TNF-a■   — IL-4 IL-10 IL-12p70 IL-17 IFN-y TNF-a
159 2603
195 2927
235 2943 7
rjm m wClo-75
n J H H H I  24 7 6 l
94 1 _ 49 *47
143 1373
103 1432
Low High
Analyte levels
Figure 4-2:Heat map showing median levels after background subtraction for various 
stimulations of cryopreserved PBMCs, conditional formatting was conducted based on 
percentile with blue being low percentile, white mid percentile and red high percentile 
separately for each stimulus. Baseline (6 weeks/ pre-vaccination), 7 weeks/ 1 week post­
vaccination, 18 weeks/12 weeks post-vaccination, data is representative of all study subjects.
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4.3.2.3 Cytokine production in response to a polyclonal stimulator is not affected by 
BCG vaccination
Following PMA/lonomycin stimulation, Th1 and Th17 cytokine responses were higher than 
anti-inflammatory responses, and levels were comparable between the vaccine groups 
indicating that any observed differences in response to specific antigens was not due to 
differences in the ability of subjects to respond to mitogenic stimulation (Fig 4-3). We did 
have some subjects that had low responses to PMA, this might be due to an effect of too 
much polyclonal expansion on already weakened/ attenuated cells, and despite this we 
did see responses to PPD.
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Figure 4-3: Cytokine responses after polyclonal (PMA/lono) stimulation. Red open circles 
represent vaccinated group, closed purple circles represent the unvaccinated group, 0 (pre­
vaccination/6 weeks), 1 (1 week post-vaccination/7 weeks) and 12 (12 weeks post-vaccination/18 
weeks).The no. of subjects at the different time points were, time point (time since vaccination/age 
of infant)no. of subjects-vaccinated, unvaccinated: 0( baseline/ 6 weeks)-34 vaccinated subjects,41 
unvaccinated infants; 1(1 week post vaccination/ 7 weeks)37 vaccinated, 40 unvaccinated; 12 (12 
weeks post-vaccination/18 weeks)23 vaccinated, 30 unvaccinated subjects.
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4.3.2.4 Differential cytokine profiles in response to BCG -specific antigens
In order to measure vaccine-specific responses we used responses following stimulation 
with PPD as a surrogate for responses to BCG. Th1 cytokine production in PPD cultures 
was similar in both groups despite the unvaccinated group not yet receiving BCG. IL-2 
and IL-12 were low at all time-points while IFN-y and TNF-a responses were higher 
generally, but not significantly different between vaccine groups. Median IL-4 levels 
remained low at all time-points in both groups, while IL-10 levels steadily increased over 
time in the unvaccinated group. IL10 levels in the vaccinated group decreased at 1-week 
post-vaccination but increased again by week post-vaccination and the Th1/Th2 ratio was 
highest at this time point. Despite the low median values observed, there was a clear cut 
distinction between responders (R) and non-responders (NR) in both vaccine groups in 
terms of cytokine production over time (Fig 4-4); however, there were no differences 
between the proportions of responders between the groups at any time-point using chi- 
square analysis.
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Figure 4-4: Cytokine responses after vaccine specific PPD antigen stimulation. Red 
open circles represent vaccinated, closed purple circles represent the unvaccinated, 0(6 
weeks/ Pre-vaccination), 1 (7 w eeks /1 week post-vaccination), 12 (18 w e e ks /12 weeks 
post-vaccination). Similar cytokine responses observed between the groups at the 
various time points. Mann Whitney U test was used to assess for differences between 
two groups and Kruskal Wallis test used to compare across three time points. The no. of 
subjects at the different time points were, time point (time since vaccination/age of 
infant) no. of subjects-vaccinated, unvaccinated: 0(baseline/ 6 weeks)-43 vaccinated 
subjects, 49 unvaccinated infants; 1(1 week post vaccination/7 weeks) 43 vaccinated, 
47 unvaccinated; 12 (12 weeks post-vaccination/ 18 weeks) 24 vaccinated, 30 
unvaccinated subjects.
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4.3.2.5 Differential responses to TLR agonists with BCG vaccination
TLR agonists were used to measure innate immune responses, which may be useful for 
future vaccine development if they could be used as vaccine adjuvants. One of the 
interesting findings was the increase in IL-12 levels in the unvaccjnated group in HKLM 
cultures (p=0.015) (Fig 4-5A). In addition, IL-17 levels were also higher in the 
unvaccinated group at 1 week post-vaccination compared to the vaccinated and 
responses were significantly higher after HKLM stimulation compared to the vaccinated 
infants (median (IQR): vaccinated=Opg/mL (0-206); unvaccinated=34pg/mL (0-424); 
p=0.0060) (Fig 4-5 B).
The same trends were observed for both Th1 and Th2 cytokine responses: the responses 
within the unvaccinated group were generally increased at 1 week post-vaccination and 
decreased again at 12 week post-vaccination , whilst the opposite was observed in the 
vaccinated group, with the early post-vaccination time-point (1 week post-vaccination) 
delineating the biggest differences between the groups as expected. For example there 
was significantly lower IL10 in the vaccinated group compared to the unvaccinated at 1 
week post-vaccination after stimulation with CLO-75 (median (IQR): unvaccinated 
174pg/mL (0-764), vaccinated 12pg/mL (0-855); p=0.0034) (Fig 4-5C); HKLM (median 
(IQR): unvaccinated 207pg/mL (0-1128), vaccinated=12pg/mL (0-843); p=0.0014) and 
LPS (median (IQR): unvaccinated 247pg/mL (0-1052), vaccinated=20pg/mL (0-951); 
p=0.0045) (Fig4-5D). Interestingly, IFN-y after CLO-75 stimulation (p=0.0166), HKLM 
(p=0.0171) and LPS (p=0.0334) stimulations also significantly lower in the vaccinated 
group.
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Figure 4-5: Cytokine production in response to TLR agonist stimulation in vitro. Red open circles 
represent vaccinated infants, closed purple circles represent the unvaccinated, 0 (6 weeks/ Pre­
vaccination), 1 (7 weeks/ 1 week post-vaccination), 12(18 weeks/ 12 weeks post-vaccination). 
Higher cytokine production to agonists observed in the unvaccinated at 1 week post-vaccination. 
Mann Whitney U test was used to assess for differences across two groups and Kruskal Wallis test 
used to compare across three time points. The no. of subjects at the different time points were, 
time point (time since vaccination/age of infant) no. of subjects-vaccinated, unvaccinated: 
0(baseline/ 6 weeks)-28 vaccinated subjects, 38 unvaccinated infants; 1(1 week post vaccination/7 
weeks) 35 vaccinated, 38 unvaccinated; 12 (12 weeks post-vaccination/18 weeks) 22 vaccinated, 
30 unvaccinated subjects.
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4.2.2.6 Lower IL-10 reactivity to unrelated pathogens in BCG-vaccinated infants
We hypothesized that BCG vaccination may enhance responses to unrelated common 
pathogens; hence we measured cytokine production after stimulation of PBMCs with heat 
killed Streptococcus pneumoniae (SP), Candida albicans (CA) and Escherichia coli (E co). 
There were very few differences seen between the groups with the most striking 
difference being lower IL-10 levels in the vaccinated compared to unvaccinated group 
after E co stimulation at 1 week post-vaccination (median (IQR): 221pg/mL (0-1367) 
compared to 11pg/mL (0-1522) in the vaccinated group; p=0.0185) (Fig 4-6A). TNF-a, 
IL12, IFN-y and IL17 showed some differences depending on the vaccine group and time- 
point but none were significantly different (Fig 4-6B-C).
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Figure 4-6: Cytokine production after stimulation with heterologous antigens. Red open 
circles represent vaccinated infants, closed purple circles represent the unvaccinated, 0 
(6 weeks/ Pre-vaccination), 1 (7 weeks/ 1 week post-vaccination), 12 (18 weeks/ 12 
weeks post-vaccination). Similar responses were observed between the two groups, the 
unvaccinated had higher IL-10 levels post vaccination after E. coli stimulation. Mann 
Whitney U test was used to assess for differences between two groups and Kruskal 
Wallis test used across three time points. The no. of subjects at the different time points 
were, time point (time since vaccination/age of infant) no. of subjects-vaccinated, 
unvaccinated: 0(baseline/6 weeks)-31 vaccinated subjects, 36 unvaccinated infants; 1(1 
week post vaccination/7 weeks)33 vaccinated, 35 unvaccinated; 12 (12 weeks post­
vaccination/18 weeks)20 vaccinated, 25unvaccinated subjects.
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4.3.2 Vaccinated females had lower IL-10 levels compared to unvaccinated females 
after unrelated pathogen and TLR agonist stimulation
It has been shown that responses to vaccines may be gender-dependent, thus all 
responses were analyzed based on gender in our study groups. No differences were seen 
after PPD stimulation, but after stimulation with E coli and SP, lower IL-10 levels were 
seen in the vaccinated compared to unvaccinated females (Fig 4-7A); E coli (vaccinated 
2.4(0-1162) pg/mL; unvaccinated 249.4(0-1367) pg/mL; p=0.005) and SP (vaccinated 
0.07(0-603.7) pg/mL; unvaccinated -102.2 (0-910.3) pg/mL; p=0.02). No differences were 
observed in the males for E co or SP responses (Fig 4-7B). However, IL-10 levels in 
males were significantly lower in the vaccinated compared to unvaccinated group after 
CLO-75 stimulation (vaccinated 23(0-232) pg/mL; unvaccinated 159(0-764) pg/mL; p= 
0.04; Fig. 4-7D). This difference was seen in females in response to all TLR agonists: 
vaccinated group: LPS, 14 pg/mL (0-951); HKLM, 7(0-843) and CLO-75, 5(0-855)pg/mL 
compared to unvaccinated: LPS, 287(0-660) p=0.03), HKLM , 234(0-665) p=0.03) and 
CLO-75 ( 240(0-708); p=0.04; Fig. 4-7C).
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Figure 4-7: Differences between vaccinated ( group 1) and unvaccinated ( group 2) 
based on gender 1 week post vaccination: a) no differences were observed between 
males of the groups after unrelated pathogen stim ulation^5 were from the 
vaccinated, 19 were from the unvaccinated ; b) vaccinated females had lower IL-10 
levels after unrelated pathogen stimulation; 18 subjects from the vaccinated group 
and 17 from the unvaccinated group; c) vaccinated males had lower IL-10 levels to 
TLR7/8 agonist only; 20 from the vaccinated and 18 from the unvaccinated group; d) 
vaccinated females had lower IL-10 levels to TLR 2, 4 and 7/8 agonists compared to 
their unvaccinated counterparts; 22 from the vaccinated group and 20 from the 
unvaccinated group.
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4.4 Discussion
BCG is given together with OPV as part of the EPI vaccine schedule to Gambian children 
as recommended by WHO. Despite evidence that BCG might have heterologous benefits 
as well as protection against childhood TB, little is known about the immunological 
mechanisms.
It has been shown that neonates have an impaired Th1 response (Angelone et al., 2006; 
Philbin & Levy, 2009; Prabhudas et al., 2011; Cuenca et al., 2013). In this regard, the 
BCG-unvaccinated infants in our study had increasing Th2 cytokine levels over time 
whereas the vaccinated infants had no increase, suggesting a possible bias towards Th2 
levels in the unvaccinated group. A decrease in plasma IFN-y levels one-week post 
vaccination goes against the modus operandi of BCG vaccination in inducing IFN-y 
(Marchant et al., 1999; Vekemans et al., 2001; Ota et al., 2002; Hanekom, 2005) however, 
these previous studies measured cytokine levels in supernatant after antigen stimulation 
as opposed to the unstimulated cytokine levels . The increase in IL-10 especially at 12 
weeks post-vaccination in the unvaccinated and not in the BCG-vaccinated group could 
be due to the effects of an innate Th2-type bias caused by hepatitis B and DTP vaccines 
(received by both groups of infants) which is opposed and balanced by the prior Th1 
enhancing BCG in the vaccinated group (Ota et al., 2002; reviewed in Marchant & 
Goldman, 2005).
Clearly the underlying cytokine milieu in the different vaccine study subjects will influence 
the antigen-specific responses we observed, however no difference in response to the 
positive control stimulus (PMA/lonomycin) was observed between the groups suggesting 
that both groups of infants were equally able to respond to mitogenic stimulation. This 
shows that differences in the antigen-induced responses were probably due to vaccine- 
related effects.
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In vitro stimulation with the BCG recall antigen PPD induced Th1 type responses, which 
were comparable between the groups suggesting no influence of BCG vaccination on the 
skewing of vaccine-specific immunity, which is in contrast to a number of studies from 
The Gambia (Ota et al., 2002; Burl et al., 2010) and elsewhere. The low responses 
following PPD stimulation might be due to the fact that we did an overnight stimulation 
which would mostly be measuring innate responses and the use of cryopreserved PBMCs 
as neonate PBMCs tend to be highly attenuated when cryopreserved, Burl and colleagues 
measured levels after 5-days culture in whole blood and had a much more robust 
response (Burl et al., 2010). Despite this, fold changes in Th1 cytokines from pre­
vaccination levels were much higher in the vaccinated than the unvaccinated subjects 
whilst the unvaccinated had higher IL-10 fold changes. These results further support a 
skewing of infant immunity to Th2 that is altered with BCG vaccination, but perhaps due to 
our small sample size this was not significant.
The innate immune response is crucial for the activation of antigen presenting cells and 
induction of adaptive immunity. PRRs are integral to this with TLRs being among the most 
important activators of APCs. BCG has been shown to have both TLR2 and TLR4 agonist 
activity (Tsuji et al., 2000; Akira et al., 2001; Uehori et al., 2003). In regards to TLR 
agonist stimulation, we found no enhancement following BCG vaccination; the 
unvaccinated had higher cytokine levels than the vaccinated group at one week post 
vaccination. In contrast, a previous cross-sectional study in Gambian infants observed an 
increase in pro-inflammatory cytokine levels from birth when compared to later age- 
groups up to one year of age, whilst acute phase cytokines (IL-1(3 and IL-6) and IL-10 
decreased over time, these changes were more prominent in the first week of life (Sarah 
Burl et al., 2011). This effect was not found in our study, as cytokine levels over time were 
quite similar regardless of vaccination status.
We measured the effect of BCG vaccination on cytokine production after heterologous 
pathogen stimulation but did not find any effect of BCG-vaccination, despite the fact that
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BCG vaccination in mice protected against candidiasis and enhanced pro-inflammatory 
responses to heat killed pathogens in BCG vaccinated adults (Kleinnijenhuis et al., 2012). 
We found similar proinflammatory cytokine levels in both groups, and higher IL-10 
production after E coli stimulation in the unvaccinated group at 7 and 18 weeks, 
suggesting that the BCG naive subjects had a skew towards an immunosuppressive 
response. One explanation might be the differences in vaccine strains used, since we 
used the Russian strain from India a much more attenuated strain while the Kleinnijenhuis 
study used BCG Copenhagen.
Several studies have found differences in inflammatory and antibody responses between 
males and females (Moxley et al., 2002; Casimir et al., 2010), however we did not find any 
differences in pro-inflammatory levels between the males and females after the various 
stimulations. Interestingly however, we found higher IL-10 (anti-inflammatory) levels in 
females in the unvaccinated compared to the vaccinated group in response to TLR 
agonists and whole killed pathogens. The observed lower IL-10 responses in the 
vaccinated females’ points to an effect of BCG in modulating the production of this anti­
inflammatory cytokine in response to non-vaccine related stimuli. Less IL-10 might lead to 
less immunoregulation and thus greater pathogen clearance. The lack of the same effect 
in males supports the long-asserted sex differences in heterologous effects of vaccines.
In conclusion, we found low plasma cytokine levels and little cytokine production to PPD 
and TT. Innate pro-inflammatory responses were more pronounced in the unvaccinated 
group, and the BCG vaccinated group had lower production of IL-10 to TLR agonists and 
unrelated pathogen stimulation when compared to their unvaccinated counterparts. This 
effect was more prominent in females. These findings therefore support the notion of sex- 
differential heterologous effects of BCG on innate immunity.
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Chapter 5: Characterization of cytokine producing cells by flow cytometry
5.1 Introduction
5.1.1 The adaptive immune response to Bacillus Calmette Guerin (BCG)
Limitations in the development of the neonatal immune response places neonates at a 
much higher risk of infections compared to the adults, and vaccine responses may be 
poorer than in adults. Therefore vaccinations are essential in early-life to help boost the 
immune response to invading pathogens. BCG, used to protect infants against pulmonary 
TB, has been shown to induce two types of immune response: the classical antigen 
specific T cell response and an innate immune response based on functional 
reprogramming of the innate immune cells. Dubbed ‘trained immunity’, innate cells such 
as monocytes are provided with characteristics of cells of adaptive immunity i.e. innate 
cells exhibit memory characteristics (heightened response) to secondary infection, exerted 
both towards the same or different (cross-protection) pathogens (Netea et al., 2011; 
Kleinnijenhuis et al., 2012) . BCG vaccination induces different phenotypes of vaccine 
specific CD4 and CD8 T cells with the ability to produce both pro- and anti-inflammatory 
cytokines (Marchant et al. 1999; Hussey et al. 2002; Murray et al. 2006; Soares et al. 
2008; Burl et al. 2010; Li et al. 2012). Long lived memory B cells have also been 
suggested to be induced after BCG vaccination in healthy adults (Sebina et al ., 2012). 
This array of responses induced after BCG vaccination contrasts with the theory that the 
infant immune response is “immature”. Despite the induction of Th1 responses, it has 
been shown that IFN-y production alone is not effective in imparting immunity needed for 
protection against TB (reviewed by Abebe, 2012). Since the measurement of a single 
cytokine at a time is believed to underestimate not only the complexity but magnitude of 
induced immunity, most recent studies carry out polyfunctional cytokine analysis as a 
better indication of mycobacterial induced immunity, however this is not correlated to 
protection (Kagina et al., 2010). This allows us to identify cells secreting more than one 
cytokine simultaneously. Vaccination at birth has been shown to elicit both CD4+ and 
CD8+ polyfunctional cells in 10 week old South African infants (Soares et al., 2008), 
whilst another study by the same group observed that CD4 T cells were more likely to be
polyfunctional in infants that had BCG at 10 weeks when compared to those that were 
vaccinated at birth (Kagina et al. 2009). A cross-sectional study of 9 month old Ugandan 
infants observed that infants vaccinated at birth had not only higher BCG-specific IFN-y 
alone, but also higher frequencies of T cells co-expressing IFN-y, IL-2 and TNFa when 
compared to infants vaccinated at 6 weeks of age (Lutwama et al., 2013).
In the previous chapter we found differential cytokine patterns following stimulation of 
BCG-vaccinated compared to unvaccinated infants with different antigens, including TLR 
agonists. However, we could not determine the source of the cytokines in these assays.. 
Thus we investigate the phenotype of cells producing cytokines after overnight stimulation 
with vaccine specific and non-related antigens using intracellular cytokine staining by flow 
cytometry in this chapter. No gender-based differences were analyzed in this chapter due 
to a disparity in numbers.
Hypothesis:
• Infants vaccinated with BCG at 6 weeks of age would have higher cytokine 
responses from different cell subtypes after mycobacterial and unrelated 
pathogens stimulation compared to BCG naive infants
• Infants vaccinated with BCG at 6 weeks would have higher polyfunctional cytokine 
responses from different cell subsets after mycobacterial and unrelated pathogen 
stimulation compared to BCG naive infants.
Aims:
• Investigate cell phenotypes producing cytokines in stimulated cryopreserved 
PBMCs from BCG vaccinated and naive infants
• Investigate polyfunctionality of these cell phenotypes after stimulation with vaccine 
specific and non-specific antigens.
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5.2 Methods
5.2.1 Study population and sample characteristics
142 pregnant mothers were sensitized about the study and 137 consented to take part in 
the study. 131 infants were bled at 6 weeks, of these 66 were randomized into group 1 
(vaccinated) whilst the rest were randomized into group 2 (delayed/unvaccinated); 66 
were females and 71 were males. 105 infants completed the study (53 in vaccinated 
group, 52 in the unvaccinated group). After cryopreservation of peripheral blood 
mononuclear cells (PBMCs), only samples with a viability of at least 60% were included 
due to a limitation in cell numbers as well only 41 subjects with cells for all three time 
points were included in the final analysis, 15 were in the vaccinated group(10 males, 5 
females) whilst 26 were in the unvaccinated group (11 males, 15 females).
5.2.2 PBMC thawing, stimulation and staining
PBMCs were thawed at 37°C in a water bath (Section 2.4.3), resuspended in 10% Fetal 
Calf Serum (FCS) in RPMI plus a final concentration 25 units/mL of Benzonuclease 
(Sigma Aldrich. USA). Cells were washed twice with 10% FCS in RPMI, resuspended in 
10% FCS in RMPI plus Benzonuclease and rested for 6 hours at 37°C 5% C 0 2. 0.5 x 106 
cells were stimulated per antigen: a negative control (medium only), a positive control 
(PMA/lonomycin) PPD and TT (vaccine specific antigens), Esat-6/CFP-10 (Mtb specific 
antigen) and Streptococcus pneumoniae, Candida albicans and E. coli (Unrelated 
pathogens) as described in Chapter 2 (section 2.4.5.1 and 2.4.5.2). Cells were then 
incubated for 2 hours prior to the addition of Brefeldin A (10pg/mL), after which an 
overnight incubation (16-18 hours) at 37°C was carried out. After overnight stimulation, 
cells were washed and stained with Live/Dead Aqua yellow, incubated for 10 mins and 
surface markers (CD3, CD8) added. Cells were then incubated at room temperature for 
30 minutes in the dark after which they were fixed, permeabilised and stained for 
Intracellular cytokines (IFNy, TNFa, IL-2, IL-10 and IL-17). After 30 minutes incubation in 
the dark, the cells were washed, resuspended in FACS buffer and acquired using a 9- 
colour Cyan ADP (Beckman Coulter, USA).
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5.2.3 Statistical analysis
ICS data were analyzed using FlowJo v10.1 (Treestar, USA). Frequencies of cytokine 
expression in the negative control samples were subtracted from antigen specific 
responses. Boolean gating was carried for each pro-inflammatory cytokine to allow for 
combinatorial analysis. A total of fifteen distinct cytokine subsets were generated. 
Statistical analysis was done using GraphPad Prism V6 (GraphPad Software, Inc., La 
Jolla, USA). Mann-Whitney U test was used to compare between two groups and Kruskal- 
Wallis test was used to compare between three groups, a q-value of 0.04 was considered 
significant using a false discovery rate of 5%. Polyfunctional analysis was performed using 
the SPICE software (this software is provided free of charge by the National Institute of 
Allergy and Infectious Disease), using a false discovery rate of 5% a q-value of 0.035 was 
considered significant.
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5.3 Results
5.3.1 Phenotypic characterization of cytokine-producing cells by flow cytometry
Different cell phenotypes have been shown to be responsible for the induction of different 
cytokines during vaccine induced and natural immunity. We have previously shown 
patterns and amount of cytokine production to vaccine-specific and non-specific antigens 
(Chapter 4). The aim of this chapter was to determine the cell types producing these 
cytokines using flow cytometry. We used surface staining for T cell markers and 
intracellular cytokine analysis for proinflammatory cytokines (IFN-y, TNF-a, IL-2 and IL-17) 
and anti-inflammatory (IL-10). Because cryopreserved cells were used, cells with 
viabilities less than 60% were excluded from analysis. 41 subjects had flow cytometry 
data included in the final analyses: 15 BCG-vaccinated and 26 unvaccinated infants. We 
first gated on the lymphocyte population (Fig. 5-1 A), excluded doublets (Fig. 5-1B) and 
gated out the dead cells using live-dead viability stain (Fig. 5-1C). We were then able to 
gate on CD3+ and CD3- neg cells (used for innate cell analysis) (Fig. 5-1D). Within the 
CD3+ population we then gated on CD4+ and CD8+ T cells (Fig. 5-1E). Within each of 
these populations, all cytokines were then analyzed using Boolean gating (Fig. 5-1F).
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Figure 5-1: The gating strategy used in identifying cytokine producing CD4+, 
CD8+ and CD3- cell subsets. Lymphocytes were gated on first (A) before 
Doublet discrimination (B); viable cells were gated on by gating out live-dead 
positive cells(C). Non- T cells were gated on by gating by gating on CD3-neg 
cells (D), whilst CD8 and CD4+ cells were gated on the CD3+ population 
(E).Plots representative of all samples.
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5.3.2 Responses to a polyclonal stimulator (PMA-ionomycin (PMA-I))
Following overnight stimulation with PMA-I comparable proportions of pro-inflammatory 
cytokine producing cells were observed from all cell types analyzed (CD4+, CD8+ and 
non-T cells) and this was alike in both groups at all time-points, indicating similar capacity 
to respond regardless of vaccination status. This is also what was found with the multiplex 
cytokine analysis in Chapter 4. No difference in single-positive IL-10 or IL-17 producing T 
cells was seen between groups at any time-point. However, the proportion of CD3- neg 
IL10+ cells increased from 1 week post-vaccination to 12 weeks post-vaccination in the 
vaccinated group, (median (IQR): 1 week post-vaccination ,0.06 (0-1.50); 12 weeks post­
vaccination, 0.20(0.03-1.60); p=0.0040) and levels were higher in the vaccinated than the 
unvaccinated infants at 12 weeks post-vaccination (median (IQR): unvaccinated, 0.02(0- 
0.70); p=0.0022) (FIG 5-3B). The same trend was observed for IL-17 production from non- 
T cells (CD3-neg) increasing from 1 week post-vaccination to 12 weeks post-vaccination 
in the vaccinated group but this was not significant (median (IQR): 1 week post­
vaccination, 0.06(0-2.50); 12 weeks post-vaccination, 0.20(0.01-2.70); p= 0.0300) and the 
vaccinated infants had more CD3-neg cells producing IL-17 at 12 week post-vaccination 
compared to the unvaccinated group (median (IQR): unvaccinated, 0.06 (0-1.5); p=0.008) 
(Fig 5-3A).
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Figure 5-3: Cytokine production from the different cell phenotypes after PMA/lonomycin 
stimulation (A&B) the vaccinated group had increased CD3-neg expressing IL-10 from 1 to 12, 
and higher than the naive group at 2 and this was observed for IL-17 response as well. (C-F) 
No differences were observed from CD4 and CD8 T cell cytokine production between the 
groups from any of the groups. Open red circles represent the vaccinated, closed purple circle 
represent the unvaccinated; 0- 6 weeks/baseline; 1-7 weeks/ 1-week post vaccination; 12-18 
weeks/ 12 weeks post-vaccination. Data is representative of 26 unvaccinated subjects and 15 
vaccinated subjects at all time points.
5.3.3 Vaccine specific antigens elicit differential cell-specific cytokine production
Vaccine specific cytokine production was measured from the different cell phenotypes 
following stimulation with PPD as a marker of BCG vaccine induced responses and TT as 
the tetanus specific component from the DTP vaccine. We found surprisingly low cytokine 
production after PPD stimulation. However, while no difference in response from CD4+ T 
cells was observed (FIG 5-4 A & B) and we observed higher levels of CD8+ IFNy+ T cells, 
1 week post-vaccination in the vaccinated compared to the unvaccinated (p=0.04 ( border­
line significance)) (FIG 5-4 C).1 week post-vaccination CD3- neg (non-T) cell production 
of IL-17 increased a in the vaccinated group but decreased in the unvaccinated group, this 
was not significant (FIG 5-4E). A highly significant increase in TNF-a production from the 
CD3- neg cells at 1 week post-vaccination was observed in the vaccinated group 
compared to pre-vaccination levels and this was also significantly higher than the 
unvaccinated group (p=0.0002 and p<0.0001, respectively) (FIG 5-4F). However, these 
levels were not maintained with a significant decrease observed in the vaccinated group 
by 12 weeks post-vaccination (p<0.0001) (FIG 5-4F).
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Figure 5-4: Vaccine specific PPD responses from the different cell phenotypes. 
Red open circles represent the vaccinated , purple closed circles represent the 
unvaccinated; 0-baseline/ 6 weeks, 1-1 week post-vaccination/7 weeks, 12- 
12weeks post-vaccination/18 weeks. Data were analyzed using Mann Whitney U 
test, significant differences are indicated. Data is representative of 15 vaccinated 
subjects and 26 unvaccinated subjects
5.3.4 Cytokine responses following ESAT-6/CFP-10 stimulation
In order to measure infants’ sensitization to tuberculosis we measured cytokine responses 
using the Mycobacterium tuberculosis (Mtb) specific antigen ESAT-6/CFP-10, which is not 
present in BCG or environmental mycobacteria. Whilst very little cytokine reactivity was 
observed from CD4 and CD3- neg cells (Fig 5-5A-B, 5-5E-F), the vaccinated group had 
decreased CD8+IFN-y production from 1 week post-vaccination to 12 weeks post­
vaccination (p=0.002); Fig 5-5C).
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Figure 5-5: Cytokine production from cell phenotypes after Esat-6/CFP-10 
stimulation, red open circles represent the vaccinated group, purple closed circles 
represent the unvaccinated group; 0- 6 weeks/ pre-vaccination, 1-7 weeks/1 week 
post-vaccination, 12-18 weeks/12 weeks post-vaccination. Data was analyzed using 
Mann Whitney U test, significant differences are indicated. Data represents 18 
vaccinated subjects and 24 unvaccinated subjects.
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5.3.5 Cytokine production after non-specific pathogen stimulation
In response to fungal (C. albicans (CA)) antigen stimulation little cytokine production was 
observed from CD4 and CD3-neg cells. It is important to note that all data presented is 
following background subtraction so all results are specific for the antigen of interest, thus 
these findings indicate a definite responsiveness of cells in the vaccinated group to both 
vaccine-specific and non-specific antigens. An increase in CA-specific CD8+ IFN-y+ cells 
was seen in the vaccinated group at 1 week post vaccination compared to baseline ( 
p=0.02) and this decreased at 12 week post-vaccination (p=0.04). Despite the fact that IL- 
10 levels from the previous chapter were higher in the unvaccinated than the vaccinated 
in response to all three pathogens, we did not find any differences in IL-10 levels to any of 
the pathogens from CD4, CD8 and CD3-neg cells by flow cytometry (Fig 5-6).
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Figure 5-6: Cytokine production after unrelated pathogens stimulation at 0(6 weeks), 1 (7 
weeks/1 week-post vaccination) and 12 (18 weeks/12 weeks-post vaccination). Red open 
circles represent the vaccinated whilst the purple closed circles represent the unvaccinated 
group. Data represents 9 vaccinated subjects and 21 unvaccinated subjects.
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5.3.6 Polyfunctional cytokine responses
We next measured qualitative polyfunctional cytokine responses from CD4 and CD8 T 
cells. Boolean gating on FlowJo was done for different combinations of IFN-y, TNF-a, IL-2 
and IL-17 positive cells with a total of 15 possible combinations, 1 possible combination for 
all four cytokines (IFNY+IL-2+TNF-a+IL-17+); 4 possible combinations for simultaneous 
production of three cytokines (IFNy+IL-2+TNF-a+IL-17-), (IFNY+IL-2+TNF-a-IL-17+), 
(IFNY+IL-2-TNF-a+IL-17+), (IFNy-IL-2+TNF-o+IL-17+); 6 possible combinations for 
simultaneous production of two cytokines only (IFNY+IL-2+TNF-0-IL-17-), (IFNy+IL-2- 
TNF-a+IL-17-)f (IFNY+IL-2-TNF-Q-IL-17+), (IFNY-IL-2+TNF-a+IL-17-), (IFNy-IL-2-TNF- 
a+IL-17+),(IFNY-IL-2+TNF-a-IL-17+); and 4 possible single cytokine only production 
(IFNY+IL-2-TNF-Q-IL-17-), (IFNY-IL-2+TNF-a-IL-17-), (IFNy-IL-2-TNF-C(+IL-17-),(IFNy-IL-2- 
TNF-a-IL-17+). A q-value of 0.035 was considered significant.
5.3.6.1 Polyfunctional T cell analysis
In response to PMA/lonomycin, no differences were found between the groups for both 
CD4 and CD8 producing T cells (Fig 5-7).
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Figure 5-7: Combinations of cytokine production after PMA/lonomycin stimulation from CD8 T 
cells at 1 week post-vaccination. No differences were observed between groups at any time 
point after polyfunctional cytokine responses analysis. Y axis represents absolute number of 
cells producing polyfunctional cytokines. Data presented represents 26 unvaccinated subjects 
and 15 vaccinated subjects.
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In response to PPD the unvaccinated group had higher proportions of CD4+ T cells 
producing any two cytokines at baseline compared to the vaccinated group (pie graphs)( 
Fig 5-8b). No differences were observed between the groups however after individual 
combination analysis at this time point (Fig. 5-8a). Additionally, the vaccinated infants had 
lower single cytokine production but this was not significant (Fig 5-8a).
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Figure 5-8: Proportions and cytokine production combinations from CD4 T cells after 
PPD stimulation a) cytokine production and the different possible combinations at 6 
weeks; absolute percentage of cells are on the y-axis and cytokine combinations on x- 
axis, b) different proportions of cytokine production over time in the unvaccinated (top 
row) and the vaccinated (bottom row).Data represents 15 vaccinated and 26 
unvaccinated subjects
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CD8 T cells from the vaccinated group had lower ability to produce multiple cytokines 
simultaneously, though this observation was not significant (Fig 5-9). No differences were 
observed in terms of cytokine combinations between the groups after multiple 
comparisons.
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the vaccinated and unvaccinated, p-values calculated on SPICE using the Wilcoxon rank 
sum test. Y-axis is absolute number of cells producing polyfunctional cytokines; data 
represents 15 vaccinated and 26 unvaccinated subjects.
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Equivalent proportions of multiple and single cytokine production was observed between 
the groups at all time points, no differences were observed in the simultaneous production 
of multiple cytokines (Figs. 5-1 Oa & b).
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CD8+ T cell production of polyfunctional cytokines was more apparent in the unvaccinated 
than the vaccinated infants at baseline (not significant), similar proportions were observed 
at 1 week post-vaccination and 12 week post-vaccination. After combinatorial analysis no 
differences were observed between the groups at all time points (data not shown).
Polyfunctional T cell responses after unrelated pathogen stimulation varied. Similar 
proportions of CD4 T cells simultaneously producing 3 cytokines per cell were observed 
after Candida albicans at all time points between the two groups. Following E. coli 
stimulation similar proportions of single and multiple cytokine producers were observed 
between the groups. Simultaneous production of 4 cytokines was observed in the 
vaccinated after S. pneumoniae stimulation at 1 week post-vaccination; equivalent 
proportions of other possible combinations were observed. No differences were observed 
between the groups from CD8+ T cells in terms of both polyfunctionality and single 
cytokine production in response to unrelated pathogens (Fig 5-11).
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5.4 Discussion
In this chapter, we compared cellular responses between the vaccinated and 
unvaccinated groups. CD4+ T cells are the primary producers of IFN-y and other pro- 
inflammatory cytokines after BCG vaccination in S. Africa and Uganda (Vekemans et al. 
2001; Soares et al. 2008; Lutwama et al. 2013) but there are little data on the cellular 
source of cytokines in Gambian infants, nor is there information on what delaying BCG 
vaccine means to overall immunity (both innate and adaptive). We have shown in Chapter 
4 that plasma cytokines (i.e. basal cytokine levels) are different between the vaccinated 
and unvaccinated infants suggesting this will affect the antigen-specific responses both at 
the global and single-cell level.
In this chapter, Th1, Th2 and Th17 cytokine profiles were examined from T and 
non-T cells both early and late post-vaccination compared to non-vaccinated infants. 
Interestingly, there was no difference in CD4 T cell Th1 cytokine production at any time 
point after BCG vaccination, in contrast to previous studies in S. Africa. However, there 
was a significantly higher proportion of IFN-y producing CD8+ T cells in vaccinated infants 
at 1 week post-vaccination. In addition, an increase in non-T cell production of TNF-a 
production 1 week after vaccination was evident in the vaccinated group and supports a 
role for the innate immune response early post-vaccination. We also measured Th17 
producing cells, which were recently implicated in the protective immune response after 
BCG vaccination (Scriba et al., 2008; Li et al., 2012), although another paper showed no 
IL-17 induction after BCG vaccination in UK adolescents (Smith et al., 2010). In Gambian 
infants, quite high levels of IL-17 production were seen following antigen stimulation but 
no difference was seen between groups and responses were similar following all 
stimulation with antigens (both vaccine-related and unrelated) indicating this is not due to 
BCG vaccination. Smith et al. attributed their lack of an IL-17 subset in their studies to the 
use of PBMCs, as Scriba et al. used whole blood assays. In this study we used 
cryopreserved PBMCs to measure our cytokine responses, and we only found responses 
from non-T cells. Smith et al. measured IL-17 from T cells and NK cells. It is possible that
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other non-T cells (mainly innate cells) are responsible for IL-17 production and not NK 
cells.
To analyze specific Mtb responses, we used Esat-6/CFP-10 (EC) overlapping 
peptides. Esat-6/CFP-10 is a part of the region of differentiation 1 (RD1) of the Mtb 
genome that is deleted in BCG and in environmental mycobacteria and therefore gives an 
indication of Mtb sensitization in our infants. CD4 IFNy levels after Esat-6/CFP-10 
simulation is indicative of TB infection via ELISpots (Adekambi et al., 2012).This was 
particularly important for the non-vaccinated group, since any evidence of infection would 
have warranted immediate investigation for TB infection. Low levels of cytokine production 
were observed after Esat-6/CFP-10 stimulation suggesting that none of the infants in our 
study had been exposed to TB. Indeed, a previous study in the same setting observed 
very low IFN-y levels to Esat-6/CFP-10 in 18 month old infants using IFN-y-ELISpot 
assay, corroborating our findings of low TB exposure (Odutola et al., 2012).
Our low response to PPD even in the vaccinated group was unexpected. It has been 
observed that prior environmental exposure might lead to an attenuated effect on the 
immune response after BCG vaccination (Black et al., 2001; Ota et al., 2002; Burl et al.,
2010), however other studies showed no effect of exposure on attenuation of vaccine 
specific responses after delayed vaccination (Marchant et al., 1999; Kagina et al., 2009). 
Furthermore Kagina and colleagues describe the induction of a better immune response 
and protection a year after BCG vaccination in infants that were vaccinated at 10 weeks 
compared to those vaccinated at birth (Kagina et al., 2009), whilst another study in 
Ugandan infants observed higher cytokine levels in infants vaccinated at birth than those 
vaccinated at 6 weeks (Lutwama et al., 2013).ln addition we measured BCG responses 1 
week post-vaccination mainly because we wanted to measure innate responses and 
another arm of the study not discussed here looking at gene transcripts, a recent study 
observed that BCG vaccine responses peak after 10 weeks of vaccination gradually 
waning till 40 weeks and returning to almost baseline levels (3 weeks post-vaccination) at 
1 year of age in BCG birth vaccinated infants (Soares et al., 2013). Thus, another reason
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for the low responses we see especially at one week post vaccination might be due to the 
timing of our bleeds.
BCG has also been associated with protection against sepsis and bacterial infections in 
neonates and infants in some studies (Aaby et al., 2011). It has recently been observed 
that BCG also protects against Candida albicans, Staphylococcus aureus and Escherichia 
coli infection by the Netea group (Kleinnijenhuis et al., 2012). We therefore measured 
cytokine responses to CA, SP, and E coli (obtained from the Netea group) using similar 
pathogen concentrations as the Netea group. Overall, we did not find an effect of BCG on 
the immune response against unrelated pathogens.
Polyfunctional T cells in lungs of mice have been shown to correlate with protection 
against TB (Forbes et al., 2008), and this was found to be dose dependent (Aagaard et 
al., 2009). Since then human studies have been exploring if polyfunctionality could be 
used as a correlate of protection especially in clinical trials. However, a recent study 
suggested that polyfunctionality might not be a correlate, as development of TB did not 
depend on the level of polyfunctionality from CD4+ T cells in S. African infants (Kagina et 
al., 2010). We did not observe any specific differences in polyfunctionality between the 
vaccinated and unvaccinated groups; indeed the unvaccinated generally had higher 
(though not significant) proportions of polyfunctionality, corroborating the above study that 
polyfunctionality might not necessarily be linked to protection, as the unvaccinated are yet 
to receive the vaccine and thus it is not expected that they would be protected against TB. 
It would be interesting to have a longitudinal study to further clarify the results and to 
determine TB incidence in this setting.
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Chapter 6: Effect of delayed BCG vaccination on antibody levels to other Expanded 
Programme of Immunization vaccines and the tuberculin skin test
6.1 Introduction
The Expanded Program on Immunization (EPI) vaccinations play a major role in 
preventive medicine and public health (Kollmann, Levy, & Hanekom, 2013). The EPI 
schedule is comprised of several vaccines against different infectious diseases; either 
killed or live attenuated vaccines as described in Chapters 1 and 2. It has been suggested 
that each group of these vaccines have either a non-vaccine related beneficial (live 
vaccines) or detrimental (killed vaccines) effect depending on the sex of the child, the 
timing of vaccination and subsequent interactions with other vaccines(Aaby et al., 2012). 
The vaccine that has been suggested to have the highest beneficial effect on the 
protective antibody levels of other EPI vaccines is BCG (Ota et al., 2002; Ritz et al., 
2013), which is generally given at birth but might sometimes be delayed due to personal 
(i.e. inaccessibility of health centres), national (i.e. war) and/or economic circumstances. 
Indeed, it has recently been accepted by the WHO that BCG vaccination at birth has a 
heterologous effect in reduction of all cause mortality (WHO, 2014).
In this chapter the effect of BCG given at 6 or 18 weeks on antibody levels to other EPI 
vaccines given several weeks later was determined. Additionally, tuberculin skin test 
(TST) reactivity was assessed to determine the influence of delayed vaccination on 
mycobacterial immunogenicity.
6.1.1 Efficacy and interaction between vaccines in the EPI schedule and sex 
differences after vaccination
Most serious infections occur in the first year of life when the immune system is still 
developing; hence a major goal of human medicine is efficacious vaccination within this 
first year. However, most vaccines were designed empirically without knowledge of the 
potential interaction with other vaccines in the EPI schedule. Recent studies have begun
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to assess these interactions with both positive and negative influences uncovered, which 
appear to be sex-dependent (Flanagan et al., 2013). In the present study we were 
interested in the interaction of BCG on the common vaccines given in The Gambia, 
namely polio, pertussis, tetanus, diphtheria and hepatitis B vaccines. In The Gambia, 
pertussis is given in combination with diphtheria (D) and tetanus (T) vaccines as DT-whole 
cell Pertussis (DTwP) vaccine at 2, 3 and 4 months (see Table 1, chapter 1). Polio and 
Hepatitis B vaccines are given at birth and together with the DTwP vaccine as part of the 
pentavalent vaccine. Combining multiple antigens in a single injection is not only 
convenient but leads to better compliance and, importantly, it has been shown that the 
above mentioned antigens combined with hepatitis B do not impact on each other’s 
immunogenicity (Prymula & Plisek, 2008). However, data from a trial of a novel TB 
vaccine in The Gambia (MVA85A) showed it had detrimental effects on other EPI 
vaccines, as co-administration with other EPI vaccines showed a much lower induction of 
IFN-y ( Ota et al., 2011) while polio vaccine has been shown to reduce responses to BCG 
(Ota et al., 2002; Sartono et al., 2010). On the other hand, BCG given at birth has been 
shown to boost responses to other EPI vaccines, especially to hepatitis B in The Gambia 
(Ota et al., 2002), whilst it did not boost hepatitis B antibody levels in Australian infants 
(Ritz et al., 2013). These data indicate the importance of understanding vaccine-vaccine 
interactions to determine the optimal vaccine schedule for each country (as differences in 
host genetics plays a role in immune responses). Women tend to develop stronger 
immunity when compared to males as they have higher antibody levels and stronger cell- 
mediated immunity (Moxley et al., 2002), whether the same applies to infants is less clear. 
Geometric mean titres for measles antibodies after measles vaccination in adolescents 
showed a 50% higher titre in females when compared to males (Green et al., 1994). 
Indeed a 2-fold increase in female but not male mortality led to withdrawal of the high titre 
measles vaccine (HTMV) by WHO (Aaby et al., 2003). Contrary to the HTMV study, 
studies in West African infants have in general shown beneficial effects on females after 
vaccinations with live vaccines including measles vaccine (Roth et al., 2006; Aaby et al.,
2011), and a detrimental effect after killed vaccines (Aaby et al., 2003). These effects are
also much more prominent depending on the vaccine that was last received (Hirve et al.,
2012), thus making sequence of immunization very important.
6.1.2 Effect of BCG vaccination on the tuberculin skin test (TST)
The tuberculin skin test (TST/Mantoux test) is a standard test for measuring infectivity and 
/or exposure to M.tuberculosis (Mtb) by injecting purified protein derivative (PPD) 
intradermally and measuring induration (in mm) 48-72 hours after injection which is 
caused by a delayed-type hypersensitivity reaction to the antigen. However, TST reactivity 
can also indicate BCG vaccination and exposure to non-tuberculous mycobacteria (NTM), 
since induration (reaction) provides a measure of overall antimycobacterial immunity 
(Cobat et al., 2012). The “cut-off’ to determine positivity as an indicator of infection with 
Mtb is not well defined and some studies have suggested that BCG vaccination can lead 
to a TST induration >10mm, with Chan et al. suggesting an induration of 21mm to be a 
more appropriate cut-off for the first year of life in Taiwanese infants (Santiago et al., 
2003; Chan et al., 2008). It has been shown that BCG vaccinated infants with a positive 
TST induration and a BCG scar had lower all cause mortality rates suggesting a 
correlation with better immunity to TB ( Roth et al., 2006). However, cross-reactivity with 
non-tuberculous mycobacteria found in the environment can affect TST reactivity. For 
example, Ota and colleagues found 22% of BCG naive infants (4.5 months old) and 20% 
of BCG-naTve adults had TST induration >10mm ( Ota et al., 2006, 2007). However 
another study in a peri-urban setting found no TST reactivity in naive infants at the same 
age (Burl et al., 2010).
Thus in this chapter we discuss the effect of BCG vaccination at 6 weeks of age on EPI 
vaccine antibody responses, including sex differences after vaccination. The effect of 
delayed BCG vaccination till 6 weeks on TST induration is also described.
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Hypothesis:
• BCG vaccinated infants at 6 weeks would have higher antibody levels to other EPI 
vaccines when compared to BCG naive infants
• BCG vaccination at 6 weeks would lead to higher indurations when compared to 
BCG naive infants
Aims:
• Measure EPI antibody levels in BCG vaccinated and unvaccinated infants
• Investigate effect of BCG vaccination at 6 weeks on TST induration when compared to 
BCG naTve infants.
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6.2 Methods:
6.2.1: EPI antibody levels
6.2.1.1 Polio neutralizing antibody levels
In order to examine the effect of BCG on polio vaccine immunity, we measured 
neutralizing antibody titres to polio 1 and 3 (the serotypes present in the vaccine given to 
Gambian infants) by culturing Human Epithelial-2 (Hep2) Cincinnati cells and measuring 
the cytopathic effect of the virus on these cells in the presence of human plasma. 
Antibody titres were measured after five days of incubation at 37°C, 5% C 02. Fig 6-1 
shows the cytopathic effect of the virus on the cells. The lowest possible measurable 
antibody titre was 8 and the protective cut-off value was a titre of >8; an antibody titre less 
than 8 (positive at 8, meaning the titre is less than 8) was given as 8. The highest possible 
titre was 1024 and any sample still negative at 1024 was given 1024 as the titre.
6.2.1.2 Hepatitis B surface antibody and DTP antibody levels
We measured surface antibody levels to hepatitis B (HBsAb) using a commercial kit 
(Diasorin, Italy) as described in Chapter 2 Section 2.4.2. 10 HJ/mL is the protective level 
for hepatitis B whilst the highest measurable level was 1000 lU/mL. For analysis purposes 
all subjects with levels below 10 lU/mL were adjusted to 10 lU/mL and those with >1000 
lU/mL were adjusted to 1000 ILI/mL.
We measured antibody levels to DTP vaccine using an in-house multiplex immuno assay 
(MIA) technique.
6.2.2 Tuberculin Skin Test (TST)
TST was done on all infants at 18 weeks, 2 weeks after the last dose of pentavalent 
vaccine was given. Induration was read longitudinally and transversely and the average 
induration (mm) recorded. Due to recent BCG vaccination an induration >10mm was 
considered positive and suggestive of Mtb infection.
119
6.3 Results
6.3.1 Vaccine antibody levels
6.3.1.1 Polio neutralizing antibody assay
We analyzed 61 unvaccinated and 62 vaccinated infants at baseline (pre-BCG 
vaccination), 59 unvaccinated and 62 vaccinated at 1-week post-vaccination, and 53 
unvaccinated and 52 vaccinated at 12-weeks post-vaccination.
No Cytopathic effect ( visible 
monolayer)-Arrow
Cytopathic effect ( no visible 
monolayer)- Arrow
Figure 6-1: Cytopathic effect of Polio virus on Hep2 Cincinnati cells in the presence of 
plasma, visible monolayer indicates no cytopathic effect (negativity) whilst no monolayer 
indicates a cytopathic effect (positivity). Arrow indicates presence or absence of a visible 
monolayer.
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By baseline, all infants had received one dose of OPV and four doses by 12 post­
vaccination. At baseline, 66% of the vaccinated group and 62% of the unvaccinated group 
were protected for Polio 1 while only 35% of the vaccinated and 25% of the unvaccinated 
were protected for Polio 3 (no significant differences). These levels were significantly 
increased in both groups by 12 weeks post-vaccination with 94% of the vaccinated and 
98% of the unvaccinated protected for Polio 1 and 97% and 85% for Polio 3 for the 
vaccinated and unvaccinated groups respectively. No differences were observed in 
antibody levels between the two groups over time, however differences were observed 
within both groups from 1 week post-vaccination to 12 weeks post-vaccination, when 
protective levels increased significantly (Fig. 6-2). We analyzed for sex differences in the 
antibody titre levels but did not find any differences between the sexes in the two groups 
at any time point (data not shown).
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Figure 6-2: Antibody titres of Neutralizing Polio antibodies in the vaccinated and 
unvaccinated groups, at 0 (baseline/6 weeks), 1 (1 week post-vaccination/7 weeks) and 
12 (12 weeks post-vaccination/18 weeks).No differences were observed between the 
groups over time. Data is representative of all study subjects.
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6.3.1.2 Hepatitis B surface antibody levels in BCG vaccinated and BCG naive 
infants
At baseline, all infants had received a dose of HepB vaccine at birth, and by 12 weeks 
post-vaccination they had received an additional 3 doses at 2, 3 and 4 months. We 
observed similar antibody levels at baseline for both the vaccinated and unvaccinated 
group with only 17% of vaccinated subjects and 21% of unvaccinated having protective 
levels. There was little difference by 1 week post-vaccination but by 12 weeks post­
vaccination, after 4 doses of the vaccine, all subjects had protective antibody levels 
against Hepatitis B (Median (IQR): BCG vaccinated: 1 week post-vaccination -10 lU/mL 
(10-717.8), 12 weeks post-vaccination -578.0 lU/mL (10.3-1000) p<0.0001; unvaccinated: 
1 week post-vaccination -10IU/mL (10-698.5), 12 weeks post-vaccination -493.2 lU/mL 
(43.8-1000) p<0.0001 (Fig 6-3)).
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Figure 6-3: Hepatitis B surface antibody levels in BCG vaccinated and unvaccinated infants 
at 0= baseline/ 6 weeks, 1=1 week post-vaccination/7 weeks and 12=12 weeks post­
vaccination/ 18 weeks. Line indicates median.
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Interestingly, unvaccinated males at 12 weeks post-vaccination had considerably higher 
antibody levels than the unvaccinated females (median (IQR): males-1000 IU/mL (10.3- 
1000); females-352.9 IU/mL (19.2-1000), p=0.02; Fig. 6-4).
vaccinated unvaccinated1500-,
0.02
1000 -
500-
• •  •  
• • •
So
Sex
Figure 6-4: Gender differences from Hepatitis B surface antibody levels in BCG vaccinated 
and unvaccinated infants at 12 weeks post-vaccination/ 18 weeks. Line indicates median. Data 
anal yzed using Mann Whitney U test and representative of all study subjects
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6.3.1.3 Antibody levels to Diphtheria, Tetanus and Pertussis
The cut off for protection for pertussis toxin (Ptx) antibodies is 25 EU/mL: at baseline 6% 
of all subjects had protective levels but by 12 weeks post-vaccination , 94% of vaccinated 
but only 84% of the unvaccinated had protective levels (p<0.0001 for both groups). The 
protective cut-off value for diphtheria toxoid (Dtx) antibodies was 0.01 IU/mL, and 44% of 
the vaccinated and 45% of the unvaccinated were protected at baseline and by 12 weeks 
post-vaccination 100% of study subjects had protective levels (Fig 6-5b). The protective 
cut-off level for tetanus toxoid (Ttx) antibody levels was 0.01 IU/mL and 100% of the 
vaccinated infants were protected and only 1 unvaccinated infant (0.016%) was 
unprotected at baseline; while all the infants had protective levels by the third visit, with no 
differences between the groups despite increase in antibody levels by 12 weeks post­
vaccination (p<0.0001) (Fig 6-5c). We did not find any sex differences for any of the DTP 
antibody levels at any time-point within or between groups.
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Figure 6-5: Antibody levels to diphtheria, tetanus and pertusis by MIA. No effect 
of BCG was observed on levels to these antigens. Open circles represent the 
vaccinated, closed circles represent unvaccinated infants. 0= baseline/6 weeks, 
1= 1 week post vaccination/ 7 weeks, 12= 12 weeks post vaccination/18 weeks.
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6.3.2 Effect of BCG vaccination on the Tuberculin Skin Test
We measured TST induration in all subjects at 18 weeks in order to assess the effect of 
delayed BCG vaccine on tuberculin reactivity. This time-point was 12 weeks post BCG 
vaccination in the BCG-vaccinated group and just prior to the unvaccinated group 
receiving their BCG dose. 45 (87%) unvaccinated subjects were non-responders (i.e. had 
an induration of Omm), 5 (9.6%) had an induration between 0 and 10 mm and 2 (3.8%) 
had an induration of ^1 Omm (and thus classified as TST positive). In the BCG-vaccinated 
group, significantly more subjects were TST+ as expected, 16(30%) having an induration 
>10mm (p<0.0001; Fig 6-6a), despite this, 21(40%) of the vaccinated infants were anergic 
(induration=0mm) and 16 (30%) had an induration between 0-1 Omm. Infants with 
indurations >10mm were investigated for TB exposure but no cases were found. 
Interestingly, in the vaccinated group, males had higher induration compared to females 
(median (IQR): males=8.5mm (0mm-16mm); females=1.3mm (0mm-13mm), p=0.012) but 
no difference was observed in the unvaccinated group between the sexes (median (IQR): 
males= Omm (0mm-9.5mm); females=0mm (0mm-12mm). The vaccinated males and 
females had higher induration than the unvaccinated males and females after stratification 
based on sex (males- p<0.0001), females-p=0.02) (Fig6- 6b).
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Figure 6-6: a) Overall differences in TST induration between the vaccinated 
and unvaccinated groups; at 18 weeks of age, the vaccinated infants had 
higher induration than the unvaccinated, b) Sex differences in TST, males and 
females of the vaccinated group had higher induration than their unvaccinated 
counterparts and males in the vaccinated group had higher induration than the 
females.
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6.4 Discussion
We measured antibody levels to different EPI vaccines and related this to BCG 
vaccination status. We expected that the vaccinated group would have higher EPI 
antibody levels when compared to the BCG unvaccinated group but we found no 
difference between the two groups. Previously, BCG has been shown to boost antibody 
levels to HepB and OPV vaccines but not to tetanus and diphtheria vaccines in Gambian 
children (Ota et al., 2002); whilst in Australian children, it did not boost levels to HepB, 
tetanus and Hib vaccines, but boosted levels to some pneumococcal vaccine serotypes 
(Ritz et al., 2013). Whilst we used the same method of analysis for polio and HepB as Ota 
et al, we did not find the differences they observed in regards to polio 1 virus or hepatitis B 
antibodies. This may be due to differences in BCG vaccine strain administered but is more 
likely associated with the different vaccination schedule we used. First of all, the infants 
who were vaccinated were 6 weeks older than in previous Gambian studies. This means 
the infants’ immune system would be different with an increase in adaptive immunity 
present, and also the timing of the vaccines would affect responses to the other EPI 
vaccines. For instance, the previous studies gave BCG together with the other EPI 
vaccines, whilst we gave BCG after the first dose of Polio and HepB but 2 weeks before 
the other EPI vaccines (DTP). Differences in vaccine strains makes direct comparisons 
between our study and previous studies difficult as the various strains perform distinctly 
from each other when used in diverse places and have different properties such as 
virulence factors, immunogenicity and efficacy (Fine, 1999; Behr, 2002; Corbel et al., 
2004; Davids et al., 2006; Leung et al., 2008; Ritz et al., 2009; Anderson et al., 2012). 
Importantly however, protective antibody levels to Polio, TT and HepB were achieved in 
all subjects regardless of vaccine group, showing that the delay in BCG vaccine is not 
detrimental to responses to other vaccines. Whilst non-specific boosting effects are a 
‘bonus’ of the BCG vaccination, their absence is not important in terms of antibody 
responses if protective levels are reached anyway.
130
Despite arguments that the presence of maternal antibodies might be partially responsible 
for sub-optimal vaccine efficacy in infants (Siegrist et al., 1998), they play a vital role in 
protection against invasive diseases in infants (Saffar et al., 2008). Expectant Gambian 
mothers receive a tetanus vaccine booster upon their first visit to the antenatal clinic and a 
second dose is recommended 6 months later, which should fall during the third trimester. 
However, many pregnant mothers do not visit antenatal clinics early thus most only 
receive one dose of tetanus during the second or third trimester (Dr. Jane Adetifa, 
personal communication). At 6 weeks of age, before receiving the first dose of the DTwP 
vaccine, all but one infant in our study had protective Ab titres against tetanus; and by 18 
weeks of age, after receiving all three doses of the DTwP vaccine, all the infants had 
protective anti-tetanus titres. This indicates the importance of protection conferred by 
maternal antibodies in our setting. And the delay in BCG vaccination did not affect this. It 
is a limitation in TB studies that antibodies are not protective and therefore analysis of 
Mtb-specific antibodies (such as the lipoarabinomannan (LAM) urine test) cannot be used 
in the same way as the HepB or polio assays. In addition, our study did not assess the 
long-term effects of BCG vaccination so we cannot ascertain the clinical end-points for 
any diseases within our study group. Unvaccinated males had significantly higher HepB 
antibody levels when compared to the females in the same group, contrary to current 
literature which suggests females tend to have higher antibody levels than males (Green 
et al., 1994; Moxley et al., 2002). These latter studies were conducted in adults and the 
situation may be different in infants.
Both BCG vaccinated and unvaccinated subjects had TST induration indicative of 
vaccination and or exposure to TB or non-tuberculous mycobacteria, but induration was 
significantly higher in the vaccinated than the unvaccinated showing the effect of BCG 
vaccination on the TST readout, an indication that the vaccine used in this study did work. 
The cut-off used to suggest TB infection was 10mm; all subjects with >10mm induration 
were followed up and investigated for TB exposure and none of them had a history of a 
close contact with anyone with signs and symptoms of TB. Indeed a previous study in
131
BCG naive Gambian infants found that 22% of infants were TST positive at 4.5 months 
(Ota et al., 2006); in contrast another Gambian study which found no reactivity in 
unvaccinated infants despite the presence of non-responders (anergic) in infants 
vaccinated at birth (Burl et al., 2010). Chan et al suggested a cut-off of 21mm as a strong 
predictor of Mtb infection in BCG vaccinated infants up to 1 year of age; and 18mm was 
proposed as a cut-off from 12-20 months of age; while suggesting that any induration 
below this could be attributed to vaccination (Chan et al., 2008). According to this 
guideline we did not observe any possible cases of Mtb infection using TST as a 
diagnostic tool. In addition, all infants in our study with a TST >10mm were followed up 
and investigated for TB exposure; none of the infants had a history of a close contact with 
anyone with signs and symptoms of TB, and the infants themselves did not have any 
signs of the disease. Therefore the responses we observed were probably due to either 
BCG vaccination in the vaccinated subjects or exposure to environmental mycobacteria in 
the unvaccinated.
In summary, we found that there was no effect of BCG vaccination at 6 weeks of age on 
other EPI vaccines given from 2 weeks after BCG; but did find that unvaccinated males 
had higher antibody responses to HepB vaccine than unvaccinated females, and 
vaccinated males had higher TST induration than their female counterparts.
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Chapter 7: General discussion
BCG is currently the only licensed vaccine against tuberculosis and is administered to 
over 90% of children in TB endemic regions; although efficacy rates are not consistent 
between or within countries. This lack of consistent and reliable protection has galvanized 
the search for new vaccination strategies using recombinant technology or heterologous 
vector based prime-boost regimens (Ottenhoff & Kaufmann, 2012; Kaufmann, 2013). 
However, in order to develop optimal vaccination strategies it is important to determine the 
precise role of innate and adaptive immunity in protection to BCG. Therefore, the aim of 
this study was to analyze responses to both vaccine-specific and unrelated antigens in 
infants who received BCG at 6 weeks of age compared to those who had delayed 
vaccination to 18 weeks.
Despite differences in Th1 responses found in previous studies between BCG vaccinated 
cohorts and unvaccinated cohorts (Marchant et al., 1999; Vekemans et al., 2001; Soares 
et al., 2008; Burl et al., 2010), we found few differences between our BCG vaccinated and 
naTve groups. This could be attributable to three main factors. Firstly, pre-sensitization to 
environmental mycobacteria blocking/masking immune responses following BCG 
vaccination is a prominent hypothesis (masking hypothesis) (Brandt et al., 2002; Fine et 
al., 1995) and it has been observed that exposure might lead to an attenuated effect on 
the immune response after BCG vaccination (Black et al., 2002; Ota et al., 2002; Burl et 
al., 2010), particularly in TB-endemic settings. All babies in this study had BCG 
vaccination delayed, with the vaccinated group only receiving the vaccine at 6 weeks of 
age compared to other studies where infants received the vaccine at birth (as per normal 
EPI schedule). Secondly, cytokine levels were measured after overnight cultures and this 
might not be enough time to see differential effects, particularly in regards to the adaptive 
response. However, we did see higher Th1/Th2 cytokine ratios in the vaccinated group 
when compared to the unvaccinated infants and the unvaccinated group had increasing 
Th2 cytokine levels over time suggesting a bias towards Th2 levels in the BCG-delayed
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group. Thirdly we measured responses to vaccines one week post vaccination and a 
previous South African study showed that BCG vaccine responses peak at 10 weeks 
post-vaccination and there is very little responses at baseline (3 week post- 
vaccination)(Soares et al., 2013), hence the time we bled after vaccination might be too 
soon to see responses. Surprisingly, the unvaccinated infants had higher Th1 and Th17 
but no difference in innate cytokine levels compared to the vaccinated infants following 
TLR agonist stimulation and few changes were observed at the different time-points. 
These results are also in contrast to a previous cross-sectional study in Gambian infants 
(Burl et al., 2011), which showed higher pro-inflammatory responses at birth, decreasing 
over time.
In South Africa, a better T cell response was observed in 1 year olds vaccinated at 10 
weeks compared to those vaccinated at birth (Kagina et al., 2009). In contrast, a study 
from Uganda supports our findings showing reduction in T cell responses in infants who 
delayed vaccinated to 6 weeks in Uganda (Lutwama et al., 2013). One of the major 
limitations of the latter study is the socioeconomic background of the study subjects: those 
vaccinated at birth were born in hospitals and those vaccinated at 6 weeks were born at 
home. All our study subjects came from the same socioeconomic background, so this was 
unlikely to be a contributing factor in the low response to PPD in the BCG vaccinated 
infants. However, it does suggest that masking with environmental bacteria, differences in 
TB exposure and differences in host genetics all contribute to the differences seen 
between study sites.
Human studies looking at vaccine efficacy have used polyfunctionality as a correlate of 
protection for almost a decade now. Previous studies in murine models have shown 
polyfunctionality to be correlated with protection against TB despite it being dose 
dependent (Forbes et al., 2008;Aagaard et al., 2009). Interestingly, we did not find any 
differences in our study in terms of polyfunctionality.
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Whilst we could not determine a disease end-point in our study, we did assess TST 
indurations at 18 weeks to determine possible Mtb infection in both groups. High TST 
indurations were seen in the unvaccinated infants suggesting mycobacterial exposure and 
priming. However, a previous Gambian study observed that 22% of infants had TST 
induration despite being BCG naTve and none were infected with Mtb suggesting an 
impact of non-tuberculous mycobacteria on the TST reading. Thus, we used a cut-off of 
10mm or above as an indicator of infection with TB and all infants with a TST >10mm 
were investigated for TB exposure. Importantly, none of the infants in either group were 
exposed to TB or showed signs/symptoms of infection. Indeed, a recent study in the 
same study setting found low exposure of 18 month old-infants to TB (Odutola et al., 
2012)..
One of the major limitations in the present study was the lack of a birth cohort whereas all 
the previously stated studies had a birth cohort to compare with the delayed group. 
Another difference with the previous studies, especially The Gambian studies is that other 
EPI vaccines were given at the same time, i.e. at birth, at 2 months or at 4 months, whilst 
in this study BCG was given alone at 6 weeks, 6 weeks after the first doses of the EPI 
vaccines and 2 weeks before the second dose. The lack of a boosting effect on the other 
antibody levels could be attributed to this since effects seen previously might have been 
due to the interactions of all the different vaccines given together and not necessarily the 
BCG vaccine. Another limitation is that we did not perform a functional assay to assess 
responses in the BCG-vaccinated infants. For example, the BCG Lux assay measures 
killing of mycobacteria in culture after vaccination and has been shown to work in TB 
endemic settings (Kampmann et al., 2000; Newton, Martineau, & Kampmann, 2011; Burl 
et al., 2013). It would have been interesting to observe differences in mycobacterial killing 
between the two groups and the effect delaying BCG till 6 weeks might have on this 
despite the low cytokine levels observed. Finally, we did not assess responses in the 
infants who had BCG vaccination delayed until 18 weeks of age. This would have been
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important to determine the influence of even further delay on BCG responses and 
responses to other EPI vaccines and may have helped to address the masking 
hypothesis.
In conclusion, BCG Russia given at 6 weeks of age showed no enhancement of Th1 
responses but decreased IL-10 responses after TLR agonist and unrelated pathogen 
stimulation compared to BCG unvaccinated infants. These effects were more prominent in 
females when compared to their male counterparts. In contrast to previous studies on 
BCG vaccination at birth, there was no effect on other EPI vaccine antibody levels when 
given at 6 weeks with all infants reaching protective levels by 18 weeks of age.
Chapter 8: References
136
A a b y ,  P ., B e n n ,  C ., N ie ls e n ,  J ., L is s e , I. M . ,  R o d r ig u e s ,  A . ,  &  R a v n , H . ( 2 0 1 2 ) .  T e s t in g  t h e  h y p o t h e s is  
t h a t  d ip h t h e r ia - t e t a n u s - p e r t u s s is  v a c c in e  h a s  n e g a t iv e  n o n - s p e c i f ic  a n d  s e x - d i f f e r e n t ia l  
e f f e c t s  o n  c h ild  s u r v iv a l  in  h ig h - m o r t a l i t y  c o u n t r ie s .  BMJ Open, 2 ( 3 ) .  d o i : 1 0 . 1 1 3 6 / b m j o p e n -  
2 0 1 1 - 0 0 0 7 0 7
A a b y ,  P ., J e n s e n ,  H . ,  G o m e s ,  J ., F e r n a n d e s ,  M . ,  &  L is s e , I. M .  ( 2 0 0 4 ) .  T h e  in t r o d u c t io n  o f  
d ip h t h e r ia - t e t a n u s - p e r t u s s is  v a c c in e  a n d  c h ild  m o r t a l i t y  in  r u r a l  G u in e a -B is s a u :  a n  
o b s e r v a t io n a l  s t u d y .  International Journal o f Epidemiology, 33(2), 3 7 4 - 8 0 .  
d o i : 1 0 . 1 0 9 3 / i j e / d y h 0 0 5
A a b y ,  P ., J e n s e n ,  H .,  S a m b , B ., C is s e , B ., S o d e m a n n ,  M . ,  J a k o b s e n ,  M . , ... W h i t t l e ,  H . ( 2 0 0 3 ) .
D i f f e r e n c e s  in  f e m a l e - m a l e  m o r t a l i t y  a f t e r  h ig h - t i t r e  m e a s le s  v a c c in e  a n d  a s s o c ia t io n  w i t h  
s u b s e q u e n t  v a c c in a t io n  w i t h  d ip h t h e r ia - t e t a n u s - p e r t u s s is  a n d  i n a c t iv a t e d  p o l io v ir u s :  
r e a n a ly s is  o f  W e s t  A f r ic a n  s tu d ie s .  Lancet, 3 6 1 ( 9 3 7 6 ) ,  2 1 8 3 - 8 .  d o i : 1 0 . 1 0 1 6 / S 0 1 4 0 -  
6 7 3 6 ( 0 3 ) 1 3 7 7 1 - 3
A a b y ,  P ., J e n s e n ,  H . ,  &  W a l r a v e n ,  G . ( 2 0 0 6 ) .  A g e - s p e c i f ic  c h a n g e s  in  t h e  f e m a l e - m a l e  m o r t a l i t y  
r a t io  r e la t e d  t o  t h e  p a t t e r n  o f  v a c c in a t io n s :  a n  o b s e r v a t io n a l  s t u d y  f r o m  r u r a l  G a m b ia .  
Vaccine, 24(22), 4 7 0 1 - 8 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 0 6 . 0 3 . 0 3 8
A a b y ,  P ., R o th ,  A . ,  R a v n , H . ,  N a p i r n a ,  B . M . ,  R o d r ig u e s ,  A . ,  L is s e , I. M . , ... B e n n ,  C . S. ( 2 0 1 1 ) .  
R a n d o m iz e d  t r i a l  o f  B C G  v a c c in a t io n  a t  b i r t h  t o  l o w - b i r t h - w e i g h t  c h i ld r e n :  b e n e f ic ia l  
n o n s p e c i f ic  e f f e c t s  in  t h e  n e o n a t a l  p e r io d ?  The Journal o f Infectious Diseases, 204(2), 2 4 5 -  
5 2 .  d o i : 1 0 . 1 0 9 3 / i n f d i s / j i r 2 4 0
A a g a a r d ,  C ., H o a n g ,  T . T .  K. T . ,  Iz z o ,  A . ,  B i l le s k o v , R ., T r o u d t ,  J ., A r n e t t ,  K . , ... D ie t r ic h ,  J. ( 2 0 0 9 ) .
P r o t e c t io n  a n d  p o ly f u n c t io n a l  T  c e lls  in d u c e d  b y  A g 8 5 B - T B 1 0 .4 / IC 3 1  a g a in s t  M y c o b a c t e r i u m  
t u b e r c u lo s is  is h ig h ly  d e p e n d e n t  o n  t h e  a n t ig e n  d o s e .  PloS One, 4(6), e 5 9 3 0 .  
d o i : 1 0 . 1 3 7 1 / j o u r n a l . p o n e . 0 0 0 5 9 3 0
A b e b e ,  F. ( 2 0 1 2 ) .  Is i n t e r f e r o n - g a m m a  t h e  r ig h t  m a r k e r  f o r  b a c i l le  C a lm e t t e - G u e r in - in d u c e d  
im m u n e  p r o t e c t io n ?  T h e  m is s in g  l in k  in  o u r  u n d e r s t a n d in g  o f  t u b e r c u lo s is  im m u n o lo g y .  
Clinical and Experimental Immunology, 169(3), 2 1 3 - 9 .  d o i : 1 0 . 1 1 1 1 / j . l 3 6 5 -  
2 2 4 9 . 2 0 1 2 . 0 4 6 1 4 . x
A b e l ,  B ., T h i e b l e m o n t ,  N . ,  Q u e s n ia u x ,  V .  J. F ., B r o w n ,  N .,  M p a g i ,  J ., M iy a k e ,  K . , ... B ih l ,  F . ( 2 0 0 2 ) .  
T o l l - L ik e  R E c e p to r  4  e x p r e s s io n  is r e q u i r e d  t o  c o n t r o l  c h r o n ic  m y c o b a c t e r iu m  t u b e r c u lo s is  
in f e c t io n  in  m ic e. Journal o f Immunology, ( 1 6 9 ) ,  3 1 5 5 - 3 1 6 2 .
A d e k a m b i ,  T . ,  Ib e g b u ,  C . C ., K a lo k h e ,  A . S ., Y u , T . ,  R a y , S . M . ,  &  R e n g a r a ja n ,  J. ( 2 0 1 2 ) .  D is t in c t
e f f e c t o r  m e m o r y  C D 4 + T  c e ll  s ig n a t u r e s  in  l a t e n t  M y c o b a c t e r i u m  t u b e r c u lo s is  in f e c t io n ,  B C G  
v a c c in a t io n  a n d  c l in ic a l ly  r e s o lv e d  t u b e r c u lo s is .  PloS One, 7 ( 4 ) ,  e 3 6 0 4 6 .  
d o i : 1 0 . 1 3 7 1 / j o u r n a l . p o n e . 0 0 3 6 0 4 6
A k ir a ,  S ., T a k e d a ,  K ., &  K a is h o , T .  ( 2 0 0 1 ) .  T o l l - l ik e  r e c e p t o r s  : c r i t ic a l  p r o t e in s  l in k in g  t h e  in n a t e  a n d  
a c q u i r e d  im m u n i t y .  Nature Immunology, 2 ( 8 ) .
A k k o c ,  T . ,  A y d o g a n ,  M . ,  Y i ld iz ,  A . ,  K a r a k o c - A y d in e r ,  E ., E i fa n ,  A . ,  K e le s , S . , ... B a r la n ,  I. B . ( 2 0 1 0 ) .  
N e o n a t a l  B C G  v a c c in a t io n  in d u c e s  IL - 1 0  p r o d u c t io n  b y  C D 4 +  C D 2 5 + T  c e lls . Pediatric Allergy 
and Imm unology: Official Publication o f the European Society o f Pediatric Allergy and 
Immunology, 21(7), 1 0 5 9 - 6 3 .  d o i : 1 0 . 1 1 1 1 / j . l 3 9 9 - 3 0 3 8 . 2 0 1 0 . 0 1 0 5 1 . x
A le x a n d r o f f ,  A . B ., J a c k s o n , A . M . ,  D o n n e l l ,  M .  A . O . ,  &  J a m e s ,  K. ( 1 9 9 9 ) .  R e v ie w  B C G  
im m u n o t h e r a p y  o f  b la d d e r  c a n c e r : 2 0  y e a r s  o n .  The Lancet, ( 3 5 3 ) ,  1 6 8 9 - 1 6 9 4 .
137
A l ls o p p  C E , N ic h o lls  SJ, L. J. ( 1 9 9 8 ) .  A  f l o w  c y t o m e t r ic  m e t h o d  t o  a s s e s s  a n t ig e n - s p e c i f ic  
p r o l i f e r a t iv e  r e s p o n s e s  o f  d i f f e r e n t  s u b p o p u la t io n s  o f  f r e s h  a n d  c r y o p r e s e r v e d  h u m a n  
p e r ip h e r a l  b lo o d  m o n o n u c le a r  c e lls . Journal o f Immunological Methods, 2 1 4 ,1 7 5 - 1 8 6 .
A m u l ic ,  B ., C a z a le t ,  C ., H a y e s ,  G . L ., M e t z l e r ,  K. D . ,  &  Z y c h lin s k y , A . ( 2 0 1 2 ) .  N e u t r o p h i l  f u n c t io n :  
f r o m  m e c h a n is m s  t o  d is e a s e .  Annual Review o f Immunology, 30, 4 5 9 - 8 9 .  
d o i : 1 0 . 1 1 4 6 / a n n u r e v - i m m u n o l - 0 2 0 7 1 1 - 0 7 4 9 4 2
A n d e r s o n ,  E. J ., W e b b ,  E . L., M a w a ,  P . a , K iz z a , M . ,  L y a d d a , N . ,  N a m p i j j a ,  M . ,  &  E l l io t t ,  A . M .  ( 2 0 1 2 ) .  
T h e  in f lu e n c e  o f  B C G  v a c c in e  s t r a in  o n  m y c o b a c t e r ia - s p e c i f ic  a n d  n o n - s p e c i f ic  im m u n e  
r e s p o n s e s  in  a  p r o s p e c t iv e  c o h o r t  o f  in f a n t s  in  U g a n d a .  Vaccine, 3 0 ( 1 2 ) ,  2 0 8 3 - 9 .  
d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 1 2 . 0 1 . 0 5 3
A n g e lo n e ,  D . F ., W e s s e ls ,  M .  R ., C o u g h l in ,  M . ,  S u t e r ,  E. E ., V a le n t in i ,  P ., K a lis h , L. A . , ... B o s to n ,  H .
( 2 0 0 6 ) .  I n n a t e  I m m u n i t y  o f  t h e  H u m a n  N e w b o r n  Is  P o la r iz e d  T o w a r d  a  H ig h  R a t io  o f  IL -6  /  
T N F -  a  P r o d u c t io n  In  V i t r o  a n d  In  V iv o .  Pediatric Research, 6 0 ( 2 ) ,  2 0 5 - 2 0 9 .  
d o i : 1 0 . 1 2 0 3 / 0 1 . p d r . 0 0 0 0 2 2 8 3 1 9 . 1 0 4 8 1 . e a
A r m s t r o n g ,  J ., &  H a r t ,  P . D . ( 1 9 7 1 ) .  R e s p o n s e  o f  c u l t u r e d  m a c r o p h a g e s  t o  M y c o b a c t e r i u m  
tu b e r c u lo s is ,  w i t h  o b s e r v a t io n s  o n  f u s io n  o f  L y s o s o m e s  w i t h  P h a g o s o m e s .  Journal o f 
Experimental Medicine, 134[3 ) .
B a n n a r d ,  O . ,  K r a m a n ,  M . ,  &  F e a r o n ,  D . ( 2 0 0 9 ) .  P a t h w a y s  o f  m e m o r y  C D 8 + T - c e l l  d e v e l o p m e n t .  
European Journal o f Immunology, 3 9 ( 8 ) ,  2 0 8 3 - 7 .  d o i : 1 0 . 1 0 0 2 / e j i . 2 0 0 9 3 9 5 5 5
B e h r ,  M .  a . ( 2 0 0 2 ) .  B C G - d i f f e r e n t  s t r a in s ,  d i f f e r e n t  v a c c in e s ?  The Lancet Infectious Diseases, 2 ( 2 ) ,  
8 6 - 9 2 .  R e t r ie v e d  f r o m  h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 1 1 9 0 1 6 5 5
B e ld e r b o s ,  M .  E ., v a n  B le e k ,  G . M . ,  L e v y , O . ,  B la n k e n ,  M .  O . ,  H o u b e n ,  M .  L ., S c h u i j f f ,  L . , ... B o n t ,  L.
( 2 0 0 9 ) .  S k e w e d  p a t t e r n  o f  T o l l - l ik e  r e c e p t o r  4 - m e d i a t e d  c y t o k in e  p r o d u c t io n  in  h u m a n  
n e o n a t a l  b lo o d :  lo w  L P S - in d u c e d  IL - 1 2 p 7 0  a n d  h ig h  IL - 1 0  p e r s is t  t h r o u g h o u t  t h e  f i r s t  m o n t h  
o f  l i f e .  Clinical Immunology, 1 3 3 ( 2 ) ,  2 2 8 - 3 7 .  d o i : 1 0 . 1 0 1 6 / j . c l i m . 2 0 0 9 . 0 7 . 0 0 3
B e n n ,  C . S ., F is k e r ,  A .  B ., R o d r ig u e s ,  A . ,  R a v n , H . ,  S a r t o n o ,  E ., W h i t t l e ,  H . , ... A a b y ,  P . ( 2 0 0 8 ) .  S e x -  
d i f f e r e n t i a l  e f f e c t  o n  in f a n t  m o r t a l i t y  o f  o r a l  p o l io  v a c c in e  a d m in is t e r e d  w i t h  B C G  a t  b i r t h  in  
G u in e a -B is s a u .  A  n a t u r a l  e x p e r im e n t .  PloS One, 3 ( 1 2 ) ,  e 4 0 5 6 .  
d o i : 1 0 . 1 3 7 1 / j o u r n a l . p o n e . 0 0 0 4 0 5 6
B e r r y ,  M .  P . R ., G r a h a m ,  C . M . ,  M c N a b ,  F. W . ,  X u , Z .,  B lo c h , S . a a , O n i ,  T . , ... O 'G a r r a ,  A .  ( 2 0 1 0 ) .  A n  
in t e r f e r o n - in d u c ib le  n e u t r o p h i l - d r iv e n  b lo o d  t r a n s c r ip t io n a l  s ig n a t u r e  in  h u m a n  
t u b e r c u lo s is .  Nature, 4 6 6 ( 7 3 0 9 ) ,  9 7 3 - 7 .  d o i : 1 0 . 1 0 3 8 / n a t u r e 0 9 2 4 7
B ie r in g - S p r e n s e n ,  S ., A a b y ,  P ., N a p i r n a ,  B. M . ,  R o th ,  A . ,  R a v n , H . ,  R o d r ig u e s ,  A . , ... B e n n ,  C . S .
( 2 0 1 2 ) .  S m a ll  r a n d o m iz e d  t r i a l  a m o n g  l o w - b i r t h - w e i g h t  c h i ld r e n  r e c e iv in g  b a c i l lu s  C a l m e t t e -  
G u e r in  v a c c in a t io n  a t  f i r s t  h e a l t h  c e n t e r  c o n t a c t .  The Pediatric Infectious Disease Journal, 
3 1 ( 3 ) ,  3 0 6 - 8 .  d o i : 1 0 . 1 0 9 7 / I N F . 0 b 0 1 3 e 3 1 8 2 4 5 8 2 8 9
B la c k , G . F ., D o c k r e l l ,  H . M . ,  C r a m p in ,  a  C ., F lo y d , S ., W e i r ,  R. E ., B lis s , L . , ... F in e ,  P . E. ( 2 0 0 1 ) .  
P a t t e r n s  a n d  im p l ic a t io n s  o f  n a t u r a l l y  a c q u i r e d  im m u n e  r e s p o n s e s  t o  e n v i r o n m e n t a l  a n d  
t u b e r c u lo u s  m y c o b a c t e r ia l  a n t ig e n s  in  n o r t h e r n  M a l a w i .  The Journal o f Infectious Diseases, 
184[3 ) ,  3 2 2 - 9 .  d o i : 1 0 . 1 0 8 6 / 3 2 2 0 4 2
B la c k , G . F ., W e i r ,  R . E ., F lo y d , S ., B lis s , L ., W a r n d o r f f ,  D . K ., C r a m p in ,  A . C . , ... D o c k r e l l ,  H .  M .
( 2 0 0 2 ) .  B C G - in d u c e d  in c r e a s e  in  i n t e r f e r o n - g a m m a  r e s p o n s e  t o  m y c o b a c t e r ia l  a n t ig e n s  a n d
138
e f f ic a c y  o f  B C G  v a c c in a t io n  in  M a l a w i  a n d  t h e  U K  : t w o  r a n d o m is e d  c o n t r o l le d  s tu d ie s .  
Lancet, ( 3 5 9 ) ,  1 3 9 3 - 1 4 0 1 .
B lo m g r a n ,  R ., &  E r n s t ,  J. D . ( 2 0 1 1 ) .  L u n g  n e u t r o p h i ls  f a c i l i t a t e  a c t iv a t io n  o f  n a iv e  a n t ig e n - s p e c i f ic  
C D 4 +  T  c e lls  d u r in g  M y c o b a c t e r iu m  t u b e r c u lo s is  in f e c t io n .  Journal o f Immunology, 1 5 5 ( 1 2 ) ,  
7 1 1 0 - 9 .  d o i : 1 0 . 4 0 4 9 / j i m m u n o l . 1 1 0 0 0 0 1
B o r r e g a a r d ,  N . ( 2 0 1 0 ) .  N e u t r o p h i ls ,  f r o m  m a r r o w  t o  m ic r o b e s .  Immunity, 3 3 ( 5 ) ,  6 5 7 - 7 0 .  
d o i : 1 0 . 1 0 1 6 / j . i m m u n i . 2 0 1 0 . 1 1 . 0 1 1
B o u s s io t is ,  V .  a , T s a i,  E . Y .,  Y u n is ,  E. J ., T h im ,  S ., D e lg a d o ,  J. C ., D a s c h e r ,  C . C . , ... G o ld f e ld ,  a E.
( 2 0 0 0 ) .  I L - 1 0 - p r o d u c in g T  c e lls  s u p p r e s s  im m u n e  r e s p o n s e s  in  a n e r g ic  t u b e r c u lo s is  p a t ie n t s .  
The Journal o f Clinical Investigation, 105(9), 1 3 1 7 - 2 5 .  d o i : 1 0 . 1 1 7 2 / J C I 9 9 1 8
B r a n d t ,  L ., C u n h a ,  J. F ., O ls e n ,  A .  W . ,  C h i l im a ,  B ., H ir s c h , P ., A p p e lb e r g ,  R ., &  A n d e r s e n ,  P . ( 2 0 0 2 ) .  
F a i lu r e  o f  t h e  M y c o b a c t e r iu m  b o v is  B C G  V a c c in e  : S o m e  S p e c ie s  o f  E n v i r o n m e n t a l  
M y c o b a c t e r ia  B lo c k  M u l t i p l i c a t i o n  o f  B C G  a n d  In d u c t io n  o f  P r o t e c t iv e  I m m u n i t y  t o  
T u b e r c u lo s is .  Infection and Immunity, 70(2), 6 7 2 - 6 7 8 .  d o i : 1 0 . 1 1 2 8 / I A I . 7 0 . 2 . 6 7 2
B r ig h t b i l l ,  H . D . ,  L ib r a ty ,  D . H .,  K r u tz ik ,  S . R ., Y a n g , R .-B .,  B e l is le ,  J. T . ,  B le h a r k s i ,  J. R . , ... N o d l in ,  R . L. 
( 1 9 9 9 ) .  H o s t  D e f e n s e  M e c h a n is m s  T r ig g e r e d  b y  M ic r o b ia l  L ip o p r o t e in s  T h r o u g h  T o l l - L ik e  
R e c e p t o r s .  Science, 2 5 5 ( 5 4 2 8 ) ,  7 3 2 - 7 3 6 .  d o i : 1 0 . 1 1 2 6 / s c i e n c e . 2 8 5 . 5 4 2 8 . 7 3 2
B r u n s , H .,  M e i n k e n ,  C ., S c h a u e n b e r g ,  P ., H a r t e r ,  G . ,  K e r n ,  P ., M o d l in ,  R . L . , ... S t e n g e r ,  S . ( 2 0 0 9 ) .  
A n t i - T N F  i m m u n o t h e r a p y  r e d u c e s  C D 8  +  T  c e ll  -  m e d ia t e d  a n t im ic r o b ia l  a c t iv i t y  a g a in s t  
M y c o b a c t e r iu m  t u b e r c u lo s is  in  h u m a n s .  The Journal o f Clinical Investigation, 119(5). 
d o i : 1 0 . 1 1 7 2 / J C I 3 8 4 8 2 . a t e d
B u r g , N .  D . ,  &  P i l l in g e r ,  M .  H . ( 2 0 0 1 ) .  T h e  n e u t r o p h i l :  f u n c t io n  a n d  r e g u la t io n  in  i n n a t e  a n d  
h u m o r a l  im m u n i t y .  Clinical Immunology, 99(1), 7 - 1 7 .  d o i : 1 0 . 1 0 0 6 / c l i m . 2 0 0 1 . 5 0 0 7
B u r l ,  S ., A d e t i f a ,  U . J ., C o x , M . ,  T o u r a y ,  E ., O t a ,  M .  O . ,  M a r c h a n t ,  A . , ... F la n a g a n ,  K. L. ( 2 0 1 0 ) .  
D e la y in g  B a c il lu s  C a m e t t e  G u e r in  V a c c in a t io n  f r o m  b i r t h  t o  4  1 / 2  m o n t h s  o f  a g e  r e d u c e s  
p o s t v a c c in a t io n  T h l  a n d  IL - 1 7  r e s p o n s e s  b u t  le a d s  t o  c o m p a r a b le  M y c b a c t e r i a l  r e s p o n s e s  a t  
9  m o n t h s  o f  a g e .  Journal o f Immunology, 185. d o i : 1 0 . 4 0 4 9 / j i m m u n o l . 1 0 0 0 5 5 2
B u r l ,  S ., A d e t i f a ,  U . J ., C o x , M . ,  T o u r a y ,  E ., W h i t t l e ,  H . ,  M c S h a n e ,  H . , ... F la n a g a n ,  K. L. ( 2 0 1 0 ) .  T h e  
t u b e r c u l in  s k in  t e s t  (T S T ) is a f f e c t e d  b y  r e c e n t  B C G  v a c c in a t io n  b u t  n o t  b y  e x p o s u r e  t o  n o n ­
t u b e r c u lo s is  m y c o b a c t e r ia  ( N T M )  d u r in g  e a r ly  l i f e .  PloS One, 5 ( 8 ) ,  e l 2 2 8 7 .  
d o i : 1 0 . 1 3 7 1 / j o u r n a l . p o n e . 0 0 1 2 2 8 7
B u r l ,  S ., H i l l ,  P . C ., J e f f r ie s ,  D . J ., H o l la n d ,  M .  J ., F o x , a , L u g o s , M .  D . , ... B r o o k e s ,  R . H . ( 2 0 0 7 ) .  F O X P 3  
g e n e  e x p r e s s io n  in  a tu b e r c u lo s is  c a s e  c o n t a c t  s t u d y .  Clinical and Experimental Immunology, 
149(1), 1 1 7 - 2 2 .  d o i : 1 0 . 1 1 1 1 / j . 1 3 6 5 - 2 2 4 9 . 2 0 0 7 . 0 3 3 9 9 . x
B u r l ,  S ., H o ld e r ,  B. S ., L o , B. K. M . ,  &  K a m p m a n n ,  B . ( 2 0 1 3 ) .  O p t im is a t io n  o f  a  f u n c t i o n a l
m y c o b a c t e r ia l  g r o w t h - in h ib i t io n  a s s a y  t o  im p r o v e  its  s u i t a b i l i t y  f o r  in f a n t  T B  v a c c in e  s t u d ie s .  
Journal o f Immunological Methods, 394(1-2), 1 2 1 - 4 .  d o i : 1 0 . 1 0 1 6 / j . j i m . 2 0 1 3 . 0 5 . 0 0 6
B u r l ,  S ., T o w n e n d ,  J ., N j ie - J o b e ,  J ., C o x , M . ,  A d e t i f a ,  U .  J ., T o u r a y ,  E . , ... L e v y , O . ( 2 0 1 1 ) .  A g e -  
d e p e n d e n t  m a t u r a t io n  o f  T o l l - l ik e  r e c e p t o r - m e d i a t e d  c y t o k in e  r e s p o n s e s  in  G a m b ia n  
in f a n t s .  PloS One, 6 ( 4 ) ,  e l 8 1 8 5 .  d o i : 1 0 . 1 3 7 1 / j o u r n a l . p o n e . 0 0 1 8 1 8 5
139
C a n a d a y ,  D . H . ,  W i lk in s o n ,  R . J ., L i, Q . ,  C l i f f o r d ,  V . ,  S i lv e r ,  R . F ., &  B o o m , W .  H . ( 2 0 0 1 ) .  C D 4 +  a n d  
C D 8 + T  c e lls  k ill i n t r a c e l lu la r  m y c o b a c t e r iu m  t u b e r c u lo s is  b y  a p e r f o r in  a n d  F a s /F a s  L ig a n d -  
In d e p e n d e n t  m e c h a n is m .  Journal o f Immunology, 167, 2 7 3 4 - 2 7 4 2 .
C a r v a lh o ,  N .  B ., O l iv e i r a ,  F. S ., D u r a e s ,  F . V ,  d e  A lm e id a ,  L. a , F lo r id o ,  M . ,  P r a t a ,  L. O . , ... O l iv e i r a ,  S. 
C . ( 2 0 1 1 ) .  T o l l - l ik e  r e c e p t o r  9  is r e q u i r e d  f o r  f u l l  h o s t  r e s is ta n c e  t o  M y c o b a c t e r iu m  a v iu m  
in f e c t io n  b u t  p la y s  n o  r o le  in  in d u c t io n  o f  T h l  r e s p o n s e s .  Infection and Immunity, 7 9 ( 4 ) ,  
1 6 3 8 - 4 6 .  d o i : 1 0 . 1 1 2 8 / I A I . 0 1 0 3 0 - 1 0
C a s im ir ,  G . J. a , M u l i e r ,  S ., H a n s s e n s , L., Z y lb e r b e r g ,  K ., &  D u c h a t e a u ,  J. ( 2 0 1 0 ) .  G e n d e r  d i f f e r e n c e s  
in  i n f l a m m a t o r y  m a r k e r s  in  c h i ld r e n .  Shock (Augusta, Ga.), 3 3 ( 3 ) ,  2 5 8 - 6 2 .  
d o i : 1 0 . 1 0 9 7 / S H K . 0 b 0 1 3 e 3 1 8 1 b 2 b 3 6 b
C D C . ( 2 0 1 1 ) .  N o  T i t l e .  R e t r ie v e d  J u ly  0 6 ,  2 0 1 3 ,  f r o m
h t t p : / / w w w . c d c . g o v / t b / t o p i c / t r e a t m e n t / d e f a u l t . h t m
C h a n ,  P .-C .,  C h a n g ,  L .-Y ., W u ,  Y . -C .,  L u , C .-Y .,  K u o , H .-S . ,  L e e , C . - Y . , ... C h e n ,  C .-J . ( 2 0 0 8 ) .  A g e -
s p e c i f ic  c u t - o f f s  f o r  t h e  t u b e r c u l in  s k in  t e s t  t o  d e t e c t  l a t e n t  t u b e r c u lo s is  in  B C G -v a c c in a t e d  
c h i ld r e n .  The International Journal o f Tuberculosis and Lung Disease, 12(12), 1 4 0 1 - 6 .  
R e t r ie v e d  f r o m  h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 1 9 0 1 7 4 4 9
C h e n ,  X . ,  Z h o u ,  B ., L i, M . ,  D e n g ,  Q . ,  W u ,  X .,  L e , X . , ... K a ts a n is ,  E. ( 2 0 0 7 ) .  C D 4 ( + ) C D 2 5 ( + ) F o x P 3 ( + )  
r e g u la t o r y  T  c e lls  s u p p r e s s  M y c o b a c t e r iu m  t u b e r c u lo s is  i m m u n i t y  in  p a t ie n t s  w i t h  a c t iv e  
d is e a s e .  Clinical Immunology, 123(1), 5 0 - 9 .  d o i : 1 0 . 1 0 1 6 / j . c l i m . 2 0 0 6 . 1 1 . 0 0 9
C o b a t ,  A . ,  B a r r e r a ,  L. F ., H e n a o ,  H . ,  A r b e la e z ,  P ., A b e l ,  L ., G a r c ia ,  L. F . , ... A lc a i's , A . ( 2 0 1 2 ) .  
T u b e r c u l in  s k in  t e s t  r e a c t iv i t y  is d e p e n d e n t  o n  h o s t  g e n e t ic  b a c k g r o u n d  in  C o lo m b ia n  
t u b e r c u lo s is  h o u s e h o ld  c o n t a c t s .  Clinical Infectious Diseases, 54(7), 9 6 8 - 7 1 .  
d o i : 1 0 . 1 0 9 3 / c i d / c i r 9 7 2
C o ld i t z ,  G . A . ,  B e r k e y ,  C . S ., M o s t e l l e r ,  F ., B r e w e r ,  T .  F ., W i ls o n ,  M .  E ., B u r d ic k ,  E ., &  F in e b e r g ,  H . V .  
( 1 9 9 5 ) .  T h e  E f f ic a c y  o f  B a c il lu s  C a lm e t t e - G u e r in  V a c c in a t io n  o f  N e w b o r n s  a n d  In f a n t s  in  t h e  
P r e v e n t io n  o f  T u b e r c u lo s is  : M e t a - A n a ly s e s  o f  t h e  P u b l is h e d  L i t e r a t u r e .  Pediatrics, 96(29).
C o o k , I. F . ( 2 0 0 8 ) .  S e x u a l d im o r p h is m  o f  h u m o r a l  i m m u n i t y  w i t h  h u m a n  v a c c in e s .  Vaccine, 26(29- 
3 0 ) ,  3 5 5 1 - 5 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 0 8 . 0 4 . 0 5 4
C o o p e r ,  A . M . ,  D a l t o n ,  D . K ., S t e w a r t ,  T .  A . ,  G r i f f in ,  J. P ., R u s s e ll ,  D . G .,  &  O r m e ,  I. M .  ( 1 9 9 3 ) .  
D is s e m in a t e d  T u b e r c u lo s is  in  I n t e r f e r o n  g  G e n e - d is r u p t e d  M ic e .  Journal o f Experimental 
Medicine, 178(D e c e m b e r ) ,  2 2 4 3 - 2 2 4 7 .
C o r b e l ,  M . ., F r u t h ,  U . ,  G r i f f i t h s ,  E ., &  K n e z e v ic ,  I. ( 2 0 0 4 ) .  R e p o r t  o n  a W H O  C o n s u l t a t io n  o n  t h e  
c h a r a c t e r is a t io n  o f  B C G  s t r a in s ,  Im p e r ia l  C o l le g e ,  L o n d o n  1 5 - 1 6  D e c e m b e r  2 0 0 3 .  Vaccine, 
22(21-22), 2 6 7 5 - 2 6 8 0 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 0 4 . 0 1 . 0 5 0
C o u r t ,  N . ,  V a s s e u r ,  V . ,  V a c h e r ,  R ., F r e m o n d ,  C ., S h e b z u k h o v ,  Y ., Y e r e m e e v ,  V .  V , ... Q u e s n ia u x ,  V .  F. 
J. ( 2 0 1 0 ) .  P a r t ia l  r e d u n d a n c y  o f  t h e  p a t t e r n  r e c o g n i t io n  r e c e p t o r s ,  s c a v e n g e r  r e c e p t o r s ,  a n d  
C - t y p e  le c t in s  f o r  t h e  lo n g - t e r m  c o n t r o l  o f  M y c o b a c t e r i u m  t u b e r c u lo s is  in f e c t io n .  Journal o f 
Immunology, 184(12), 7 0 5 7 - 7 0 .  d o i : 1 0 . 4 0 4 9 / j i m m u n o l . 1 0 0 0 1 6 4
C u e n c a ,  A . G .,  W y n n ,  J. L ., M o l d a w e r ,  L. L., &  L e v y , O . ( 2 0 1 3 ) .  R o le  o f  in n a t e  i m m u n i t y  in  n e o n a t a l  
in f e c t io n .  American Journal o f Perinatology, 30(2), 1 0 5 - 1 2 .  d o i : 1 0 . 1 0 5 5 / s - 0 0 3 2 - 1 3 3 3 4 1 2
140
D a v id s ,  V . ,  H a n e k o m ,  W .  a , M a n s o o r ,  N . ,  G a m ie ld ie n ,  H . ,  G e ld e r b lo e m ,  S . J ., H a w k r id g e ,  A . , ... 
K a p la n ,  G . ( 2 0 0 6 ) .  T h e  e f f e c t  o f  b a c i l le  C a lm e t t e - G u e r in  v a c c in e  s t r a in  a n d  r o u t e  o f  
a d m in is t r a t io n  o n  in d u c e d  im m u n e  r e s p o n s e s  in  v a c c in a t e d  in f a n t s .  The Journal o f Infectious 
Diseases, 1 5 3 ( 4 ) ,  5 3 1 - 6 .  d o i : 1 0 . 1 0 8 6 / 4 9 9 8 2 5
D e J o n g , R ., A l t a r e ,  F ., H a a g e n ,  l . - A . ,  E l f e r in k ,  D . G .,  B o e r ,  T .  d e ,  V r ie s m a n ,  P . J. v a n  B . , ... O t t e n h o f f ,  
T .  H . . ( 1 9 9 8 ) .  S e v e r e  M y c o b a c t e r ia l  a n d  S a lm o n e l la  In f e c t io n s  in  I n t e r l e u k i n - 1 2  R e c e p t o r -  
D e f ic ie n t  P a t ie n t s .  Science, 2 8 0 ( 5 3 6 8 ) ,  1 4 3 5 - 1 4 3 8 .  d o i : 1 0 . 1 1 2 6 / s c i e n c e . 2 8 0 . 5 3 6 8 . 1 4 3 5
D e m is s ie ,  A . ,  W a s s ie ,  L ., A b e b e ,  M . ,  A s e f f a ,  A . ,  R o o k , G .,  Z u m la ,  A . , ... G r o u p ,  S . V .  ( 2 0 0 6 ) .  T h e  6 -  
K ilo d a l t o n  E a r ly  S e c r e t e d  A n t ig e n ic  C o n ta c ts  o f  T u b e r c u lo s is  P a t ie n t s  E x p re s s  E le v a t e d  L e v e ls  
o f  ln t e r l e u k i n - 4  a n d  R e d u c e d  L e v e ls  o f  G a m m a  I n t e r f e r o n  T h e  6 - K i lo d a l t o n  E a r ly  S e c r e t e d  
A n t ig e n ic  T a r g e t - R e s p o n s i v e , A s y m p t o m a t ic  C o n ta c ts  o f  T u b e r c u lo s is .  Infection and 
Immunity, 7 4 ( 5 ) ,  2 8 1 7 - 2 8 2 2 .  d o i : 1 0 . 1 1 2 8 / I A I . 7 4 . 5 . 2 8 1 7
D in a r e l lo ,  C . a .  ( 2 0 0 0 ) .  P r o in f la m m a t o r y  C y to k in e s .  CHEST Journal, 1 1 8 ( 2 ) ,  5 0 3 .  
d o i : 1 0 . 1 3 7 8 / c h e s t . 1 1 8 . 2 . 5 0 3
D o f f in g e r ,  R ., P a t e l ,  S ., &  K u m a r a r a t n e ,  D . S . ( 2 0 0 5 ) .  H u m a n  im m u n o d e f ic ie n c ie s  t h a t  p r e d is p o s e  
t o  in t r a c e l lu la r  b a c t e r ia l  in f e c t io n s .  Current Opinion in Rheumatology, 1 7 ( 4 ) ,  4 4 0 - 6 .
R e t r ie v e d  f r o m  h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 1 5 9 5 6 8 4 1
D r e n n a n ,  M .  B ., N ic o l le ,  D . ,  Q u e s n ia u x ,  V .  J. F ., J a c o b s , M . ,  A l l ie ,  N . ,  M p a g i ,  J . , ... R y f fe l ,  B . ( 2 0 0 4 ) .  
T o l l - l ik e  r e c e p t o r  2 - d e f i c i e n t  m ic e  s u c c u m b  t o  M y c o b a c t e r i u m  t u b e r c u lo s is  in f e c t io n .  The 
American Journal o f Pathology, 1 6 4 ( 1 ) ,  4 9 - 5 7 .  d o i : 1 0 . 1 0 1 6 / S 0 0 0 2 - 9 4 4 0 ( 1 0 ) 6 3 0 9 5 - 7
D u v ig n e a u ,  J. C ., S ip o s , W . ,  H a r t l ,  R . T . ,  B a y e r ,  M . ,  M o ld z io ,  R ., S te v e n s o n ,  L . , ... G e m e i n e r ,  M .
( 2 0 0 7 ) .  H e p a r in  a n d  E D T A  a s  a n t ic o a g u la n t  d i f f e r e n t i a l l y  a f f e c t  c y t o k in e  m R N A  le v e l  o f  
c u l t u r e d  p o r c in e  b lo o d  c e lls . Journal o f Immunological Methods, 3 2 4 ( 1 - 2 ) ,  3 8 - 4 7 .  
d o i : 1 0 . 1 0 1 6 / j . j i m . 2 0 0 7 . 0 4 . 0 1 2
E r n s t ,  J. D . ( 1 9 9 8 ) .  M a c r o p h a g e  R e c e p to r s  f o r  M y c o b a c t e r iu m  t u b e r c u lo s is .  Infection and 
Immmunity, 3 ( 4 1 ) ,  1 2 7 7 - 1 2 8 1 .
E u m , S .-Y .,  K o n g , J .-H . ,  H o n g ,  M . - S . ,  L e e ,  Y .-J ., K im , J . -H . ,  H w a n g ,  S . - H . , ... B a r r y ,  C . E . ( 2 0 1 0 ) .  
N e u t r o p h i ls  a r e  t h e  p r e d o m i n a n t  in f e c t e d  p h a g o c y t ic  c e lls  in  t h e  a i r w a y s  o f  p a t ie n t s  w i t h  
a c t iv e  p u lm o n a r y  T B . Chest, 1 3 7 ( 1 ) ,  1 2 2 - 8 .  d o i : 1 0 . 1 3 7 8 / c h e s t . 0 9 - 0 9 0 3
F e r w e r d a ,  G .,  G i r a r d in ,  S . E ., K u l lb e r g ,  B ., B o u r h is ,  L. L e , J o n g , D . J. D e ,  L a n g e n b e r g ,  D . M .  L . , ... 
N e t e a ,  M .  G . ( 2 0 0 5 ) .  N O D 2  a n d  T o l l - L ik e  R e c e p t o r s  A r e  N o n r e d u n d a n t  R e c o g n i t io n  S y s te m s  
o f  M y c o b a c t e r iu m  t u b e r c u lo s is .  Plos Pathogens, 1 ( 3 ) .  d o i : 1 0 . 1 3 7 1 / j o u r n a l . p p a t . 0 0 1 0 0 3 4
F e s k e , S . ( 2 0 0 7 ) .  C a lc iu m  s ig n a l l in g  in  l y m p h o c y t e  a c t iv a t io n  a n d  d is e a s e .  Nature Reviews 
Immunology, 7 . d o i : 1 0 . 1 0 3 8 / n r i 2 1 5 2
F in e ,  P . E. ( 1 9 9 5 ) .  V a r ia t io n  in  p r o t e c t io n  b y  B C G : im p l ic a t io n s  o f  a n d  f o r  h e t e r o lo g o u s  i m m u n i t y .  
Lancet, 3 4 6 ( 8 9 8 6 ) ,  1 3 3 9 - 4 5 .  R e t r ie v e d  f r o m  
h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 7 4 7 5 7 7 6
F in e ,  P . E. M .  ( 1 9 9 9 ) .  Is s u e s  r e la t in g  t o  t h e  u s e  o f  B C G  in  im m u n iz a t io n  p r o g r a m m e s  A  d is c u s s io n  
d o c u m e n t .  WHO Dicussion Paper. R e t r ie v e d  f r o m  W H O
141
F la n a g a n ,  K . L ., K le in ,  S . L ., S k a k k e b a e k ,  N .  E ., M a r r i o t t ,  I . ,  M a r c h a n t ,  A . ,  S e l in ,  L . , ... A a b y ,  P .
( 2 0 1 1 ) .  S e x  d i f f e r e n c e s  in  t h e  v a c c in e - s p e c i f ic  a n d  n o n - t a r g e t e d  e f f e c t s  o f  v a c c in e s .  Vaccine, 
29(13), 2 3 4 9 - 5 4 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 1 1 . 0 1 . 0 7 1
F la n a g a n ,  K. L ., v a n  C r e v e l ,  R ., C u r t is ,  N . ,  S h a n n ,  F ., &  L e v y , 0 .  ( 2 0 1 3 ) .  H e t e r o lo g o u s  ( " n o n s p e c i f ic " )  
a n d  s e x - d i f f e r e n t ia l  e f f e c t s  o f  v a c c in e s :  e p id e m io lo g y ,  c lin ic a l  t r ia ls ,  a n d  e m e r g in g  
im m u n o lo g ic  m e c h a n is m s .  Clinical Infectious Diseases, 5 7 ( 2 ) ,  2 8 3 - 9 .  d o i : 1 0 . 1 0 9 3 / c i d / c i t 2 0 9
F ly n n ,  J. L ., C h a n ,  J ., T r ie b o ld ,  K. J ., D a l t o n ,  D . K ., S t e w a r t ,  T .  A . ,  &  B lo o m ,  B . R . ( 1 9 9 3 ) .  A n  e s s e n t ia l  
r o le  f o r  in t e r f e r o n  g  in  r e s is ta n c e  t o  M y c o b a c t e r iu m  tu b e r c u lo s is  in f e c t io n .  Journal o f 
Experimental Medicine, 178, 2 2 4 9 - 2 2 5 4 .
F o r b e s ,  E. K ., S a n d e r ,  C ., R o n a n ,  E. 0 . ,  M c S h a n e ,  H .,  H i l l ,  a .  V .  S ., B e v e r le y ,  P . C . L ., &  T c h i l ia n ,  E. Z .
( 2 0 0 8 ) .  M u l t i f u n c t i o n a l ,  H ig h -L e v e l  C y t o k in e - P r o d u c in g  T h l  C e lls  in  t h e  L u n g , b u t  N o t  S p le e n ,  
C o r r e la t e  w i t h  P r o t e c t io n  a g a in s t  M y c o b a c t e r iu m  tu b e r c u lo s is  A e r o s o l  C h a l le n g e  in  M ic e .
The Journal o f Immunology, 181(7), 4 9 5 5 - 4 9 6 4 .  d o i : 1 0 . 4 0 4 9 / j i m m u n o l . 1 8 1 . 7 . 4 9 5 5
F u j iw a r a  S, A k iy a m a  M ,  Y a m a k id o  M ,  S e y a m a  T ,  K o b u k e  K, H a k o d a  M ,  K y o iz u m i S, J. S . ( 1 9 8 6 ) .  
C r y o p r e s e r v a t io n  o f  h u m a n  ly m p h o c y t e s  f o r  a s s e s s m e n t  o f  ly m p h o c y t e  s u b s e ts  a n d  n a t u r a l  
k i l le r  c y t o t o x ic i t y .  Journal o f Immunological Methods, 90(2 6 5 - 2 7 3 ) .
G e g in a t ,  J ., S a l lu s to ,  F ., &  L a n z a v e c c h ia ,  a .  ( 2 0 0 1 ) .  C y t o k in e - d r iv e n  p r o l i f e r a t io n  a n d
d i f f e r e n t i a t i o n  o f  h u m a n  n a iv e ,  c e n t r a l  m e m o r y ,  a n d  e f f e c t o r  m e m o r y  C D 4 ( + )  T  c e l ls .  The 
Journal o f Experimental Medicine, 194(12), 1 7 1 1 - 9 .  R e t r ie v e d  f r o m
h t t p : / / w w w . p u b m e d c e n t r a l . n i h . g o v / a r t i c l e r e n d e r . f c g i ? a r t i d = 2 1 9 3 5 6 8 & t o o l = p m c e n t r e z & r e n
d e r t y p e = a b s t r a c t
G r e e n ,  M .  S ., S h o h a t ,  T . ,  L e r m a n ,  Y . ,  C o h e n ,  D .,  S le p o n ,  R ., D u v d e v a n i ,  P . , ... M e n d e l s o n ,  E. ( 1 9 9 4 ) .  
S e x  d i f f e r e n c e s  in  t h e  h u m o r a l  a n t ib o d y  r e s p o n s e  t o  l iv e  m e a s le s  v a c c in e  in  y o u n g  a d u l t s .  
International Journal o f Epidemiology, 23(5), 1 0 7 8 - 8 1 .  R e t r ie v e d  f r o m  
h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 7 8 6 0 1 5 9
G u t ie r r e z ,  M .  G .,  M a s t e r ,  S . S ., S in g h , S . B ., T a y lo r ,  G . a ,  C o lo m b o ,  M .  I . ,  &  D e r e t ic ,  V .  ( 2 0 0 4 ) .
A u t o p h a g y  is a d e f e n s e  m e c h a n is m  in h ib i t in g  B C G  a n d  M y c o b a c t e r iu m  t u b e r c u lo s is  s u r v iv a l  
in  in f e c t e d  m a c r o p h a g e s .  Cell, 119(6), 7 5 3 - 6 6 .  d o i : 1 0 . 1 0 1 6 / j . c e l l . 2 0 0 4 . 1 1 . 0 3 8
G u y o t - R e v o l ,  V . ,  In n e s ,  J. a , H a c k f o r t h ,  S ., H in k s , T . ,  &  L a lv a n i,  A . ( 2 0 0 6 ) .  R e g u la t o r y  T  c e lls  a r e  
e x p a n d e d  in  b lo o d  a n d  d is e a s e  s ite s  in  p a t ie n t s  w i t h  t u b e r c u lo s is .  American Journal o f  
Respiratory and Critical Care Medicine, 173(7), 8 0 3 - 1 0 .  d o i : 1 0 . 1 1 6 4 / r c c m . 2 0 0 5 0 8 - 1 2 9 4 0 C
H a m a s u r ,  B ., H a i le ,  M . ,  P a w lo w s k i ,  a , S c h r o d e r ,  U . ,  K a l le n iu s ,  G . ,  &  S v e n s o n ,  S . B . ( 2 0 0 4 ) .  A  
m y c o b a c t e r ia l  l ip o a r a b in o m a n n a n  s p e c if ic  m o n o c lo n a l  a n t ib o d y  a n d  its  F ( a b ')  f r a g m e n t  
p r o lo n g  s u r v iv a l  o f  m ic e  in f e c t e d  w i t h  M y c o b a c t e r iu m  t u b e r c u lo s is .  Clinical and 
Experimental Immunology, 138(1), 3 0 - 8 .  d o i : 1 0 . 1 1 1 1 / j . l 3 6 5 - 2 2 4 9 . 2 0 0 4 . 0 2 5 9 3 . x
H a n e k o m ,  W .  a .  ( 2 0 0 5 ) .  T h e  i m m u n e  r e s p o n s e  t o  B C G  v a c c in a t io n  o f  n e w b o r n s .  Annals o f the 
New York Academy o f Sciences, 1062, 6 9 - 7 8 .  d o i : 1 0 . 1 1 9 6 / a n n a l s . 1 3 5 8 . 0 1 0
H e ld w e in ,  K. a ,  &  F e n t o n ,  M .  J. ( 2 0 0 2 ) .  T h e  r o le  o f  T o l l - l ik e  r e c e p t o r s  in  im m u n i t y  a g a in s t  
m y c o b a c t e r ia l  in f e c t io n .  Microbes and Infection, 4(9), 9 3 7 - 4 4 .  R e t r ie v e d  f r o m  
h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 1 2 1 0 6 7 8 6
H e n d e r s o n ,  R . A . ,  W a t k in s ,  S . C ., &  F ly n n , J. L. ( 1 9 9 7 ) .  A c t iv a t io n  o f  H u m a n  D e n d r i t i c  C e lls  
F o l lo w in g  In f e c t io n  w i t h .  Journal o f Immunology, ( 1 5 9 ) ,  6 3 5 - 6 4 3 .
142
H ir v e ,  S ., B a v d e k a r ,  A . ,  J u v e k a r ,  S ., B e n n ,  C . S ., N ie ls e n ,  J ., &  A a b y ,  P . ( 2 0 1 2 ) .  N o n - s p e c i f ic  a n d  s e x -  
d i f f e r e n t i a l  e f f e c t s  o f  v a c c in a t io n s  o n  c h ild  s u r v iv a l  in  r u r a l  w e s t e r n  In d ia .  Vaccine, 3 0 ( 5 0 ) ,  
7 3 0 0 - 8 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 1 2 . 0 9 . 0 3 5
H u s s e y , G . D . ,  W a t k in s ,  M .  L. V ,  G o d d a r d ,  E. a , G o t t s c h a lk ,  S ., H u g h e s ,  E . J ., I lo n i ,  K . , ... R e s s , S . R. 
( 2 0 0 2 ) .  N e o n a t a l  m y c o b a c t e r ia l  s p e c if ic  c y t o t o x ic  T - ly m p h o c y t e  a n d  c y t o k in e  p r o f i le s  in  
r e s p o n s e  t o  d is t in c t  B C G  v a c c in a t io n  s t r a t e g ie s .  Immunology, 1 0 5 ( 3 ) ,  3 1 4 - 2 4 .  R e t r ie v e d  
f r o m
h t t p : / / w w w . p u b m e d c e n t r a l . n i h . g o v / a r t i c l e r e n d e r . f c g i ? a r t i d = 1 7 8 2 6 6 1 & t o o l = p m c e n t r e z & r e n
d e r t y p e = a b s t r a c t
Iw a s a k i ,  A . ,  &  M e d z h i t o v ,  R. ( 2 0 0 4 ) .  T o l l - l ik e  r e c e p t o r  c o n t r o l  o f  t h e  a d a p t iv e  im m u n e  r e s p o n s e s .  
Nature Immunology, 5 ( 1 0 ) ,  9 8 7 - 9 5 .  d o i : 1 0 . 1 0 3 8 / n i l l l 2
J o b e , K . B. ( 2 0 0 6 ) .  The Gambia NATIONAL EXPANDED PROGRAMME ON DESK REVIEW REPORT 
( p p .  1 - 5 0 ) .
J o h n s o n ,  C . M . ,  C o o p e r ,  A .  M . ,  F r a n k ,  A .  A . ,  B o n o r in o ,  C . B. C ., W y s o k i ,  L. J ., &  O r m e ,  I. M .  ( 1 9 9 7 ) .  
M y c o b a c t e r iu m  t u b e r c u lo s is  a e r o g e n ic  r e c h a l le n g e  in f e c t io n s  in  B c e l l - d e f i c i e n t  m ic e .  
Tubercle and Lung Disease, 7 8 ( 5 ) ,  2 5 7 - 2 6 1 .
J u n q u e ir a - k ip n is ,  A . P ., K ip n is , A . ,  J a m ie s o n ,  A .,  G o n z a le z ,  M . ,  D ie f e n b a c h ,  A . ,  R a u le t ,  D . H . , ... 
O r m e ,  I. M .  ( 2 0 0 3 ) .  N k  c e lls  R e s p o n d  t o  p u lm o n a r y  In f e c t io n  w i t h  M y c o b a c t e r i u m  
t u b e r c u lo s is ,  b u t  p la y  a m in im a l  r o le  in  p r o t e c t io n .  Journal o f Immunology, 171, 6 0 3 9 - 6 0 4 5 .
K a g in a ,  B . M .  N . ,  A b e l ,  B ., B o w m a k e r ,  M . ,  S c r ib a ,  T .  J ., G e ld e r b lo e m ,  S ., S m it ,  E . , ... H a n e k o m ,  W .  A .
( 2 0 0 9 ) .  D e la y in g  B C G  v a c c in a t io n  f r o m  b i r t h  t o  1 0  w e e k s  o f  a g e  m a y  r e s u l t  in  a n  e n h a n c e d  
C D 4 T  c e ll  r e s p o n s e .  Vaccine, 2 7 ( 4 0 ) ,  5 4 8 8 - 5 4 9 5 .  
d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 0 9 . 0 6 . 1 0 3 . D e la y in g
K a g in a , B . M .  N . ,  A b e l ,  B ., S c r ib a ,  T .  J ., H u g h e s ,  E . J ., K e y s e r ,  A . ,  S o a r e s ,  A . , ... M a h o m e d ,  H . ( 2 0 1 0 ) .  
S p e c if ic  T  C e ll  F r e q u e n c y  a n d  C y t o k in e  E x p r e s s io n  P r o f i le  D o  N o t  C o r r e la t e  w i t h  P r o t e c t io n  
a g a in s t  T u b e r c u lo s is  ' r in  V a c c in a t io n  o f  N e w b o r n s  a f t e r  B a c il lu s  C a l m e t t e - G u e .  American 
Journal o f Respiratory and Critical Care Medicine, 182[2 4 ) .  d o i : 1 0 . 1 1 6 4 / r c c m . 2 0 1 0 0 3 -  
0 3 3 4 0 C
K a is h o , T . ,  H o s h in o ,  K ., Iw a b e ,  T . ,  T a k e u c h i ,  O . ,  Y a s u i,  T . ,  &  A k ir a ,  S . ( 2 0 0 2 ) .  E n d o t o x in  c a n  in d u c e  
M y D 8 8 - d e f i c i e n t  d e n d r i t i c  c e lls  t o  s u p p o r t  T h  2  c e l l  d i f f e r e n t i a t i o n .  International 
Immunology, 1 4 ( 7 ) ,  6 9 5 - 7 0 0 .
K a m p m a n n ,  B ., G a o r a ,  P . O . ,  S n e w in ,  V .  a , G a r e s ,  M .  P ., Y o u n g ,  D . B ., &  L e v in ,  M .  ( 2 0 0 0 ) .
E v a lu a t io n  o f  h u m a n  a n t im y c o b a c t e r ia l  i m m u n i t y  u s in g  r e c o m b in a n t  r e p o r t e r  m y c o b a c t e r ia .  
The Journal o f Infectious Diseases, 1 8 2 ( 3 ) ,  8 9 5 - 9 0 1 .  d o i : 1 0 . 1 0 8 6 / 3 1 5 7 6 6
K a u f m a n n ,  S . H . ( 2 0 0 1 ) .  H o w  c a n  im m u n o lo g y  c o n t r ib u t e  t o  t h e  c o n t r o l  o f  t u b e r c u lo s is ?  Nature 
Reviews. Immunology, 1 ( 1 ) ,  2 0 - 3 0 .  d o i : 1 0 . 1 0 3 8 / 3 5 0 9 5 5 5 8
K a u f m a n n ,  S . H . E. ( 2 0 1 3 ) .  T u b e r c u lo s is  v a c c in e s :  T im e  t o  t h i n k  a b o u t  t h e  n e x t  g e n e r a t i o n .  
Seminars in Immunology, 2 5 ( 2 ) ,  1 7 2 - 8 1 .  d o i : 1 0 . 1 0 1 6 / j . s m i m . 2 0 1 3 . 0 4 . 0 0 6
K h a d e r ,  S . A . ,  &  C o o p e r ,  A . M .  ( 2 0 0 7 ) .  IL -2 3  a n d  IL - 1 7  in  t u b e r c u lo s is .  Cytokine, 4 1 ( 2 0 0 8 ) ,  7 9 - 8 3 .  
d o i : 1 0 . 1 0 1 6 / j . c y t o . 2 0 0 7 . 1 1 . 0 2 2
143
K ir w a n ,  S . E ., &  B u r s h t y n ,  D . N .  ( 2 0 0 7 ) .  R e g u la t io n  o f  n a t u r a l  k i l le r  c e ll  a c t iv i t y .  Current Opinion in 
Immunology, 19[1), 4 6 - 5 4 .  d o i : 1 0 . 1 0 1 6 / j . c o i . 2 0 0 6 . 1 1 . 0 1 2
K le in n i je n h u is ,  J ., Q u in t in ,  J ., P r e i je r s ,  F ., J o o s te n ,  L. a  B ., I f r im ,  D . C .; S a e e d ,  S . , ... N e t e a ,  M .  G .
( 2 0 1 2 ) .  B a c il le  C a lm e t t e - G u e r in  in d u c e s  N O D 2 - d e p e n d e n t  n o n s p e c i f ic  p r o t e c t io n  f r o m  
r e in f e c t io n  v ia  e p ig e n e t ic  r e p r o g r a m m in g  o f  m o n o c y t e s .  Proceedings o f the National 
Academy o f Sciences o f the United States o f America, 1 0 5 ( 4 3 ) ,  1 7 5 3 7 - 4 2 .  
d o i : 1 0 . 1 0 7 3 / p n a s . 1 2 0 2 8 7 0 1 0 9
K o b a y a s h i ,  K. S ., C h a m a i l la r d ,  M . ,  O g u r a ,  Y .,  H e n e g a r iu ,  O . ,  In o h a r a ,  N . ,  N u n e z ,  G .,  &  F la v e l l ,  R . A .
( 2 0 0 5 ) .  N o d 2 - D e p e n d e n t  R e g u la t io n  o f  I n n a t e  a n d  A d a p t iv e  Im m u n i t y  in  t h e  In t e s t in a l  T r a c t .  
Science, 3 0 7 ( 7 3 1 ) .  d o i : 1 0 . 1 1 2 6 / s c i e n c e . 1 1 0 4 9 1 1
K o l lm a n n ,  T . R ., C r a b t r e e ,  J., R e in - W e s t o n ,  A . ,  B l im k ie ,  D . ,  T h o m m a i ,  F ., W a n g ,  X . Y . , ... W i ls o n ,  C .
B . ( 2 0 0 9 ) .  N e o n a t a l  in n a t e  T L R - m e d ia t e d  r e s p o n s e s  a r e  d is t in c t  f r o m  t h o s e  o f  a d u l t s .  Journal 
o f Immunology, 1 3 3 ( 1 1 ) ,  7 1 5 0 - 6 0 .  d o i : 1 0 . 4 0 4 9 / j i m m u n o l . 0 9 0 1 4 8 1
K o l lm a n n ,  T .  R ., L e v y , O . ,  &  H a n e k o m ,  W .  ( 2 0 1 3 ) .  V a c c in e - in d u c e d  i m m u n i t y  in  e a r ly  l i f e .  Vaccine, 
3 1 ( 2 1 ) ,  2 4 8 1 - 2 4 8 2 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 1 3 . 0 4 . 0 2 5
K r is te n s e n ,  I. ,  A a b y ,  P .,  &  J e n s e n ,  H . ( 2 0 0 0 ) .  R o u t in e  v a c c in a t io n s  a n d  c h ild  s u r v i v a l : f o l l o w  u p  
s t u d y  in . BMJ, 3 2 1 ( D e c e m b e r ) .
K v a r n s t r o m ,  M . ,  J e n m a lm ,  M .  C ., &  E k e r f e l t ,  C . ( 2 0 0 4 ) .  E f f e c t  o f  c r y o p r e s e r v a t io n  o n  e x p r e s s io n  o f  
T h l  a n d  T h 2  c y t o k in e s  in  b lo o d  m o n o n u c le a r  c e lls  f r o m  p a t ie n t s  w i t h  d i f f e r e n t  c y t o k in e  
p r o f i le s ,  a n a ly s e d  w i t h  t h r e e  c o m m o n  a s s a y s : a n  o v e r a l l  d e c r e a s e  o f  i n t e r l e u k i n - 4 .  
Cryobiology, 4 9 ( 2 ) ,  1 5 7 - 6 8 .  d o i : 1 0 . 1 0 1 6 / j . c r y o b i o l . 2 0 0 4 . 0 6 . 0 0 3
L a n z a v e c c h ia ,  A . ,  &  S a l lu s to ,  F . ( 2 0 0 5 ) .  U n d e r s t a n d in g  t h e  g e n e r a t io n  a n d  f u n c t io n  o f  m e m o r y  T  
c e ll  s u b s e ts .  Current Opinion in Immunology, 1 7 ( 3 ) ,  3 2 6 - 3 2 .  d o i : 1 0 . 1 0 1 6 / j . c o i . 2 0 0 5 . 0 4 . 0 1 0
L e u n g , A . S ., T r a n ,  V . ,  W u ,  Z .,  Y u , X . ,  A le x a n d e r ,  D . C ., G a o ,  G . F . , ... L iu , J. ( 2 0 0 8 ) .  N o v e l  g e n o m e  
p o ly m o r p h is m s m  in  B C G  v a c c in e  s t r a in s  a n d  im p a c t  o n  e f f ic a c y .  BMC Genomics, 1 2 ,1 - 1 2 .  
d o i : 1 0 . 1 1 8 6 / 1 4 7 1 - 2 1 6 4 - 9 - 4 1 3
L e v y , O . ( 2 0 0 7 ) .  In n a t e  im m u n i t y  o f  t h e  n e w b o r n :  b a s ic  m e c h a n is m s  a n d  c l in ic a l  c o r r e la t e s .
Nature Reviews. Immunology, 7 ( 5 ) ,  3 7 9 - 9 0 .  d o i : 1 0 . 1 0 3 8 / n r i 2 0 7 5
L e w in s o h n ,  D . a , H e in z e l ,  A . S ., G a r d n e r ,  J. M . ,  Z h u ,  L ., A ld e r s o n ,  M .  R ., &  L e w in s o h n ,  D . M .  ( 2 0 0 3 ) .  
M y c o b a c t e r i u m  tu b e r c u lo s is - s p e c i f ic  C D 8 +  T  c e lls  p r e f e r e n t i a l l y  r e c o g n iz e  h e a v i ly  in f e c t e d  
c e lls . American Journal o f Respiratory and Critical Care Medicine, 168{1 1 ) ,  1 3 4 6 - 5 2 .  
d o i : 1 0 . 1 1 6 4 / r c c m . 2 0 0 3 0 6 - 8 3 7 0 C
L e w is , R. S . ( 2 0 0 1 ) .  C a lc iu m  s ig n a l in g  m e c h a n is m s  in  T  l y m p h o c y t e s .  Annual Review o f 
Immunology, 19, 4 9 7 - 5 2 1 .  d o i : 1 0 . 1 1 4 6 / a n n u r e v . i m m u n o l .  1 9 . 1 . 4 9 7
Li, Q . ,  Li, J ., T ia n ,  J ., Z h u ,  B ., Z h a n g ,  Y ., Y a n g , K . , ... H u , Y . ( 2 0 1 2 ) .  IL - 1 7  a n d  IF N -  y  p r o d u c t io n  in  
p e r ip h e r a l  b lo o d  f o l lo w in g  B C G  v a c c in a t io n  a n d  M y c o b a c t e r iu m  t u b e r c u lo s is  in f e c t io n  in  
h u m a n .  European Review fo r Medical and Pharmacological Sciences, 16, 2 0 2 9 - 2 0 3 6 .
L u c e y , D . R ., C le r ic i ,  M . ,  &  S h e a r e r ,  G . M .  ( 1 9 9 6 ) .  T y p e  1  a n d  t y p e  2  c y t o k in e  d y s r e g u la t io n  in  
h u m a n  in f e c t io u s ,  n e o p la s t ic ,  a n d  i n f l a m m a t o r y  d is e a s e s . Clinical Microbiology Reviews, 
9 ( 4 ) ,  5 3 2 - 6 2 .  R e t r ie v e d  f r o m
144
h t t p : / / w w w . p u b m e d c e n t r a l . n i h . g o v / a r t i c l e r e n d e r . f c g i ? a r t i d = 1 7 2 9 0 9 & t o o l = p m c e n t r e z & r e n d
e r t y p e = a b s t r a c t
L u t w a m a ,  F .; K a g in a ,  B . M . ,  W a j j a ,  a , W a is w a ,  F ., M a n s o o r ,  N . ,  K i r im u n d a ,  S . , ... H a n e k o m ,  W .  a .
( 2 0 1 3 ) .  D is t in c t  T - C e l l  R e s p o n s e s  W h e n  B C G  V a c c in a t io n  Is D e la y e d  F r o m  B ir th  t o  6  W e e k s  o f  
A g e  in  U g a n d a n  In f a n t s .  The Journal o f Infectious Diseases, 1 2 , 1 - 1 1 .  
d o i : 1 0 . 1 0 9 3 / i n f d i s / j i t 5 7 0
M a c h in g a id z e ,  S ., W iy s o n g e ,  C . S ., &  H u s s e y , G . D .  ( 2 0 1 3 ) .  S t r e n g t h e n in g  t h e  e x p a n d e d  
p r o g r a m m e  o n  im m u n iz a t io n  in  A f r ic a :  lo o k in g  b e y o n d  2 0 1 5 .  PLoS Medicine, 1 0 ( 3 ) ,  
e l 0 0 1 4 0 5 .  d o i : 1 0 . 1 3 7 1 / j o u r n a l . p m e d . 1 0 0 1 4 0 5
M a r c h a n t ,  A . ,  G o e t g h e b u e r ,  T . ,  O t a ,  M .  O . ,  C e e s a y , S . J ., G r o o t e ,  D . D e ,  C o r r a h ,  T . , ... W o l f e ,  I.
( 1 9 9 9 ) .  N e w b o r n s  d e v e lo p  a  T H - 1  t y p e  I m m u n e  r e s p o n s e  t o  M y c o b a c t e r i u m  b o v is  B a c il lu s  
C a lm e t t e - G u e r in  V a c c in a t io n .  Journal o f Immunology, ( 1 6 3 ) ,  2 2 4 9 - 2 2 4 5 .
M a r c h a n t ,  A . ,  &  G o ld m a n ,  M .  ( 2 0 0 5 ) .  T  c e l l - m e d ia t e d  im m u n e  r e s p o n s e s  in  h u m a n  n e w b o r n s :  
r e a d y  t o  le a r n ?  Clinical and Experimental Immunology, 1 4 1 ( 1 ) ,  1 0 - 8 .  d o i : 1 0 . 1 1 1 1 / j . l 3 6 5 -  
2 2 4 9 . 2 0 0 5 . 0 2 7 9 9 . x
M e a n s ,  T .  K ., W a n g ,  S ., L ie n , E ., G o le n b o c k ,  D . T . ,  &  F e n t o n ,  M .  J. ( 1 9 9 9 ) .  H u m a n  T o l l - L ik e
R E c e p to r s  m e d i a t e  c e l lu la r  A c t iv a t io n  b y  M y c o b a c t e r iu m  t u b e r c u lo s is .  Journal o f Immuology, 
1 6 3 ( 1 6 3 ) ,  3 9 2 0 - 3 9 2 7 .
M e d z h i t o v ,  R ., &  J a n e w a y ,  C . A . ( 1 9 9 7 ) .  In n a t e  i m m u n i t y : im p a c t  o n  t h e  a d a p t iv e  im m u n e  
r e s p o n s e .  Current Opinion In Immunology, 9, 4 - 9 .
M e d z h i t o v ,  R ., P r e s t o n - h u r lb u r t ,  P ., &  J a n e w a y ,  C . A . ( 1 9 9 7 ) .  A  h u m a n  h o m o lo g u e  o f  t h e  
D r o s o p h i la  T o l l  p r o t e in  s ig n a ls  a c t iv a t io n  o f  a d a p t iv e  im m u n i t y .  Nature, 3 8 8 ( J u ly ) ,  6 - 9 .
M is h r a ,  A . K ., D r ie s s e n ,  N . N . ,  A p p e lm e lk ,  B . J ., &  B e s ra , G . S . ( 2 0 1 1 ) .  L ip o a r a b in o m a n n a n  a n d  
r e la t e d  g ly c o c o n ju g a t e s :  s t r u c t u r e ,  b io g e n e s is  a n d  r o le  in  M y c o b a c t e r i u m  t u b e r c u lo s is  
p h y s io lo g y  a n d  h o s t - p a t h o g e n  i n t e r a c t io n .  FEMS Microbiology Reviews, 3 5 ( 6 ) ,  1 1 2 6 - 5 7 .  
d o i : 1 0 . 1 1 1 1 / j . 1 5 7 4 - 6 9 7 6 . 2 0 1 1 . 0 0 2 7 6 . x
M is h r a ,  B . B ., M o u r a - a lv e s ,  P ., S o n a w a n e ,  A . ,  H a c o h e n ,  N .,  G r i f f i t h s ,  G . ,  M o i t a ,  L. F ., &  A n e s ,  E.
( 2 0 1 0 ) .  M y c o b a c t e r iu m  t u b e r c u lo s is  p r o t e in  E S A T -6  is a  p o t e n t  a c t i v a t o r  o f  t h e  N L R P 3 / A S C  
i n f l a m m a s o m e .  Cellular Microbiology, 1 2 ( 8 ) ,  1 0 4 6 - 1 0 6 3 .  d o i : 1 0 . 1 1 1 1 / j . l 4 6 2 -  
5 8 2 2 . 2 0 1 0 . 0 1 4 5 0 . x
M o x le y ,  G .,  P o s t h u m a ,  D .,  C a r ls o n , P ., E s t r a d a ,  E ., H a n ,  J ., B e n s o n ,  L. L ., &  N e a le ,  M .  C . ( 2 0 0 2 ) .  
S e x u a l d im o r p h is m  in  in n a t e  im m u n i t y .  Arthritis and Rheumatism, 4 6 ( 1 ) ,  2 5 0 - 8 .  
d o i : 1 0 . 1 0 0 2 / 1 5 2 9 - 0 1 3 1 ( 2 0 0 2 0 1 ) 4 6 : l < 2 5 0 : : A I D - A R T 1 0 0 6 4 > 3 . 0 . C O ; 2 - T
M u r r a y ,  P . J ., W a n g ,  L ., O n u f r y k ,  C ., T e p p e r ,  R ., &  Y o u n g ,  R . A .  ( 1 9 9 7 ) .  T - c e l l  d e r iv e d  IL - 1 0
a n t a g o n iz e s  m a c r o p h a g e  f u n c t io n  in  m y c o b a c t e r ia l  in f e c t io n .  Journal o f Immunology, 158, 
3 1 5 - 3 2 1 .
M u r r a y ,  R. A . ,  M a n s o o r ,  N . ,  H a r b a c h e u s k i ,  R ., S o le r ,  J ., D a v id s ,  V . ,  S o a r e s ,  A . , ... H a n e k o m ,  W .  A .
( 2 0 0 6 ) .  B a c il lu s  C a lm e t t e  G u e r in  V a c c in a t io n  o f  H u m a n  N e w b o r n s  In d u c e s  a  S p e c if ic ,  
F u n c t io n a l  C D 8 + T  c e ll  R e s p o n s e .  Journal o f Immunology, ( 1 7 7 ) ,  5 6 4 7 - 5 6 5 1 .
N e t e a ,  M .  G .,  Q u in t in ,  J ., &  v a n  d e r  M e e r ,  J. W .  M .  ( 2 0 1 1 ) .  T r a in e d  im m u n i t y :  a m e m o r y  f o r  in n a t e  
h o s t  d e f e n s e .  Cell Host & Microbe, 9 ( 5 ) ,  3 5 5 - 6 1 .  d o i : 1 0 . 1 0 1 6 / j . c h o m . 2 0 1 1 . 0 4 . 0 0 6
145
N e w p o r t ,  M .  J ., H u x le y ,  C . M . ,  H u s t o n  S a r a ,  H a w r y lo w ic s ,  C . M . ,  O o s t r a ,  B . A . ,  W i l l ia m s o n ,  R ., &  
L e v in ,  M .  ( 1 9 9 6 ) .  A  m u t a t i o n  in  t h e  I n t e r f e r o n - y - r e c e p t o r  g e n e  a n d  s u s c e p t ib i l i t y  t o  
m y c o b a c t e r ia l  in f e c t io n .  The New England Journal o f Medicine, 3 3 5 ( 2 6 ) ,  1 9 4 1 - 1 9 4 9 .
N e w t o n ,  S ., M a r t i n e a u ,  A . ,  &  K a m p m a n n ,  B . ( 2 0 1 1 ) .  A  f u n c t io n a l  w h o le  b lo o d  a s s a y  t o  m e a s u r e  
v ia b i l i t y  o f  m y c o b a c t e r ia ,  u s in g  r e p o r t e r - g e n e  t a g g e d  B C G  o r  M . T b  ( B C G Iu x /M .T b  lu x ) .
Journal o f Visualized Experiments :JoVE, ( 5 5 ) ,  3 - 7 .  d o i : 1 0 . 3 7 9 1 / 3 3 3 2
O d u t o la ,  a  a ,  O w o la b i ,  0 .  a , O w ia f e ,  P . K ., M c S h a n e ,  H . ,  &  O t a ,  M .  0 .  C . ( 2 0 1 2 ) .  A  n e w  T B  v a c c in e ,  
M V A 8 5 A ,  in d u c e s  d u r a b le  a n t ig e n - s p e c i f ic  r e s p o n s e s  1 4  m o n t h s  a f t e r  v a c c in a t io n  in  A f r ic a n  
in f a n t s .  Vaccine, 3 0 ( 3 8 ) ,  5 5 9 1 - 4 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 1 2 . 0 6 . 0 5 4
O t a ,  M .  0 .  C ., B r o o k e s ,  R . H .,  H i l l ,  P . C ., O w ia f e ,  P . K ., Ib a n g a ,  H . B ., D o n k o r ,  S . , ... A d e g b o la ,  R. a .
( 2 0 0 7 ) .  T h e  e f f e c t  o f  t u b e r c u l in  s k in  t e s t  a n d  B C G  v a c c in a t io n  o n  t h e  e x p a n s io n  o f  P P D -  
s p e c if ic  IF N - g a m m a  p r o d u c in g  c e lls  e x  v iv o .  Vaccine, 2 5 ( 5 2 ) ,  8 8 6 1 - 7 .  
d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 0 7 . 1 0 . 0 2 5
O t a ,  M .  0 .  C ., G o e t g h e b u e r ,  T . ,  V e k e m a n s ,  J ., O k o k o ,  B. J ., N e w p o r t ,  M .  J ., M c A d a m ,  K. P . W .  J ., &  
M a r c h a n t ,  A .  ( 2 0 0 6 ) .  D is s o c ia t io n  b e t w e e n  t u b e r c u l in  s k in  t e s t  a n d  in  v i t r o  IF N - g a m m a  
r e s p o n s e s  f o l lo w in g  n e o n a t a l  B C G  v a c c in a t io n .  Journal o f Tropical Pediatrics, 5 2 ( 2 ) ,  1 3 6 - 4 0 .  
d o i : 1 0 . 1 0 9 3 / t r o  p e j / f  m  i0 8 7
O t a ,  M .  O . C ., K id d , M . ,  W h i t t l e ,  H . ,  M c a d a m ,  K . P . W .  J ., M o r g a n ,  G .,  M a r c h a n t ,  A . ,  &  S m i t h k l in e ,
G . ( 2 0 0 2 ) .  T  c e ll  r e s p o n s e s  t o  v a c c in e s  in  in f a n t s  : d e f e c t iv e  IF N  g  p r o d u c t io n  a f t e r .  CLinical 
Experimental Immunology, 127, 4 9 5 - 4 9 8 .
O t a ,  M .  0 .  C ., O d u t o la ,  A . A . ,  O w ia f e ,  P . K ., D o n k o r ,  S ., O w o la b i ,  0 .  A . ,  B r i t t a in ,  N . J . , ... M c s h a n e ,
H . ( 2 0 1 1 ) .  Im m u n o g e n ic i t y  o f  t h e  T u b e r c u lo s is  V a c c in e  M V A 8 5 A  Is R e d u c e d  b y  
C o a d m in is t r a t io n  w i t h  EP I V a c c in e s  in  a  R a n d o m iz e d  C o n t r o l le d  T r ia l  in  G a m b ia n  In f a n t s .  
Science, 56. d o i : 1 0 . 1 1 2 6 / s c i t r a n s l m e d . 3 0 0 2 4 6 1
O t a ,  M .  0 .  C ., V e k e m a n s ,  J ., S c h le g e l - H a u e t e r ,  S . E ., F ie ld in g ,  K ., S a n n e h ,  M . ,  K id d , M . , ...
M a r c h a n t ,  A .  ( 2 0 0 2 ) .  In f lu e n c e  o f  M y c o b a c t e r i u m  b o v is  B a c il lu s  C a l m e t t e  G e u r in  o n  
A n t ib o d y  a n d  c y t o k in e  r e s p o n s e s  t o  h u m a n  n e o n a t a l  v a c c in a t io n .  Journal o f Immunology, 
( 1 6 8 ) ,  9 1 9 - 9 2 5 .
O t t e n h o f f ,  T .  H . M . ,  &  K a u f m a n n ,  S . H . E. ( 2 0 1 2 ) .  V a c c in e s  a g a in s t  t u b e r c u lo s is :  w h e r e  a r e  w e  a n d  
w h e r e  d o  w e  n e e d  t o  g o ?  PLoS Pathogens, 8 ( 5 ) ,  e l 0 0 2 6 0 7 .  
d o i : 1 0 . 1 3 7 1 / j o u r n a l . p p a t . 1 0 0 2 6 0 7
P a y n e ,  S ., T o w n e n d ,  J ., J a s s e h , M . ,  L o w e  J a l lo w ,  Y .,  &  K a m p m a n n ,  B. ( 2 0 1 3 ) .  A c h ie v in g
c o m p r e h e n s iv e  c h i ld h o o d  im m u n iz a t io n :  a n  a n a ly s is  o f  o b s ta c le s  a n d  o p p o r t u n i t i e s  in  T h e  
G a m b ia .  Health Policy and Planning. d o i : 1 0 . 1 0 9 3 / h e a p o l / c z t 0 0 4
P e p p e r ,  M . ,  &  J e n k in s ,  M .  K . ( 2 0 1 1 ) .  O r ig in s  o f  C D 4 +  e f f e c t o r  a n d  c e n t r a l  m e m o r y  T  c e l ls .  Nature  
Immunology, 1 3 1 ( 6 ) ,  4 6 7 - 4 7 1 .  d o i : 1 0 . 1 0 3 8 / n i . 2 0 3 8
P h i lb in ,  V .  J ., &  L e v y , 0 .  ( 2 0 0 9 ) .  D e v e lo p m e n t a l  b io lo g y  o f  t h e  in n a t e  im m u n e
r e s p o n s e : im p l ic a t io n s  f o r  n e o n a t a l  a n d  in f a n t  v a c c in e  d e v e l o p m e n t .  Pediatric Research, 
6 5 ( 2 ) ,  1 - 1 7 .  d o i : 1 0 . 1 2 0 3 / P D R . 0 b 0 1 3 e 3 1 8 1 9 f l 9 5 d . D e v e l o p m e n t a l
P i l la y ,  J ., d e n  B r a b e r ,  I. ,  V r is e k o o p ,  N . ,  K w a s t ,  L. M . ,  d e  B o e r ,  R . J ., B o r g h a n s ,  J. a  M . , ...
K o e n d e r m a n ,  L. ( 2 0 1 0 ) .  In  v iv o  la b e l in g  w i t h  2 H 2 0  r e v e a ls  a  h u m a n  n e u t r o p h i l  l i f e s p a n  o f  5 . 4  
d a y s . Blood, 1 1 6 ( 4 ) ,  6 2 5 - 7 .  d o i : 1 0 . 1 1 8 2 / b l o o d - 2 0 1 0 - 0 1 - 2 5 9 0 2 8
146
P o r t e v in ,  D . ,  V ia ,  L. E ., E u m , S ., &  Y o u n g ,  D . ( 2 0 1 2 ) .  N a t u r a l  k i l le r  c e lls  a r e  r e c r u i t e d  d u r in g
p u lm o n a r y  t u b e r c u lo s is  a n d  t h e i r  e x  v iv o  r e s p o n s e s  t o  m y c o b a c t e r ia  v a r y  b e t w e e n  h e a l t h y  
h u m a n  d o n o r s  in  a s s o c ia t io n  w i t h  K IR  h a p lo t y p e .  Cellular Microbiology, 1 4 ( 1 1 ) ,  1 7 3 4 - 4 4 .  
d o i : 1 0 . 1 1 1 1 / j .  1 4 6 2 - 5 8 2 2 . 2 0 1 2 . 0 1 8 3 4 . x
P r a b h u d a s ,  M . ,  A d k in s ,  B ., G a n s , H . ,  K in g , C ., L e v y , 0 . ,  R a m i lo ,  0 . ,  &  S ie g r is t ,  C . ( 2 0 1 1 ) .  C h a l le n g e s  
in  in f a n t  i m m u n i t y  : im p l ic a t io n s  f o r  r e s p o n s e s  t o  in f e c t io n  a n d  v a c c in e s .  Nature 
Immunology, 1 2 ( 3 ) .
P r e m a c k ,  B. A . ,  &  G a r d n e r ,  P . ( 1 9 9 2 ) .  S ig n a l t r a n s d u c t io n  b y  T - c e l l  r e c e p t o r s  : m o b i l i z a t io n  o f  C a  
a n d  r e g u la t io n  o f  C a - d e p e n d e n t  e f f e c t o r  m o le c u le s .  American Journal o f Physiology, 263{6  
P t  1 ) ,  C 1 1 1 9 - 4 0 .
P r y m u la ,  R ., &  P lis e k , S . ( 2 0 0 8 ) .  C l in ic a l  e x p e r ie n c e  w i t h  D T P w - H B V  a n d  D T P w - H B V  /  H ib .  Expert 
Opinion in Biological Therapy, 8 ( 4 ) ,  5 0 3 - 5 1 4 .
R a ja ,  A . ( 2 0 0 4 ) .  Im m u n o lo g y  o f  t u b e r c u lo s is .  Indian Journal o f Medical Research, 120{ O c t o b e r ) ,  
2 1 3 - 2 3 2 .
R a n d h a w a ,  A . K ., S h e y , M .  S .,  K e y s e r ,  A . ,  P e ix o t o ,  B ., W e l ls ,  R . D . ,  K o c k , M .  D e , ... T e a m ,  T .  S . A .  T .
V .  in i t i a t i v e .  ( 2 0 1 1 ) .  A s s o c ia t io n  o f  H u m a n  T L R 1  a n d  T L R 6  D e f ic ie n c y  w i t h  A l t e r e d  Im m u n e  
R e s p o n s e s  t o  B C G  V a c c in a t io n  in  S o u t h  A f r ic a n  In f a n t s .  PLoS Pathogens, 7 ( 8 ) .  
d o i : 1 0 . 1 3 7 1 / j o u r n a l . p p a t . l 0 0 2 1 7 4
R a v ig l io n e ,  M .  C ., &  S m it h ,  I. M .  ( 2 0 0 7 ) .  X D R  t u b e r c u l o s i s - i m p l i c a t i o n s  f o r  g lo b a l  p u b l ic  h e a l t h .
The New England Journal o f Medicine, 356(7), 6 5 6 - 9 .  d o i : 1 0 . 1 0 5 6 / N E J M p 0 6 8 2 7 3
R ib e ir o - R o d r ig u e s ,  R ., R e s e n d e  C o , T . ,  R o ja s , R ., T o o s s i,  Z . ,  D ie t z e ,  R ., B o o m , W .  H . , ... H ir s c h , C . S.
( 2 0 0 6 ) .  A  r o le  f o r  C D 4 + C D 2 5 +  T  c e lls  in  r e g u la t io n  o f  t h e  im m u n e  r e s p o n s e  d u r in g  h u m a n  
tu b e r c u lo s is .  Clinical and Experimental Immunology, 144(1), 2 5 - 3 4 .  d o i : 1 0 . 1 1 1 1 / j . l 3 6 5 -  
2 2 4 9 . 2 0 0 6 . 0 3 0 2 7 . x
R itz ,  N . ,  M u i ,  M . ,  B a l lo c h ,  A . ,  &  C u r t is ,  N . ( 2 0 1 3 ) .  N o n - s p e c i f ic  e f f e c t  o f  B a c il le  C a l m e t t e - G u e r i n  
v a c c in e  o n  t h e  im m u n e  r e s p o n s e  t o  r o u t in e  im m u n is a t io n s .  Vaccine, 31(30), 3 0 9 8 - 1 0 3 .  
d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 1 3 . 0 3 . 0 5 9
R itz , N . ,  T e b r u e g g e ,  M . ,  C o n n e l l ,  T .  G .,  S ie v e r s ,  A . ,  R o b in s - B r o w n e ,  R ., &  C u r t is ,  N .  ( 2 0 0 9 ) .
S u s c e p t ib i l i t y  o f  M y c o b a c t e r i u m  b o v is  B C G  v a c c in e  s t r a in s  t o  a n t i t u b e r c u lo u s  a n t ib io t ic s .  
Antimicrobial Agents and Chemotherapy, 53(1), 3 1 6 - 8 .  d o i : 1 0 . 1 1 2 8 / A A C . 0 1 3 0 2 - 0 8
R o o k , G . A . ., &  H e r n a n a d e z - P a n d o ,  R . ( 1 9 9 6 ) .  T h e  P a t h o g e n e s is  o f  T u b e r c u lo s is .  Annual Review o f 
Microbiology, 50, 2 5 9 - 8 4 .
R o th ,  A .  E ., S t e n s b a l le ,  L. G ., G a r iy ,  M .  L., &  A a b y ,  P . ( 2 0 0 6 ) .  B e n e f ic ia l  n o n - t a r g e t e d  e f f e c t s  o f  
B C G - e t h ic a l  im p l ic a t io n s  f o r  t h e  c o m in g  in t r o d u c t io n  o f  n e w  T B  v a c c in e s .  Tuberculosis,
86(6), 3 9 7 - 4 0 3 .  d o i : 1 0 . 1 0 1 6 / j . t u b e . 2 0 0 6 . 0 2 . 0 0 1
R o th ,  A . ,  S o d e m a n n ,  M . ,  J e n s e n ,  H . ,  P o u ls e n ,  A . ,  G u s t a f s o n ,  P ., W e is e ,  C . , ... A a b y ,  P . ( 2 0 0 6 ) .  
T u b e r c u l in  r e a c t io n ,  B C G  s c a r ,  a n d  l o w e r  f e m a l e  m o r t a l i t y .  Epidemiology (Cambridge,
Mass.), 1 7 ( 5 ) ,  5 6 2 - 8 .  d o i : 1 0 . 1 0 9 7 / 0 1 . e d e . 0 0 0 0 2 3 1 5 4 6 . 1 4 7 4 9 . a b
S a f f a r ,  M . - J . ,  K h a l i l ia n ,  A . -R . ,  A ja m i ,  A . ,  S a f f a r ,  H . ,  &  Q a h e r i ,  A .  ( 2 0 0 8 ) .  S e r o i m m u n i t y  t o  d ip h t h e r ia  
a n d  t e t a n u s  a m o n g  m o t h e r - i n f a n t  p a irs ;  t h e  r o le  o f  m a t e r n a l  i m m u n i t y  o n  i n f a n t  i m m u n e
147
r e s p o n s e  t o  d i p h t h e r i a - t e t a n u s  v a c c in a t io n .  Swiss Medical Weekly, 2 3 8 ( 1 7 - 1 8 ) ,  2 5 6 - 6 0 .  
d o i : 2 0 0 8 / 1 7 / s m w - 1 1 8 4 0
S a l lu s to ,  F ., G e g in a t ,  J ., &  L a n z a v e c c h ia ,  A .  ( 2 0 0 4 ) .  C e n t r a l  m e m o r y  a n d  e f f e c t o r  m e m o r y  T  c e ll  
s u b s e ts :  f u n c t io n ,  g e n e r a t io n ,  a n d  m a in t e n a n c e .  Annual Review o f Immunology, 22, 7 4 5 - 6 3 .  
d o i : 1 0 . 1 1 4 6 / a n n u r e v . i m m u n o l . 2 2 . 0 1 2 7 0 3 . 1 0 4 7 0 2
S a l lu s t o ,  F ., &  L a n z a v e c c h ia ,  A . ( 2 0 0 9 ) .  H e t e r o g e n e i t y  o f  C D 4 +  m e m o r y  T  c e lls :  f u n c t io n a l  m o d u le s  
f o r  t a i lo r e d  im m u n i t y .  European Journal o f Immunology, 3 9 ( 8 ) ,  2 0 7 6 - 8 2 .  
d o i : 1 0 . 1 0 0 2 / e j i . 2 0 0 9 3 9 7 2 2
S a l lu s to ,  F ., L e n ig , D . ,  F o , R ., L ip p , M . ,  &  L a n z a v e c c h ia ,  A .  ( 1 9 9 9 ) .  T w o  s u b s e ts  o f  m e m o r y  T  
ly m p h o c y t e s  w i t h  d is t in c t  h o m in g  p o t e n t ia ls .  Nature, 401[O c t o b e r ) ,  7 0 8 - 7 1 2 .
S a n t ia g o ,  E. M . ,  L a w s o n , E ., G i l l e n w a t e r ,  K ., K a la n g i ,  S ., L e s c a n o , a . G .,  D u  Q u e l la ,  G . , ... G i lm a n ,  R.
H . ( 2 0 0 3 ) .  A  P r o s p e c t iv e  S t u d y  o f  B a c il lu s  C a lm e t t e - G u e r in  S c a r  F o r m a t io n  a n d  T u b e r c u l in  
S k in  T e s t  R e a c t iv i t y  in  In f a n t s  in  L im a , P e r u .  Pediatrics, 112[A), e 2 9 8 - e 2 9 8 .  
d o i : 1 0 . 1 5 4 2 / p e d s . H 2 . 4 . e 2 9 8
S a r t o n o ,  E ., L is s e , I. M . ,  T e r v e e r ,  E. M . ,  S a n d e ,  P . J. M .  V a n  D e ,  W h i t t l e ,  H . ,  A n e ,  B . , ... B e n n ,  C . S.
( 2 0 1 0 ) .  O r a l  P o l io  V a c c in e  In f lu e n c e s  t h e  I m m u n e  R e s p o n s e  t o  B C G  V a c c in a t io n  . A  N a t u r a l  
E x p e r im e n t .  PloS One, ( M a y ) .  d o i : 1 0 . 1 3 7 1 / j o u r n a l . p o n e . 0 0 1 0 3 2 8
S c h n a r e ,  M . ,  B a r t o n ,  G . M . ,  H o l t ,  a  C ., T a k e d a ,  K ., A k ir a ,  S ., &  M e d z h i t o v ,  R . ( 2 0 0 1 ) .  T o l l - l i k e
r e c e p t o r s  c o n t r o l  a c t iv a t io n  o f  a d a p t iv e  im m u n e  r e s p o n s e s .  Nature Immunology, 2 ( 1 0 ) ,  9 4 7 -  
5 0 .  d o i : 1 0 . 1 0 3 8 / n i 7 1 2
S c r ib a ,  T . J ., K a ls d o r f ,  B ., A b r a h a m s ,  D .,  Is a a c s , F ., H o f m e is t e r ,  J ., B la c k , G .,  &  H a s s a n , H . Y . ( 2 0 0 8 ) .  
D i s t i n c t , s p e c if ic  IL -1 7  a n d  IL - 2 2 - p r o d u c in g  C D 4  +  T  c e ll  s u b s e ts  c o n t r i b u t e  t o  t h e  h u m a n  
a n t i - m y c o b a c t e r ia l  im m u n e  r e s p o n s e l .  Journal o f Immunology, 2 8 0 ( 3 ) ,  1 9 6 2 - 1 9 7 0 .
S e b in a ,  I., C l i f f ,  J. M . ,  S m it h ,  S . G .,  N o g a r o ,  S ., W e b b ,  E. L ., R ile y , E. M . , ... C o s e , S . ( 2 0 1 2 ) .  L o n g -  
L iv e d  M e m o r y  B -C e ll  R e s p o n s e s  f o l lo w in g  B C G  V a c c in a t io n .  PloS One, ( D e c e m b e r ) ,  1 - 7 .  
d o i : 1 0 . 1 3 7 1 / j o u r n a l . p o n e . 0 0 5 1 3 8 1
S e t ia ,  M .  S ., S t e in m a u s ,  C ., H o ,  C . S ., &  R u t h e r f o r d ,  G . W .  ( 2 0 0 6 ) .  T h e  r o le  o f  B C G  in  p r e v e n t io n  o f  
le p r o s y :  a  m e t a - a n a ly s is .  The Lancet Infectious Diseases, 6 ( 3 ) ,  1 6 2 - 7 0 .  d o i : 1 0 . 1 0 1 6 / S 1 4 7 3 -  
3 0 9 9 ( 0 6 ) 7 0 4 1 2 - 1
S h a n n ,  F. ( 2 0 1 0 ) .  T h e  n o n - s p e c i f ic  e f f e c t s  o f  v a c c in e s .  Archives of Disease in Childhood, 9 5 ( 9 ) ,  
6 6 2 - 7 .  d o i : 1 0 . 1 1 3 6 / a d c . 2 0 0 9 . 1 5 7 5 3 7
S ie g r is t ,  C . a , C o r d o v a ,  M . ,  B r a n d t ,  C ., B a r r io s ,  C ., B e r n e y ,  M . ,  T o u g n e ,  C . , ... L a m b e r t ,  P . H . ( 1 9 9 8 ) .  
D e t e r m in a n t s  o f  in f a n t  r e s p o n s e s  t o  v a c c in e s  in  p r e s e n c e  o f  m a t e r n a l  a n t ib o d ie s .  Vaccine, 
2 6 ( 1 4 - 1 5 ) ,  1 4 0 9 - 1 4 .  R e t r ie v e d  f r o m  h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 9 7 1 1 7 8 0
S ie g r is t ,  C .-A .,  &  K o v a r ik ,  J. ( 1 9 9 8 ) .  I m m u n i t y  in  e a r ly  l i f e .  Immunology Today, 2 9 ( 4 ) ,  1 5 0 - 1 5 2 .
S m i t h ,  S . G .,  L a lo r , M .  K ., G o r a k - S t o l in s k a ,  P ., B litz ,  R ., B e v e r id g e ,  N . E. R ., W o r t h ,  A . , ... D o c k r e l l ,  H . 
M .  ( 2 0 1 0 ) .  M y c o b a c t e r iu m  t u b e r c u lo s is  P P D - in d u c e d  im m u n e  b io m a r k e r s  m e a s u r a b le  in  
v i t r o  f o l lo w in g  B C G  v a c c in a t io n  o f  U K  a d o le s c e n t s  b y  m u l t ip le x  b e a d  a r r a y  a n d  i n t r a c e l lu la r  
c y t o k in e  s ta in in g .  BMC Immunology, 2 2 ( 3 5 ) .  d o i : 1 0 . 1 1 8 6 / 1 4 7 1 - 2 1 7 2 - l l - 3 5
148
S o a r e s ,  A . P ., K w o n g  C h u n g , C . K . C ., C h o ic e ,  T . ,  H u g h e s ,  E . J ., J a c o b s , G .,  v a n  R e n s b u r g ,  E . J . , ... 
H a n e k o m ,  W .  a . ( 2 0 1 3 ) .  L o n g i t u d in a l  c h a n g e s  in  C D 4 ( + )  T -c e l l  m e m o r y  r e s p o n s e s  in d u c e d  b y  
B C G  v a c c in a t io n  o f  n e w b o r n s .  The Journal o f Infectious Diseases, 207{7), 1 0 8 4 - 9 4 .  
d o i : 1 0 . 1 0 9 3 / i n f d i s / j i s 9 4 1
S o a r e s ,  A . P ., S c r ib a ,  T . J ., J o s e p h , S ., H a r b a c h e u s k i ,  R ., M u r r a y ,  R . A . ,  G e ld e r b lo e m ,  S. J . , ...
H a n e k o m ,  W .  A . ( 2 0 0 8 ) .  B a c il lu s  C a lm e t t e  G u e r in  v a c c in a t io n  o f  h u m a n  n e w b o r n s  in d u c e s  T  
c e lls  w i t h  C o m p le x  c y t o k in e  a n d  p h e n o t y p ic  p r o f i le s .  Journal o f Immuology, ( 1 8 0 ) ,  3 5 6 9 -  
3 5 7 7 .
S o u d ja ,  S . M . ,  C h a n d r a b o s ,  C ., Y a k o b ,  E ., V e e n s t r a ,  M . ,  P a l l is e r ,  D . ,  &  L a u v a u ,  G . ( 2 0 1 4 ) .  M e m o r y -  
T - C e l l - D e r iv e d  I n t e r f e r o n - y  In s t r u c t s  P o t e n t  I n n a t e  C e ll A c t iv a t io n  f o r  P r o t e c t iv e  Im m u n i t y .  
Immunity, 6 ( L m ) .  d o i : 1 0 . 1 0 1 6 / j . i m m u n i . 2 0 1 4 . 0 5 . 0 0 5
S o u s a , A . O . ,  M a z z a c c a r o ,  R. J ., R u s s e ll ,  R . G .,  L e e , F. K ., T u r n e r ,  O . C ., H o n g ,  S . , ... B lo o m ,  B . R.
( 2 0 0 0 ) .  R e la t iv e  c o n t r ib u t io n s  o f  d is t in c t  M H C  c la s s  l - d e p e n d e n t  c e l l  p o p u la t io n s  in  
p r o t e c t io n  t o  t u b e r c u lo s is  in f e c t io n  in  m ic e .  Proceedings o f the National Academy of 
Sciences o f the United States o f America, 9 7 ( 8 ) ,  4 2 0 4 - 8 .  R e t r ie v e d  f r o m  
h t t p : / / w w w . p u b m e d c e n t r a l . n i h . g o v / a r t i c l e r e n d e r . f c g i ? a r t i d = 1 8 1 9 7 & t o o l = p m c e n t r e z & r e n d e  
r t y p e = a b s t r a c t
S t e n g e r ,  S ., H a n s o n ,  D . A . ,  T e i t e l b a u m ,  R ., D e w a n ,  P ., N ia z i ,  K. R ., F r o e l ic h ,  C . J . , ... M o d l i n ,  R. L. 
( 1 9 9 8 ) .  A n  A n t im ic r o b ia l  A c t iv i t y  o f  C y t o ly t ic  T  C e lls  M e d i a t e d  b y  G r a n u ly s in .  Science, 
2 8 2 ( 5 3 8 6 ) ,  1 2 1 - 1 2 5 .  d o i : 1 0 . 1 1 2 6 / s c i e n c e . 2 8 2 . 5 3 8 6 . 1 2 1
S t e n g e r ,  S ., M a z z a c c a r o ,  R. J ., U y e m u r a ,  K ., C h o , S ., B a r n e s , P . F ., R o s a t ,  J . - P . , ... M o d l i n ,  R . L.
( 1 9 9 7 ) .  D i f f e r e n t ia l  E f fe c ts  o f  C y t o ly t ic  T  C e ll S u b s e ts  o n  In t r a c e l lu la r  I n f e c t io n .  Science, 
2 7 6 ( 5 3 1 9 ) ,  1 6 8 4 - 1 6 8 7 .  d o i : 1 0 . 1 1 2 6 / s c i e n c e . 2 7 6 . 5 3 1 9 . 1 6 8 4
S t e n s b a l le ,  L. G .,  N a n t e ,  E ., J e n s e n ,  I. P ., K o fo e d ,  P .-E . ,  P o u ls e n ,  A . ,  J e n s e n , H . , ... A a b y ,  P . ( 2 0 0 5 ) .  
A c u t e  l o w e r  r e s p i r a t o r y  t r a c t  in f e c t io n s  a n d  r e s p i r a t o r y  s y n c y t ia l  v ir u s  in  in f a n t s  in  G u in e a -  
B is s a u : a b e n e f ic ia l  e f f e c t  o f  B C G  v a c c in a t io n  f o r  g ir ls  c o m m u n i t y  b a s e d  c a s e - c o n t r o l  s t u d y .  
Vaccine, 2 3 ( 1 0 ) ,  1 2 5 1 - 7 .  d o i : 1 0 . 1 0 1 6 / j . v a c c i n e . 2 0 0 4 . 0 9 . 0 0 6
T e i t e l b a u m ,  R ., G la t m a n - F r e e d m a n ,  A . ,  C h e n ,  B ., R o b b in s , J. B ., U n a n u e ,  E ., C a s a d e v a l l ,  A . ,  &
B lo o m , B . R . ( 1 9 9 8 ) .  A  m A b  r e c o g n iz in g  a s u r f a c e  a n t ig e n  o f  M y c o b a c t e r i u m .  Proceedings o f 
the National Academy o f Sciences o f the United States o f America, 9 5 , 1 5 6 8 8 - 1 5 6 9 3 .
T ia n ,  T . ,  W o o d w o r t h ,  J ., S k o ld ,  M . ,  B e h a r ,  M . ,  S k o , M . ,  &  B e h a r ,  S . M .  ( 2 0 0 5 ) .  In  v iv o  D e p le t io n  o f  
C D l l c +  C e lls  d e la y s  t e h  C d 4 +  T  c e ll  r e s p o n s e  t o  m y c o b a c t e r iu m  t u b e r c u lo s is  a n d  
e x a c e r b a t e s  t h e  o u t c o m e  o f  in f e c t io n .  Journal o f Immunology, 175, 3 2 6 8 - 3 2 7 2 .
T s u j i ,  S ., M a t s u m o t o ,  M . ,  T a k e u c h i ,  O . ,  A k ir a ,  S ., A z u m a ,  I . ,  H a y a s h i ,  A . , ... S e y a ,  T .  ( 2 0 0 0 ) .
M a t u r a t i o n  o f  H u m a n  D e n d r i t ic  C e lls  b y  C e ll W a l l  S k e le t o n  o f  M y c o b a c t e r i u m  b o v is  B a c il lu s  
C a lm e t t e - G u e r in  : I n v o lv e m e n t  o f  T o l l - L ik e  R e c e p to r s .  Infection and Immunity, 6 8 ( 1 2 ) ,  6 8 8 3 -  
6 8 9 0 .
U e h o r i ,  J ., M a t s u m o t o ,  M . ,  T s u j i ,  S ., T a k e u c h i ,  O . ,  A k ir a ,  S ., K a w a t a ,  T . , ... S e y a , T .  ( 2 0 0 3 ) .
S im u l t a n e o u s  B lo c k in g  o f  H u m a n  T o l l - L ik e  R e c e p t o r s  2  a n d  4  S u p p r e s s e s  M y e l o i d  D e n d r i t i c  
C e ll A c t iv a t io n  In d u c e d  b y  M y c o b a c t e r i u m  b o v is  B a c il lu s  S im u l t a n e o u s  B lo c k in g  o f  H u m a n  
T o l l -L ik e  R e c e p to r s  2  a n d  4  S u p p r e s s e s  M y e lo id  D e n d r i t ic  C e ll A c t iv a t io n  In d u c e d .  Infection 
and Immmunity, 7 4 ( 8 ) ,  4 2 3 8 - 4 2 4 9 .  d o i : 1 0 . 1 1 2 8 / I A I . 7 1 . 8 . 4 2 3 8
149
U m e m u r a ,  M . ,  Y a h a g i ,  A . ,  H a m a d a ,  S ., B e g u m ,  D .,  W a t a n a b e ,  H . ,  K a w a k a m i ,  K ., ... A le r t s ,  E . ( 2 0 0 7 ) .  
I L - 1 7  m e d ia t e d  r e g u la t io n  o f  in n a t e  a n d  a c q u i r e d  i m m u n e  r e s p o n s e  a g a in s t  p u lm o n a r y  
m y c o b a c t e r iu m  b o v is  B a c il le  C a l m e t t e  G u e r in .  Journal o f Immunology, 178{6 ) ,  3 7 8 6 - 3 7 9 6 .
V a n  C r e v e l ,  R ., K a r y a d i ,  E ., P r e y e r s ,  F ., L e e n d e r s ,  M . ,  K u l lb e r g ,  B . J., N e l w a n ,  R . H . ,  &  v a n  d e r  M e e r ,  
J. W .  ( 2 0 0 0 ) .  In c r e a s e d  p r o d u c t io n  o f  i n t e r le u k in  4  b y  C D 4 +  a n d  C D 8 +  T  c e lls  f r o m  p a t ie n t s  
w i t h  tu b e r c u lo s is  is r e la t e d  t o  t h e  p r e s e n c e  o f  p u lm o n a r y  c a v it ie s .  The Journal o f Infectious 
Diseases, 1 8 1 ( 3 ) ,  1 1 9 4 - 7 .  d o i : 1 0 . 1 0 8 6 / 3 1 5 3 2 5
V a n  G a g e ld o n k ,  P . G . M . ,  v a n  S c h a ijk ,  F . G .,  v a n  d e r  K lis , F. R ., &  B e r b e r s ,  G . a M .  ( 2 0 0 8 ) .  
D e v e l o p m e n t  a n d  v a l id a t io n  o f  a m u l t ip le x  im m u n o a s s a y  f o r  t h e  s im u l t a n e o u s  
d e t e r m i n a t i o n  o f  s e r u m  a n t ib o d ie s  t o  B o r d e t e l la  p e r tu s s is ,  d ip h t h e r ia  a n d  t e t a n u s .  Journal 
o f Immunological Methods, 3 3 5 ( 1 - 2 ) ,  7 9 - 8 9 .  d o i : 1 0 . 1 0 1 6 / j . j i m . 2 0 0 8 . 0 2 . 0 1 8
V e k e m a n s ,  J ., A m e d e i ,  A . ,  O t a ,  M .  O . ,  E lio s , M .  M .  D .,  Is m a i l i ,  J ., N e w p o r t ,  M .  J . , ... M a r c h a n t ,  A .
( 2 0 0 1 ) .  N e o n a t a l  b a c i l lu s  C a lm e t t e - G u  e r in  v a c c in a t io n  in d u c e s  a d u l t - l i k e  IF N -  q  p r o d u c t io n  
b y  C D 4  +  T  ly m p h o c y t e s .  European Journal o f Immunology, 3 1 , 1 5 3 1 - 1 5 3 5 .
W a t s o n ,  V .  E ., H i l l ,  L. L ., O w e n - S c h a u b ,  L. B ., D a v is ,  D . W . ,  M c C o n k e y ,  D . J ., J a g a n n a t h ,  C . , ... A c t o r ,  
J. K. ( 2 0 0 0 ) .  A p o p t o s is  in  m y c o b a c t e r iu m  t u b e r c u lo s is  in f e c t io n  in  m ic e  e x h ib i t in g  v a r ie d  
im m u n o p a t h o lo g y .  The Journal o f Pathology, 1 9 0 ( 2 ) ,  2 1 1 - 2 0 .  d o i : 1 0 . 1 0 0 2 / ( S I C I ) 1 0 9 6 -  
9 8 9 6 ( 2 0 0 0 0 2 ) 1 9 0 : 2 < 2 1 1 : : A I D - P A T H 5 3 0 > 3 . 0 . C O ; 2 - 3
W e s t ,  A .  P ., K o b la n s k y , A . A . ,  &  G h o s h ,  S . ( 2 0 0 6 ) .  R e c o g n i t io n  a n d  s ig n a l in g  b y  t o l l - l i k e  r e c e p t o r s .  
Annual Review o f Cell and Developmental Biology, 2 2 ,4 0 9 - 3 7 .  
d o i : 1 0 . 1 1 4 6 / a n n u r e v . c e l l b i o . 2 1 . 1 2 2 3 0 3 . 1 1 5 8 2 7
W H O .  ( 2 0 0 2 ) .  W O R L D  H E A L T H  O R G A N IZ A T IO N  U S E  O F  A N T IC O A G U L A N T S  IN  D IA G N O S T IC .
W H O .  ( 2 0 1 0 ) .  Gambia Factsheets o f Health Statistics (p .  6 8 ) .  R e t r ie v e d  f r o m  
h t t p : / / w w w . a f r o . w h o . i n t / e n / g a m b i a / c o u n t r y - h e a l t h - p r o f i l e . h t m l
W H O .  ( 2 0 1 2 ) .  GLobal Tuberculosis report. R e t r ie v e d  f r o m
h t t p : / / a p p s . w h o . i n t / i r i s / b i t s t r e a m / 1 0 6 6 5 / 7 5 9 3 8 / l / 9 7 8 9 2 4 1 5 6 4 5 0 2 _ e n g . p d f
W H O .  ( 2 0 1 4 ) .  WHO SAGE REVIEW 2014  ( p p .  2 2 1 - 2 3 6 ) .  R e t r ie v e d  f r o m  
h t t p : / / w w w . w h o . i n t / e n t i t y / w e r / 2 0 1 4 / w e r 8 9 2 1 . p d f ? u a = l
W o z n ia k ,  T .  M . ,  R y a n , A . A . ,  W a r w ic k ,  J ., &  B r i t t o n ,  W .  J. ( 2 0 0 6 ) .  IL -2 3  R E s to r e s  i m m u n i t y  t o
m y c o b a c t e r iu m  tu b e r c u lo s is  in f e c t io n  in  IL - 1 2 p 4 0 - d e f i c i e n t  m ic e  a n d  is n o t  r e q u i r e d  f o r  t h e  
d e v e l o p m e n t  o f  IL -1 7  s e c r e t in g  T  c e ll  r e s p o n s e s .  Journal o f Immunology, 177, 8 6 8 4 - 8 6 9 2 .
W o z n ia k ,  T .  M . ,  S a u n d e r s ,  B . M . ,  R y a n , A . a , &  B r i t t o n ,  W .  J. ( 2 0 1 0 ) .  M y c o b a c t e r i u m  b o v is  B C G -  
s p e c if ic  T h l 7  c e lls  c o n f e r  p a r t ia l  p r o t e c t io n  a g a in s t  M y c o b a c t e r iu m  t u b e r c u lo s is  in f e c t io n  in  
t h e  a b s e n c e  o f  g a m m a  in t e r f e r o n .  Infection and Immunity, 7 3 ( 1 0 ) ,  4 1 8 7 - 9 4 .  
d o i : 1 0 . 1 1 2 8 / I A I . 0 1 3 9 2 - 0 9
Z u n ig a ,  J ., T o r r e s - g a r c ,  D . ,  S a n t o s - m e n d o z a ,  T . ,  R o d r ig u e z - r e y n a ,  T .  S ., G r a n a d o s ,  J ., &  Y u n is ,  E . J.
( 2 0 1 2 ) .  C e l lu la r  a n d  H u m o r a l  M e c h a n is m s  In v o lv e d  in  t h e  C o n t r o l  o f  T u b e r c u lo s is .  Clinical & 
Developmental Immunology. d o i : 1 0 . 1 1 5 5 / 2 0 1 2 / 1 9 3 9 2 3
150
